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Abstract 
The key component of the Wnt/β-catenin pathway is β-catenin, a 780 amino acid protein 
which was originally identified as a component of E-cadherin junctions, where it links E-cadherin 
with α-catenin and consequently to the actin cytoskeleton. In the absence of Wnt signalling, 
cytoplasmic β-catenin is phosphorylated and subsequently degraded by ubiquitinylation. 
Activation of Wnt signalling stabilises cytoplasmic β-catenin, which translocates into the nucleus 
where it binds to nuclear transcription factors TCF/LEF and regulates the expression of over thirty 
genes, including cell cycle activating genes. 
The Wnt/β-catenin pathway is essential for nervous system development and it is 
aberrantly active in common malignant tumours of the central nervous system, such as 
glioblastoma in adults and medulloblastoma in children.  
We have generated a mouse model expressing a Cre-recombinase-inducible form of 
degradation-resistant (oncogenic) β-catenin. We generated compound mutant mice to activate 
the Wnt/β-catenin pathway in specific brain regions and during several developmental time 
points. Compound mutant transgenic mice expressed dominant active β-catenin in vivo, but did 
not show developmental abnormalities or brain tumours even in combination with inactivated p53 
alleles. Similarly, neural stem cells expressing dominant active β-catenin did not show a growth 
advantage or altered self-renewal. We attributed these results to low level expression of dominant 
active -catenin. 
In addition, we later acquired mice that carry an inducible deletion of the exon 3 of β-
catenin (containing the phosphorylation site). Expression of this form of β-catenin did not increase 
neural stem cell growth and self-renewal. However, in vivo expression results in brain 
malformation and lethality depending on the cells in which β-catenin was activated, however, 
recombination in adult stem cells in vivo did not result in brain tumours. 
  
6 | P a g e  
 
Table of contents 
Declaration .................................................................................................................... 2 
Acknowledgements ....................................................................................................... 3 
Abstract ......................................................................................................................... 5 
Table of contents ........................................................................................................... 6 
Index of figures and tables ........................................................................................... 10 
List of abbreviations and acronyms .............................................................................. 13 
1 Introduction ......................................................................................................... 19 
1.1 Brain tumours ................................................................................................................... 20 
1.1.1 Medulloblastomas .................................................................................................. 21 
1.1.2 CNS Primary neuroectodermal tumours (PNETs) ................................................... 23 
1.1.3 Turcot’s syndrome .................................................................................................. 23 
1.2 Stem cells & cancer stem cells .......................................................................................... 24 
1.3 Wnt Signalling ................................................................................................................... 29 
1.3.1 Wnt synthesis and secretion ................................................................................... 31 
1.3.2 Receptors ................................................................................................................ 36 
1.3.3 Extracellular Antagonists of the Wnt pathway ....................................................... 39 
1.3.4 The Wnt/PCP or Wnt/JNK pathway ........................................................................ 42 
1.3.5 The Wnt/Ca2+ pathway ........................................................................................... 44 
1.3.6 The canonical Wnt/β-catenin pathway .................................................................. 46 
1.4 Mouse models ................................................................................................................... 76 
1.4.1 Conventional loss-of-function/knockout Models ................................................... 76 
1.4.2 Mouse models of conditional gene inactivation (Cre-loxP system) ....................... 82 
1.4.3 Conditional Models for studying the Wnt/β-catenin pathway in CNS tumours..... 85 
2 Materials and methods ......................................................................................... 87 
2.1 Mice .................................................................................................................................. 87 
2.1.1 Genotyping.............................................................................................................. 87 
2.1.2 Embryonic LacZ expression ..................................................................................... 87 
2.1.3 BrdU injection of mice ............................................................................................ 87 
2.1.4 Adenovirus-Cre intraventricular injection .............................................................. 87 
2.2 Tissue harvesting and preparation ................................................................................... 88 
2.2.1 Brain and peripheral organ harvesting ................................................................... 88 
7 | P a g e  
 
2.2.2 β-galactosidase staining assay ................................................................................ 88 
2.3 Generation of the pcall2-GSK-β-catenin-IRES-GFP vector.............................................. 89 
2.3.1 Restriction enzyme digestion and ligation .............................................................. 89 
2.3.2 Bacterial transformation and purification .............................................................. 89 
2.3.3 ES cells electroporation .......................................................................................... 90 
2.3.4 ES cell selection for LacZ ......................................................................................... 90 
2.3.5 Southern blot analysis............................................................................................. 91 
2.4 Cell culture ........................................................................................................................ 92 
2.4.1 Transfection of N2a cells......................................................................................... 92 
2.4.2 SVZ dissection and growth of neural stem cells ..................................................... 92 
2.4.3 Infection of cultures with Adenovirus .................................................................... 94 
2.4.4 WST-1 assay ............................................................................................................ 95 
2.4.5 Hoechst proliferation assay .................................................................................... 95 
2.4.6 NS size ..................................................................................................................... 96 
2.4.7 Limited dilution assay ............................................................................................. 96 
2.4.8 Differentiation of neural stem cells ........................................................................ 96 
2.4.9 Immunostaining of differentiated neurospheres ................................................... 96 
2.5 Immunohistochemistry (Paraffin Histology) ..................................................................... 97 
2.6 Protein extraction and Western blot ................................................................................ 98 
2.7 Techniques involving nucleic acids ................................................................................. 101 
2.7.1 Extraction of DNA from tails or ear biopsies ........................................................ 101 
2.7.2 Polymerase Chain Reaction .................................................................................. 101 
2.7.3 Agarose Gel Electrophoresis ................................................................................. 103 
3 Generation and expression analysis of GSK-β-catenin transgenic mice .............. 104 
3.1 Background ..................................................................................................................... 104 
3.1.1 Aims ...................................................................................................................... 105 
3.1.2 Methods ................................................................................................................ 105 
3.2 Results ............................................................................................................................. 106 
3.2.1 Generation of the pcall2-GSK-β-catenin-IRES-GFP vector ................................. 106 
3.2.2 N2a cells transfected with pcall2-GSK-β-catenin-IRES-GFP vector express GSK-β-
catenin following Cre-mediated recombination ................................................... 107 
3.2.3 Selection of embryonic stem cells transfected with the pcall2-GSK-β-catenin-IRES-
GFP vector for blastocyst injection ....................................................................... 108 
8 | P a g e  
 
3.2.4 GSK-β-catenin mice express LacZ in the brain and other organs ......................... 110 
3.2.5 Nestin-Cre; GSK-β-catenin mice do not show embryonic lethality .................... 113 
3.2.6 Recombination in Nestin-Cre; GSK-β-catenin mouse brains .............................. 115 
3.2.7 Nestin-Cre; ΔGSK-β-catenin mice express ΔGSK-β-catenin in the brain .............. 118 
3.2.8 GSK-β-catenin expression does not alter brain architecture or cellular morphology
 121 
3.3 Discussion ........................................................................................................................ 124 
3.4 Summary ......................................................................................................................... 126 
4 In vitro analysis of GSK-β-catenin expression .................................................... 127 
4.1 Background ..................................................................................................................... 127 
4.1.1 Aims ...................................................................................................................... 128 
4.1.2 Methods ................................................................................................................ 128 
4.2 Results ............................................................................................................................. 129 
4.2.1 In vitro expression of GSK-β-catenin does not influence neuronal stem cell biology
 130 
4.2.2 Additional deletion of p53 does not affect brain morphology and does not promote 
neoplastic transformation .................................................................................... 135 
4.2.3 Additional deletion of p53 or Rb in neural stem cells does not have a consistent 
effect on proliferation ........................................................................................... 140 
4.2.4 In vivo recombination in the SVZ niche of GSK-β-cateninA/- ; p53flox/flox mice does 
not cause CNS neoplasia ....................................................................................... 144 
4.3 Discussion ........................................................................................................................ 145 
4.4 Summary ......................................................................................................................... 149 
5 Analysis of β-cateninΔex3 expression in the CNS .................................................... 150 
5.1.1 Background ........................................................................................................... 150 
5.1.2 Aims ...................................................................................................................... 151 
5.1.3 Methods ................................................................................................................ 151 
5.2 Results ............................................................................................................................. 153 
5.2.1 Adeno-Cre treated β-cateninlox(ex3)/wt NSCs do not show an enhanced growth 
potential ................................................................................................................ 153 
5.2.2 Expression of β-cateninlox(ex3)/wt does not increase differentiation ....................... 160 
5.2.3 Nuclear wild type β-catenin is more abundant than nuclear β-cateninΔex3 in Adeno-
Cre treated cells .................................................................................................... 164 
5.2.4 En2-Cre; β-cateninlox(ex3)/wt mice show developmental abnormalities .................. 166 
9 | P a g e  
 
5.2.5 β-cateninlox(ex3)/wt mice develop SVZ hyperpasia, but no neoplasia following Adeno-
Cre injection .......................................................................................................... 169 
5.3 Discussion ........................................................................................................................ 171 
5.4 Summary ......................................................................................................................... 178 
6 Conclusion and future work ................................................................................ 179 
6.1 Summary ......................................................................................................................... 179 
6.2 Future work ..................................................................................................................... 180 
6.3 Synergism between Wnt/β-catenin, p53, PTEN and Rb pathways in CNS tumours ....... 180 
6.3.1 TP53, PTEN and RB in gliomas .............................................................................. 180 
6.3.2 TP53, PTEN and RB in medulloblastomas ............................................................. 181 
6.3.3 Tumour suppressor genes on chromosome 6 ...................................................... 183 
7 References .......................................................................................................... 185 
 
  
10 | P a g e  
 
Index of figures and tables 
Figure 1.1 Models for tumour development .................................................................................... 25 
Figure 1.2 Neurogenesis at the sub-ventricular zone of adult mice ................................................ 27 
Figure 1.3 A possible model for Wg synthesis and secretion ........................................................... 35 
Figure 1.4 Domains of the receptors of the Wnt signalling pathway (not to scale) ......................... 38 
Figure 1.5 Mechanism for Wnt protein antagonism......................................................................... 41 
Figure 1.6 Schematic representation of the Wnt/PCP pathway in Drosophila ................................ 43 
Figure 1.7 Wnt/Calcium pathway ..................................................................................................... 45 
Figure 1.8 Schematic representation of the Wnt/β-catenin pathway signalling cascade ................ 47 
Figure 1.9 Schematic representation of Wnt/β-catenin pathway intracellular members (not to 
scale) ................................................................................................................................................. 51 
Figure 1.10 Wnt/β-catenin pathway OFF state ................................................................................ 54 
Figure 1.11 Wnt/β-catenin pathway ON state .................................................................................. 58 
Figure 1.12 Activation of the cell cycle by cyclin D1 ......................................................................... 61 
Figure 1.13 Generation of knockout mice ........................................................................................ 77 
Figure 1.14 Cre-recombinase recombination events ....................................................................... 83 
Figure 2.1 Dissection of the SVZ part 1 ............................................................................................. 93 
Figure 3.1 pcall2-GSK-β-catenin-IRES-GFP vector ........................................................................ 106 
Figure 3.2 Cre-mediated recombination of pcall2-GSK-β-catenin-IRES-GFP results in expression of 
GSK-β-catenin and EGFP in N2a cells............................................................................................ 107 
Figure 3.3 Transfected ES cell clones were selected according to their EcoR I band pattern ........ 109 
Figure 3.4 GSK-β-catenin transgenic mice express LacZ in the brain ........................................... 111 
Figure 3.5 LacZ expression in somatic organs of GSK-β-catenin transgenic mice ........................ 112 
Figure 3.6 The ΔGSK-β-catenin construct is expressed in the CNS during development ............... 114 
Figure 3.7 Nestin-Cre recombination of GSK-β-catenin mouse brains (sagittal sections)............ 116 
Figure 3.8 Nestin-Cre recombination of GSK-β-catenin mouse brains (coronal sections) ........... 117 
Figure 3.9 Nestin-Cre recombination activates the expression of ΔGSK-β-catenin ....................... 119 
Figure 3.10 No abnormalities were detected in the cerebellum of Nestin-Cre; GSK-β-catenin mice
 ........................................................................................................................................................ 121 
Figure 3.11 No abnormalities in the hippocampus of Nestin-Cre; GSK-β-catenin brains ............ 122 
Figure 3.12 No abnormalities in the cortex and thalamus of Nestin-Cre; GSK-β-catenin brains . 123 
11 | P a g e  
 
Figure 4.1 Adeno-Cre infected NSCs express ΔGSK-β-catenin, but do not show increased cyclin D1 
levels ............................................................................................................................................... 130 
Figure 4.2 Adeno-Cre infected NSCs do not show increased proliferation potential ..................... 131 
Figure 4.3 Adeno-Cre infected NSCs are not bigger than controls ................................................. 132 
Figure 4.4 Adeno-Cre infected NSCs do not show increased self-renewal potential ..................... 133 
Figure 4.5 No obvious difference in the differentiation of ΔGSK-β-cateninA/- NSCs ....................... 134 
Figure 4.6 There are no abnormalities in the cerebellum of Nestin-Cre; GSK-β-catenin; p53-/- 
brains .............................................................................................................................................. 136 
Figure 4.7 There are no abnormalities in the hippocampus of Nestin-Cre; GSK-β-catenin; 
p53loxP/loxP brains .............................................................................................................................. 137 
Figure 4.8 There are no abnormalities in the cortex and thalamus of Nestin-Cre; GSK-β-catenin; 
p53loxP/loxP brains .............................................................................................................................. 138 
Figure 4.9 No significant difference in brain weight between GSK-β-cateninA/-; p53loxP/loxP and 
Nestin-Cre; GSK-β-cateninA/-; p53loxP/loxP mice .............................................................................. 139 
Figure 4.10 Adeno-Cre-infected GSK-β-cateninA/A; RbloxP/loxP and GSK-β-cateninA/A; p53loxP/loxP 
NSCs show a slightly enhanced proliferation potential .................................................................. 141 
Figure 4.11 Adeno-Cre-infected GSK-β-cateninA/A; RbloxP/loxP and GSK-β-cateninA/A; p53loxP/loxP 
neurospheres are smaller than controls ......................................................................................... 142 
Figure 4.12 Adeno-Cre-infected GSK-β-cateninA/A; p53loxP/loxP NSCs show higher self-renewal, but 
GSK-β-cateninA/A; RbloxP/loxP NSCs do not ....................................................................................... 143 
Figure 4.13 SVZ recombined GSK-β-cateninA/- ; p53flox/flox mice do not develop abnormal cell 
proliferations................................................................................................................................... 144 
Figure 5.1 Adeno-Cre infected β-cateninlox(ex3)/wt NSCs express β-cateninΔex3, but do not have 
increased cyclin D1 levels ............................................................................................................... 154 
Figure 5.2 The optimal starting cell number for the WST-1 proliferation assay is 3.5  x 103 cells/ml
 ........................................................................................................................................................ 155 
Figure 5.3 No difference in the proliferation of β-cateninΔex3 expressing NSCs (WST-1 proliferation 
assay) .............................................................................................................................................. 156 
Figure 5.4 No difference in the proliferation of β-cateninΔex3 expressing NSCs (Hoechst proliferation 
assay) .............................................................................................................................................. 157 
Figure 5.5 No difference in the size of neurospheres from β-cateninΔex3 expressing NSCs ............ 158 
Figure 5.6 There is no difference in self-renewal between Adeno-Cre and Adeno-GFP treated NSCs
 ........................................................................................................................................................ 159 
12 | P a g e  
 
Figure 5.7 β-cateninlox(ex3)/wt NSCs express MAP2, O4 and GFAP ..................................................... 161 
Figure 5.8 β-cateninlox(ex3)/wt NSCs express Nestin, β-catenin and GFAP ......................................... 162 
Figure 5.9 No difference in differentiation between Adeno-Cre and Adeno-GFP treated β-
cateninlox(ex3)/wt NSCs ........................................................................................................................ 163 
Figure 5.10 β-cateninΔex3 protein is not detected in the nucleus of Adeno-Cre recombined NSCs 165 
Figure 5.11 The cerebella of En2-Cre; β-cateninΔex3/wt mice show signs of severe hypoplasia 
(coronal) .......................................................................................................................................... 167 
Figure 5.12 The cerebella of En2-Cre; β-cateninlox(ex3)/wt mice show signs of severe hypoplasia 
(sagittal) .......................................................................................................................................... 168 
Figure 5.13 β-cateninlox(ex3)/wt mice develop SVZ enlargements after Adeno-Cre intra cranial (i.c.) 
injections ......................................................................................................................................... 170 
Figure 5.14 Patterning of the midbrain/hindbrain region .............................................................. 175 
Figure 5.15 Granule neurone development in mice ....................................................................... 177 
 
 
 
 
Table 1.1 Gene nomenclature of key Wnt pathway proteins, antagonists and receptors ............... 30 
Table 1.2 Nomenclature for genes involved in the Wnt/β-catenin pathway ................................... 48 
Table 1.3 Mutations of the Wnt/β-catenin pathway in selected human cancers ............................ 67 
Table 1.4 Hypermethylation of Wnt antagonists in selected human cancers .................................. 71 
Table 1.5 De-regulation of the Wnt/β-catenin pathway in CNS tumours ........................................ 72 
Table 1.6 Phenotypes of Wnt protein ‘conventional’ knockout mice .............................................. 79 
Table 1.7 Phenotypes of Fzd and Lrp ‘conventional’ knockout mice ............................................... 80 
Table 1.8 Phenotypes of Wnt/β-catenin downstream component ‘conventional’ knockout mice . 81 
Table 5.1 Selected literature regarding β-cateninΔex3 transgenic mice ........................................... 152 
Table 6.1 Selection of tumour suppressor genes located on the human chromosome 6 .............. 183 
 
  
13 | P a g e  
 
List of abbreviations and acronyms 
aa amino acid 
ACC Acinal cell carcinoma 
ADP Adenosine diphosphate ribose 
AIM1 Absent in melanoma 1 
APAF-1 Apoptotic protease-activating factor 1 
APC Adenomatous poliposis coli 
APS Ammonium Persulfate 
ARF ADP rybosylation factor 
AVL Avian leukosis virus 
Bax Bcl-2 associated X protein 
BCA Bicinchoninic acid 
Bcl-2 B-cell lymphoma 2 
BMP Bone morphogenic protein 
bp base pair 
BrdU 5-Bromo-2-deoxyuridine 
BSA Bovine serum albumin 
β-TrCP β-transducin repeats-containing protein 
Ca2+ Calcium 
CAK Cyclin activating kinase 
CaMK Calmodulin-dependent kinase 
cAMP cyclin Adenosine monophosphate 
CBP cAMP-binding protein 
CCNC Cyclin C 
Cdc42 Cell division cycle 42 
CDK Cyclin-dependent kinase 
CDKN1A Cyclin-dependent kinase inhibitor 1A 
cDNA complementary DNA 
Ck1α Casein kinase 1α 
cm centimetre 
CNS Central nervous system 
CRC Colorectal cancer 
CRD Cysteine rich domain 
Cre Causes recombination 
Cre-ER Cre-Oestrogen receptor binding-domain 
CSC Cancer stem cells 
CtBP C-terminal binding protein 
Daam1 Dishevelled associated activator of morphogenesis 1 
DAG Diacylglycerol 
Dally Division abnormally delayed 
DNA Deoxyribonucleic acid 
DEP Dvl-egl10-Pleckstrin 
Dgo Diego 
14 | P a g e  
 
DIX Dishevelled-Axin 
Dkk Dickkopf 
DLG Discs-large protein 
DlgA Drosophila disc large tumour suppressor 
Dly Dally-like 
DMEM Dulbecco’s modified Eagle’s medium  
DMSO Dimethyl sulfoxide 
dNTP deoxyribonucleotide triphosphate 
Drl Derailed 
Dsh/Dvl Dishevelled 
DTT Dithriothreitol 
E2F E2 transcription factor 
EB1 End-binding protein 1 
ECM Extracellular cell matrix 
EDTA Ethylenediaminetetraacetic acid 
EF3 Elongation factor 3 
EGF Epidermal growth factor 
EGL External granule layer 
En1/2 Engrailed 1/2 
ER Endoplasmic reticulum 
ER Oestrogen receptor 
ErB4 Oestrogen receptor β4  
ES Embryonic stem 
FAP Familial Adenomatous polyposis 
FCS Foetal calf serum 
FGFβ Fibroblast growth factor β 
Fmi Flamingo 
Fz Frizzled 
g gram 
g gravitational force 
GAG Glycosaminoglycan 
GBM Glioblastoma 
GBP Gsk3β binding protein  
Gbx2 Gastrulation brain homeobox 2 
GCN5 General control nonderepressible 5  
GFAP Glial fibrillary acidic protein  
GFP Green fluorescent protein 
GPI Glycosylphosphatidylinisotol 
GPCR G-protein coupled receptor 
Gsk3β Glycogen synthase kinase 3β 
H&E Haematoxylin and Eosin  
H3/4 Histone 3/4 
HAT Histone acetyltransferase 
HCC Hepatocellular carcinoma 
15 | P a g e  
 
HDAC Histone deacetylase 
HEAT Huntingtin-EF3-PP2A-TOR1 
HEK Human embryonal kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLH-LZ Helix-loop-helix leucine zipper 
HMG High mobility group 
HMT Histone methyltransferase 
HNPCC Hereditary non-polyposis colorectal carcinoma 
HRP Horseradish peroxidase 
HSPG Heparin sulfate proteoglycans 
IGL Internal granule layer 
IO Isthmic organizer  
IP3 Inositol 1,4,5-triphosphate  
IPTG isopropyl β-D-1-thiogalactopyranoside 
IQ Intelligence quotient 
IRES Internal ribosome entry site 
JNK Jun kinase 
kb Kilo base 
kDa Kilo Dalton 
Krm Kremen 
L Litre 
LATS1 Large tumour suppresor 1 
LB Luria-Bertani 
LDL Low-density lipoprotein 
LDLR LDL receptor 
LEF Lymphoid enhancer factor 
loxP Locus of crossover (x) in P1 
LPP Lipoprotein 
LRP LDLR-related protein 
M Molar 
MAP2 Microtubule associated protein-2  
MAPK Mitogen activated protein kinase 
MAPKKK Mitogen activated protein kinase kinase kinase 
Mcl-1 Myeloid cell leukaemia-1  
MCR Mutational cluster region 
MDCK Madin Darby canine kidney 
µg microgram 
mg milligram 
min minute 
µL microlitre 
mL millilitre 
MLH1/2 MutL homolog 1/2 
mM millimolar 
mm millimetre 
16 | P a g e  
 
µm micrometer 
µM micromolar 
MMP-7 Matrix metalloproteinase-7 
MOI Multiplicity of infection 
MOMP Mitochondrial outer membrane permeabilisation 
mRNA messenger RNA 
Nck2 NCK adaptor protein 2 
NeuN Neuronal nuclei 
NF200 Neurofilament 200 
NFAT Nuclear factor of activated T cells 
NFκB kappa-light-chain-enhancer of activated B cells  
ng nanogram 
NLK Nemo-like kinase 
NLS Nuclear localisation signal 
nm nanometre 
NOL7A Nucleolar protein 7 
NOS not otherwise specified 
NS Neurospehere 
NSC Neuronal stem cell 
OD Optical density 
Otx2 Orthodenticle homeobox 2 
P/S Penicillin/Streptamicin  
pA polyAdenosine 
PBS Phosphate buffered saline 
PCNA Proliferating cell nuclear antigen 
PCP Planar cell polarity 
PCR Polymerase chain reaction 
PDZ PSD95-DlgA-Zo1 
PI Phosphatidylinositol 
PI3K Phosphatidylinositol-3-kinase  
PIP2 Phosphatidylinositol (4,5) biphosphate 
Pk Prickle 
PKC Protein kinase C 
PLAGL1 Pleiomorphic Adenoma gene-like 1 
PLC Phospholipase C 
pM picomolar 
PMS2 Postmeiotic segregation increased 2 
PNET Primary neuroectodermal tumour 
porc Porcupine 
PP2A Protein phosphatase 2A 
PrP Prion protein 
PSD95 Post synaptic density protein 95 
PTCH Patched 
PTEN Phosphatase and tensin homolog 
17 | P a g e  
 
PTPRK Protein tyrosine phosphatase receptor K 
Rac Ras-related C3 botulinum toxin substrate  
Rb Retinoblastoma 
RGS Regulator of G protein signalling 
Rho Rhodopsin 
RhoA Ras homolog gene A  
RIPA Radio-immunoprecipitation assay 
RMS Rostral migratory stream 
RNA Ribonucleic acid 
Rok Rho kinase 
rpm revolution per minute 
rRNA ribosomal RNA 
RT Room temperature 
RTK Receptor tyrosine kinase 
S37A Serine37Alanine 
SAMP Serine-Alanine-Methionine-Proline 
SASH1 SAM and SH3 domain containing 1 
SCF Skp1-Cullin1-F box protein 
SCID Severe combined immuno-defficiency 
SCZ Sub-callosal zone 
SDS Sodium dodecyl sulphate 
sFRP secreted frizzled related protein 
SGZ Sub-granular zone 
shh sonic hedgehog 
SL-IC SCID leukaemia-initiating cell 
sPNET supratentorial PNET 
SPT Solid-pseudopapillary tumour 
Stbm Strabismus 
SVZ Sub-ventricular zone 
Syp Synaptophysin 
TAE Tris base-acetic acid-EDTA 
TBP TATA-binding protein 
TBST Tris-buffered saline Tween-20 
TCF T-cell factor 
TE Tris-EDTA 
TEAD1 TEA domain 1 
TEMED Tetramethylethylenediamine 
TGFβ Tumour necrosis factor β 
TIP TATA-interactive protein 
TLE-1 Transducin-like enhancer of split-1 
tRNA transfer RNA 
TRRAP Transformation/transcription domain-associated protein  
U units 
V volt 
18 | P a g e  
 
Vps Vacuolar sorting protein 
Wg Wingless 
WHO World health organisation 
WIF Wnt inhibitory factor 
Wls Wntless 
Wnt Wg/int 
Wts Warts 
WTX Wilms tumour gene on the chromosome X 
YAP1 Yes-associated protein 1 
Yki Yorkie 
Zo-1 Zonula occludens-1 protein  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 | P a g e  
 
1 Introduction 
Brain tumours are associated with poor prognosis and a high mortality rate. The current 
approach to treating these tumours is a combination of surgical resection, radiotherapy and 
chemotherapy depending on the specific type of tumour. Evidence suggests that a population of 
cells with stem-like properties exist within tumours, called ‘cancer stem cells’ (CSCs) (Al Hajj et al., 
2003; Bonnet and Dick, 1997; Singh et al., 2004). As these cells are rare, a small residual 
population may survive treatment; continue dividing and regenerate the tumour mass. Studies 
have demonstrated that these cells are resistant to chemotherapy and often have aberrant DNA 
repair mechanisms making them also resistant to radiotherapy (Bao et al., 2006; Woodward et al., 
2007). Therefore, it is imperative to carefully analyse the molecular and genetic mechanisms 
underlying the transformation of these cells in order to develop more specific and targeted 
treatments. Stem cells and ‘cancer stem cells’ share many common pathways, one of which is the 
Wnt/β-catenin pathway, important in differentiation, development and tumourigenesis (Haegele 
et al., 2003; Koch et al., 1999; Nusse and Varmus, 1982; Thomas and Capecchi, 1990). In this 
pathway, β-catenin, a nuclear protein, has a key role (Siegfried et al., 1994). 
To study the role of the Wnt/β-catenin pathway in tumourigenesis of the central nervous 
system (CNS) we developed a mouse model that inducibly expresses an oncogenic form of β-
catenin. More specifically, the well-established Cre-loxP system was used to induce expression in 
the CNS or in adult neural stem cells to determine the oncogenic potential of activating this 
pathway. 
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1.1 Brain tumours 
A tumour is an abnormal mass of tissue, which proliferates due to increased cell division 
and/or resistance to apoptosis. These properties, especially resistance to apoptosis, significantly 
increase the rate by which tumour cells accumulate random mutations. Some of these mutations 
confer improved growth/survival characteristics to tumour cells, which can result in a more 
aggressive phenotype (Sidransky et al., 1992). Brain tumours can be either primary (arising from 
brain tissue) or secondary (arising from other organs and spreading to the brain by metastasis or 
direct invasion). Brain tumours are classified according to the patterns or features they express. 
The World Health Organisation (WHO) classification of tumours of the CNS (2007) provides 
morphological and immunohistochemical criteria by which to classify brain tumours and predict 
their biological behaviour. This WHO classification also grades tumours according to their 
malignancy in a scale from I to IV.  
WHO grade I brain tumours are generally tumours with low proliferation, can be cured by 
surgical resection and have a low risk of recurrence. Grade II tumours also proliferate slowly, but 
they often recur after surgical resection, sometimes transforming to higher-grade tumours. 
Patients with WHO grade II tumours typically survive for more than five years following clinical 
diagnosis. In contrast, patients with WHO grade III tumours tend to survive for two to three years 
post-diagnosis. WHO grade IV tumours are the most malignant type and are rapidly fatal if left 
untreated. The prognosis of patients with WHO grade IV tumours is greatly determined by the 
availability of effective treatment regimens. 
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1.1.1 Medulloblastomas 
  Medulloblastomas (WHO grade IV) are the most common malignant brain tumours in 
childhood, affecting 1 in 200,000 children younger than fifteen years old (Central Brain Tumor 
Registry of the United States, 1995). Medulloblastomas are largely made up of poorly 
differentiated cells (Ellison, 2002). There have been significant advances in the treatment of 
childhood medulloblastomas; in the last five years 60-70 % of patients, compared to 30 % 
previously, survive for five years (Central Brain Tumor Registry of the United States, 2005). 
However, most patients suffer from severe long-term cognitive problems (Copeland et al., 1999; 
Mulhern et al., 1998; Mulhern et al., 1999; Mulhern et al., 2001; Palmer et al., 2001; Palmer et al., 
2003; Ris et al., 2001). The most common method for assessing these neuro-cognitive problems 
has been the Intelligence Quotient (IQ) test.  Longitudinal and cross-sectional studies on patients 
receiving treatment for medulloblastomas have consistently shown a significant correlation of IQ 
deficiency with tumour resection, radiation dose and age of treatment (Mulhern et al., 1999; 
Palmer et al., 2001; Palmer et al., 2003; Ris et al., 2001). Deficits in memory and attention have 
also been observed (Copeland et al., 1999; Mulhern et al., 1998; Mulhern et al., 2001). 
Histopathologically, medulloblastomas can be sub-divided into classic medulloblastoma, 
desmoplastic/nodular medulloblastoma, medulloblastoma with extensive nodularity, anaplastic 
medulloblastoma and large cell medulloblastoma. These sub-divisions correlate with prognosis 
and are therefore clinically relevant. Large cell and anaplastic medulloblastomas have significantly 
poorer prognosis, while medulloblastomas with nodular features tend to have a favourable 
outcome (Brown et al., 2000; Eberhart et al., 2002a; Giangaspero et al., 1992; Giangaspero et al., 
2006; Lamont et al., 2004; McManamy et al., 2003; Rutkowski et al., 2005; Sure et al., 1995). 
  The most common genetic event in medulloblastoma is isochromosomy of 17q. This 
entails loss of 17p and gain of a second copy of 17q, and occurs in up to 40 % of medulloblastoma 
cases (Bigner et al., 1988; Griffin et al., 1988). Other common chromosomal losses include 10q (21 
%), 8p (15-22 %), 16q (16-17 %) and 11q (11-16 %) (Eberhart et al., 2002b; Rickert and Paulus, 
2004).  
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1.1.1.1 De-regulation of developmental signalling pathways in medulloblastomas  
  The over-activation of developmentally important pathways such as Sonic Hedgehog, 
Notch and Wnt is common in medulloblastoma (Fan et al., 2004; Lasser et al., 1994; Pomeroy et 
al., 2002). The Sonic Hedgehog (Shh) pathway is activated in a subset of medulloblastomas and the 
most common event is inactivation of Patched (PTCH ) (8 % of medulloblastomas), which results in 
constitutive activation of the pathway (Pietsch et al., 1997; Raffel et al., 1997; Vorechovsky et al., 
1997; Wolter et al., 1997; Zurawel et al., 2000). Shh is an important mitogen for cerebellar granule 
cell progenitors, which are thought to be the cells of origin for the majority of medulloblastomas 
(Wechsler-Reya and Scott, 1999). Activation of the Shh pathway is associated with 
desmoplastic/nodular medulloblastomas (Pomeroy et al., 2002; Schofield et al., 1995; Thompson 
et al., 2006). 
  Adenomatous polyposis coli (APC) protein is a key negative regulator of the Wnt pathway 
originally identified as a mutant form in familial Adenomatous polyposis (FAP), an inherited colon 
cancer syndrome (Groden et al., 1991; Joslyn et al., 1991; Kinzler et al., 1991). FAP patients have 
an increased susceptibility for other types of cancer, one of which is medulloblastoma. 
Subsequently, mutations of components of the Wnt pathway have been found in approximately 
20 % of sporadic medulloblastomas (Table 1.5).  However, pathway activation has been identified 
in as many as 25 % of medulloblastomas (Eberhart et al., 2000; Ellison et al., 2005; Yokota et al., 
2002). Interestingly, although Wnt/β-catenin pathway activation is normally associated with 
enhanced proliferation and tumour aggressiveness, pathway activation in medulloblastomas 
appears to be a marker of favourable prognosis (Bondi et al., 2004; Clifford et al., 2006; Ellison et 
al., 2005; Kotsinas et al., 2002; Nhieu et al., 1999; Zechner et al., 2003). Studies have shown that 
92 % of patients with nucleo-positive β-catenin medulloblastomas have an overall survival of five 
years in contrast to 65 % percent of patients with non-nuclear (i.e. cytoplasm or membrane-
bound) β-catenin medulloblastomas (Clifford et al., 2006; Ellison et al., 2005). This prolonged 
survival may be due to the presence of fewer genetic mutations in medulloblastomas with an 
aberrant Wnt/β-catenin pathway (when compared to other medulloblastomas) (Clifford et al., 
2006). Genomic alteration analysis of three β-catenin nucleo-positive medulloblastomas using 
array-comparative genomic hybridization techniques found that these tumours possessed few 
chromosomal mutations other than the loss of a copy of chromosome 6 (chromosome 6 
monosomy) (Clifford et al., 2006). In contrast, sixteen β-catenin nucleo-negative 
medulloblastomas harboured widespread chromosomal abnormalities (Clifford et al., 2006).  
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1.1.2 CNS Primary neuroectodermal tumours (PNETs) 
  Another type of CNS tumours, in which aberrant activation of the Wnt/β-catenin pathway 
has been identified, is the primitive neuroectodermal tumours of the CNS (CNS PNETs). These are 
a group of heterogeneous embryonal tumours, which predominantly arise in children (Central 
Brain Tumor Registry of the United States, 2006). ‘CNS PNET, not otherwise specified’ (CNS PNET, 
NOS), also termed supratentorial PNET (sPNET), is a WHO grade IV tumour composed of 
undifferentiated or poorly differentiated neuroepithelial cells arising from within the brain. The 
incidence of these tumours is difficult to determine due to their rarity and unclear classification. 
The percentage of cells undergoing proliferation in sPNET is generally high, reaching up to 85 % 
within a high-power field of view. Although medulloblastomas are also called infratentorial PNETs, 
they do not share genetic similarity with sPNETs (Pomeroy et al., 2002). SPNETs are scarce, making 
it hard to determine the way in which these tumours arise. Wnt/β-catenin pathway activation has 
been observed in these tumours, but its role remains unclear (Koch et al., 2001; Rogers et al., 
2009).  
 
1.1.3 Turcot’s syndrome 
  Turcot’s syndrome is a rare hereditary disease and presents with CNS tumours and 
colorectal polyps or colorectal cancer (Hamilton et al., 1995; Lasser et al., 1994; Mori et al., 1994; 
TURCOT et al., 1959). According to the underlying genetic cause, Turcot’s syndrome can be divided 
into two types (Hamilton et al., 1995). Type I involves glioblastomas or astrocytomas along with 
hereditary non-polyposis colorectal carcinoma (HNPCC) and germline mutations in the DNA 
mismatch repair genes, postmeiotic segregation increased 2 (PMS2), mutL homolog 1 (MLH1) 
and/or MSH2 (Hamilton et al., 1995). Type II is characterised by medulloblastomas and FAP, as a 
result of APC truncation mutations in the germline (Hamilton et al., 1995; Lasser et al., 1994; Mori 
et al., 1994). 
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1.2 Stem cells & cancer stem cells 
  There are two hypotheses that explain how tumours arise and develop: the stochastic 
model and the hierarchical model [reviewed in (Dick, 2009)] (Figure 1.1). The stochastic model 
predicts that all the cells in a tumour are heterogeneous, but can promote tumour progression 
due to intrinsic or extrinsic variables [reviewed in (Dick, 2009)]. The hierarchical model predicts 
that only a small subset of cells in a tumour is capable of re-generating the bulk of the tumour, 
with the rest of the cells being more differentiated [reviewed in (Dick, 2009)]. The hierarchical 
model corroborates with the cancer stem cell (CSC) hypothesis, which postulates that tumours are 
initiated and maintained by a population of cells with similar properties to adult stem cells; 
termed CSCs (Al Hajj et al., 2003; Bonnet and Dick, 1997). The first of these cells to be described 
was the severe combined immunodeficiency (SCID) leukaemia-initiating cell (SL-IC) in 1997 
(Bonnet and Dick, 1997). Similarly, CSCs have been identified in breast and colon cancer and it is 
widely thought that the same may be true for most, if not all, cancers (Al Hajj et al., 2003; O'Brien 
et al., 2007; Ricci-Vitiani et al., 2007). Recently, a third model containing elements of both the 
hierarchical and stochastic models has been suggested [reviewed in (Greaves, 2010)]. This model 
proposes that CSCs in a tumour may be heterogeneous, with sub-clones becoming more or less 
dominant than others due to stochastic and seemingly random variations. 
  
25 | P a g e  
 
 
 
Figure 1.1 Models for tumour development
1
 
(A) Stochastic model for tumour development. This model predicts that all cells types in a tumour have the 
potential to be tumourigenic. (B) The hierarchical model predicts that only specific cells in a tumour have the 
capacity to drive tumour progression and re-generate the bulk of the tumour after treatment. The other cell 
populations in the tumour are made up of more differentiated cells. 
  
                                                          
1
 Adapted by permission from Macmillan Publishers Ltd: Nature Biotechnology, John E. Dick, Looking ahead 
in cancer stem cell research, 27, pp. 44-46, copyright (2009). 
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Stem cells are defined by two key properties: their ability to differentiate into multiple cell 
types of the organ they are derived from (multipotency), and their ability to divide symmetrically 
or asymmetrically to maintain the stem cell pool (self-renewal). 
  For many years, the adult brain was thought to be capable of proliferation (Altman and 
Das, 1965; Dacey and Wallace, 1974; MESSIER et al., 1958; Reynolds and Weiss, 1992). Since then, 
this has been convincingly demonstrated in rats, mice, humans and many other species (Eriksson 
et al., 1998; Gould et al., 1998; Kirschenbaum et al., 1994; Kukekov et al., 1999; Lois and Alvarez-
Buylla, 1993; Luskin, 1993). 
  To date, four distinct stem cell niches have been identified in the murine brain. These 
include (i) the sub-ventricular zone (SVZ) of the lateral ventricle, (ii) the sub-granular zone (SGZ) in 
the dentate gyrus of the hippocampus, (iii) the sub-callosal zone (SCZ) located between the 
hippocampus and the corpus callosum, and (iv) a reservoir between the internal granule layer 
(IGL) and the white matter of the cerebellum (Doetsch et al., 1999; Lee et al., 2005; Seri et al., 
2001; Seri et al., 2006). The largest of these areas is the SVZ (Figure 1.2). Alvarez-Buylla and 
colleagues identified a subset of cells within this area, which possess characteristics of both stem 
cells and astrocytes (Doetsch et al., 1999). These were termed B-type cells and were shown to 
regenerate the whole SVZ cell population following in vitro ablation (Doetsch et al., 1999). B-type 
cells are capable of slow division and differentiation into transiently amplifying C-type cells, which 
can rapidly proliferate and differentiate to give rise to large numbers of young neuroblasts (type A 
cells) (Doetsch et al., 1999). Type A cells are restricted to a neuronal fate and migrate along the 
rostral migratory stream (RMS) until they reach the olfactory bulb where they differentiate into 
interneurones (Doetsch and Alvarez-Buylla, 1996; Lois et al., 1996; Lois and Alvarez-Buylla, 1994). 
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Figure 1.2 Neurogenesis at the sub-ventricular zone of adult mice
2
 
(A) Diagram of a coronal section of a mouse brain. Neural stem cells (dark blue dots) are located in the sub- 
ventricular zone (SVZ) in the lateral wall of the lateral ventricle. These cells migrate out of the SVZ as they 
undergo differentiation. (B) Schematic diagram of cellular organisation of the SVZ at the lateral ventricle 
(LV), which comprises ependymal cells (E), type A neuroblasts (A), astrocytic putative stem cells (B), and 
transiently amplifying stem cells (C). (C) Type B cells undergo asymmetric division to generate a sister Type B 
cell and a Type C cell. Type C cells divide rapidly and differentiate to give rise to Type A neuroblasts, which 
migrate to the olfactory bulb to integrate as interneurones.  
                                                          
2
 Adapted by permission of Expert Reviews Ltd: Samantha J. Richardson et al., Hormones and adult 
neurogenesis in mammals, Expert reviews of Endocrinology & Metabolism, 2, pp. 261-276, copyright (2007). 
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  Neuronal stem cell (NSC) properties can be investigated in vitro by growing them under 
non-adherent conditions in medium rich in mitogens such as epidermal growth factor (EGF) and 
fibroblast growth factor β (FGFβ) (Doetsch et al., 1999; Doetsch et al., 2002; Gritti et al., 1996; 
Gritti et al., 1999). Under these conditions most differentiated cells undergo apoptosis, while NSCs 
grow in response to the growth factors. An interesting property of in vitro cultured stem cells is 
their ability to grow as spherical conglomerates, termed ‘neurospheres’ (NS). NSCs can be serially 
passaged and cultured under these conditions confirming their ability to self-renew (Gritti et al., 
1996). Upon removal of growth factors NSCs differentiate into neurones, astrocytes or 
oligodendrocytes (Gritti et al., 1996; Gritti et al., 1999). Cells with stem-like characteristics were 
discovered in glioblastoma multiforme and medulloblastoma after use of such mitogen-enriched 
medium (Hemmati et al., 2003; Ignatova et al., 2002). The study by Ignatova and colleagues 
showed that these cells form spheres and that they could be serially passaged and differentiated 
along neuronal and glial lineages (astrocytes, oligodendrocytes) (Ignatova et al., 2002). 
Furthermore, Hemmati et al, 2003 were able to show that transplantation of glioblastoma cells, 
grown in vitro, into nude mice reproduced the original tumour (Hemmati et al., 2003). Similarly, 
neurosphere growing cells from these tumours can be isolated and re-grafted to recapitulate 
glioblastoma, thus showing the in vivo self-renewal potential of these CSCs (Galli et al., 2004) .  
  The growth similarities between intrinsic NSCs and CSCs are a good indication that parallel 
growth, survival and proliferation pathways are active in both types of cells. An important pathway 
in stem cells proliferation and differentiation is the Wnt signalling pathway, which is the focus of 
this thesis. 
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1.3 Wnt Signalling 
Correct development requires precise coordination between evolutionary conserved 
signalling pathways [reviewed in (Chopra and Levine, 2009; Raible, 2006)]. One of these pathways 
is the Wnt signalling pathway, which has been shown to play a critical role in embryonic 
patterning/cell polarity, differentiation (Funayama et al., 1995; Huelsken et al., 2000; Lie et al., 
2005) and is de-regulated in tumours (Table 1.3 and Table 1.5). There are currently 19 Wnt 
proteins described in mammals (www.stanford.edu/~rnusse/Wntwindow.html). Loss of function 
of Wnt genes has been shown to cause severe developmental abnormalities (Table 1.6). There are 
at least three pathways attributed to Wnt proteins; the Wnt/planar cell polarity (PCP) pathway 
(also known as the Wnt/JNK pathway in vertebrates), the Wnt/Calcium (Ca2+) pathway and the 
canonical Wnt/β-catenin pathway. The focus of this thesis is on the canonical pathway, mainly 
because of its de-regulation in human cancers (Table 1.3 and Table 1.5). The Wnt/PCP and the 
Wnt/Ca2+ pathway will also be briefly described. 
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Table 1.1 Gene nomenclature of key Wnt pathway proteins, antagonists and receptors 
Values in parentheses are the number of known homologues 
 
Species 
Function in Wnt 
pathway 
Nomenclature (gene) 
Human Mouse Drosophila 
Wnt Ligand  WNT (19) Int/Wnt (19) Wg, DWnt (7)  
Porc Palmitoylation PORC (4) Porc (4) porc 
Wls Wnt secretion WLS  Wls wls 
Dkk Wnt antagonist DKK (4) Dkk  - 
sFRP Wnt antagonist SFRP1, 2, 4, 5, FRZB Sfrp1, 2, 4, 5, FrzB - 
Fz Receptor FZD (10), SMO Fzd (10), smo Fz, dfz (5) 
LRP Co-receptor LRP (2) Lrp (11) arrow  
Ryk Co-receptor RYK Ryk Derailed 
Ror Co-receptor ROR (2) Ror (2) Ror 
Knypek Co-receptor GPC4, GPC6 Gpc4, Gpc6 dlp 
Krm Co-receptor KREMEN (2) Kremen (2) - 
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1.3.1 Wnt synthesis and secretion 
1.3.1.1 Wnt Synthesis 
Wnt proteins are excreted as lipid-modified glycoproteins, which contain 23 cysteine 
residues, an N-terminal signal sequence and some possible N-glycosylation sites (Kurayoshi et al., 
2007; van Ooyen et al., 1985). The highly conserved spacing of the cysteine residues suggests that 
intra-molecular disulphide bridges may be important for correct Wnt protein folding. Although not 
evident from the primary sequence, Wnt proteins are lipid modified by palmitoylation at two 
residues (Takada et al., 2006; Willert et al., 2003). The first modification discovered was in 
Cysteine77 on Wnt3A (Willert et al., 2003). This residue, and by extrapolation the palmitate group, 
is conserved in all Wnt proteins. Mutation at this residue greatly impairs the signalling activity of 
Wnt proteins (Willert et al., 2003). Recently, a second lipid modification was identified at 
Serine209 on Wnt3A (Takada et al., 2006). This palmitoylation event is essential for proper 
intracellular trafficking of Wnt proteins as mutations have been demonstrated to lead to the 
accumulation of Wnt in the endoplasmic reticulum (ER) (Takada et al., 2006). The acyltransferase 
porcupine (porc) has been suggested to catalyse palmitoylation at this residue, as loss of function 
of this protein mimics the Serine209 phenotype (Takada et al., 2006). Porc encodes an ER multi-
pass transmembrane protein from the O-acyltransferase superfamily (Hofmann, 2000; Kadowaki 
et al., 1996). However, it is unclear if it also catalyses Cysteine77 palmitoylation, since any 
possible phenotype is probably masked by loss of the lipid modification at Serine209.  
  
32 | P a g e  
 
1.3.1.2 Wnt Secretion 
Recent studies have identified factors involved in Wnt protein secretion (Bartscherer et 
al., 2006; Coudreuse et al., 2006). These factors consist of the retromer complex and the 
multi-pass transmembrane protein Wntless (WLS). Three independent laboratories have 
identified a protein called Wntless (Wls), which is required for secretion of Wnt proteins, in vivo and 
in vitro (Banziger et al., 2006; Bartscherer et al., 2006; Goodman et al., 2006). Wls is a multi-pass 
transmembrane protein conserved in C. elegans and mammals, which directly interacts with Wnt 
proteins (Banziger et al., 2006; Bartscherer et al., 2006; Goodman et al., 2006). It has been localised at 
the plasma membrane, the Golgi and endosomes (Bartscherer et al., 2006; Belenkaya et al., 2008; 
Port et al., 2008). Whereas the molecular function of Wls remains to be elucidated, it has been 
proposed to help localisation and secretion of Wnt proteins (Yang et al., 2008). Studies using a Wls-
green fluorescent protein (GFP) fusion protein have shown that Wls is enriched in the apical 
membrane of polarised Drosophila follicle cells and largely absent at the basolateral membrane 
(Bartscherer et al., 2006). Wingless (Wg), the Drosophila Wnt protein, accumulates at the apical side 
of polarised cells, but is retained in the ER in the absence of Wls (Marois et al., 2006; Port et al., 2008). 
This supports the idea that Wls might work as a cargo receptor assisting Wg/Wnt to reach the apical 
membrane, from where it is released (Figure 1.3). 
In 2006, the retromer was shown to be able to regulate Wnt proteins (Coudreuse et al., 2006; 
Prasad and Clark, 2006). The retromer is a complex of evolutionary conserved proteins from the Vps 
family. In yeast, the retromer complex is made up of Vacuolar sorting protein (Vps) 5, Vps17, Vps26, 
Vps29 and Vps35 and orthologs exist in C. Elegans, Drosophila and mammals [reviewed in (Seaman, 
2005)]. These proteins function to selectively retrieve cargo receptors to the Golgi to rescue them 
from endosome-mediated degradation (Arighi et al., 2004; Seaman, 2004). A key example of this is 
the recovery of mannose-6-phosphate in mammals (Arighi et al., 2004). In the absence of retromer, 
Wnt protein secretion is abrogated (Coudreuse et al., 2006). This phenotype closely resembles loss of 
Wls, suggesting that the retromer might act by recycling Wls back to the Golgi (Belenkaya et al., 2008; 
Franch-Marro et al., 2008; Port et al., 2008). This hypothesis is strengthened by assays showing co-
immunoprecipitation of Vps35 and Wls and antibody-uptake assays showing recycling of Wls 
(Belenkaya et al., 2008; Franch-Marro et al., 2008). 
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1.3.1.3 Extra-cellular transport 
Extra-cellular detection of Wg in wing imaginal discs reveals two types of signalling: a steep 
and narrow gradient at the apical side termed short-range signalling and a broad Wg gradient across 
the basolateral surface, termed long-range signalling (Panakova et al., 2005; Strigini and Cohen, 2000). 
The latter type is capable of up-regulating genes up to twenty to thirty cells away from the secreting 
cells (Zecca et al., 1996). The way this is achieved is currently unclear as Wnt proteins are hydrophobic 
and possibly membrane-bound through lipid modifications (Takada et al., 2006; Willert et al., 2003). 
Currently, there are two hypotheses to explain how long-range signalling may occur. First, studies 
have indicated that palmitoylation may allow Wnt proteins to interact with each other to form 
multimeric complexes (Takada et al., 2006; Willert et al., 2003). Palmitoylation has been implicated in 
the extracellular movement of Hedgehog, another lipid-modified secreted morphogen (Chen et al., 
2004). In this manner Wnt proteins could overcome their inherent hydrophobicity and potentiate 
their signalling capacity. Second, recent studies in Drosophila have suggested that Wnt proteins may 
be secreted bound to lipoproteins (LPPs), which could act as vehicles facilitating long-range signalling 
(Panakova et al., 2005). LPPs are spherical bodies consisting of a lipid monolayer, apolipoproteins and 
cholesterol, which contain triacylglycerides in their core [reviewed in (Brown and Goldstein, 1986)]. 
Once they bind to low density lipoprotein (LDL) receptors on receptor cells, they are endocytosed and 
their cargo is used by the cell [reviewed in (Brown and Goldstein, 1986)]. In Drosophila, Wg has been 
found to be associated with LPPs in the extracellular space and loss of lipophorin (the Drosophila LPP) 
reduces the range of Wg signalling (Panakova et al., 2005). Both Wg and lipophorin localise to 
endosomes (Chen et al., 2004). As such, it is possible that they become loaded into lipophorin and 
subsequently secreted at the basolateral membrane (Chen et al., 2004).   
Accumulating evidence suggests that glycosaminoglycan (GAG)-modified proteins might 
facilitate the extracellular movement of Wnt proteins (Baeg et al., 2001; Lin and Perrimon, 1999; 
Nakato et al., 1995; Perrimon et al., 1996; Tsuda et al., 1999). In Drosophila, mutations in two 
enzymes involved in the synthesis of heparin sulphate proteoglycans (HSPGs), namely sugarless 
(encodes a UDP-glucose dehydrogenase) and sulfateless (encodes a heparin sulphate N-
deacetylase/N-sulfotransferase), result in aberrant Wg signalling (Binari et al., 1997; Hacker et al., 
1997; Haerry and Gehring, 1997; Lin and Perrimon, 1999). HSPGs are extracellular cell membrane and 
cell surface proteins with attached heparin sulphate GAGs [reviewed in (Bernfield et al., 1999)]. 
Various genetic screens have shown that two HSPGs, Dally (division abnormally delayed) and Dally-
like (Dly) appear to be required for Wnt signalling (Baeg et al., 2001; Tsuda et al., 1999). This became 
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apparent when a study using dsRNA to knock-down the expression of these proteins recapitulated the 
phenotype seen when Wg is lost (Baeg et al., 2001; Tsuda et al., 1999). Dally and Dly belong to the 
glypican family of cell surface HSPGs, and are linked to the plasma membrane via a 
glycosylphosphatidylinisotol (GPI) anchor (Tsuda et al., 1999). The exact method by which these 
receptors mediate Wnt protein signalling is not understood. It has been hypothesised that they may 
interact with secreted Wnt proteins to sequester them at the membrane and promote binding to Wnt 
receptors (Cadigan et al., 1998). Alternatively, interaction between Wnt proteins and Dally and Dly 
may be required for endocytosis and recycling of Wnt proteins. Finally, it may be that GPI-linked Dally 
and Dly stabilise Wnt proteins as they are transported in LPPs. Experimental evidence for this later 
hypothesis came from GFP studies in LPPs of Drosophila wing imaginal disc cells, which were found to 
express GPI-linked GFP (Greco et al., 2001).  
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Figure 1.3 A possible model for Wg synthesis and secretion
3
 
Wingless (Wg) is palmytoylated by Porcupine (Porc) in the endoplasmic reticulum. Subsequently, Wg is 
transported through the Golgi apparatus and secreted to the apical side in a complex with Wntless (Wls). At 
the apical side, Wg can mediate short range signalling. For basolateral secretion, Wg is endocytosed 
alongside Wls. In the endosome, Wls dissociates from Wg and is recycled to the Golgi apparatus by the 
retromer complex. Wg complexes with lipoproteins and is secreted at the basolateral side, where it can 
mediate long-range signalling.  
                                                          
3
 Adapted by permission of Macmillan Publishers Ltd: EMBO Reports, Kerstin Bartscherer & Michael Boutros, 
Regulation of Wnt protein secretion and its role in gradient formation, 9, pp. 977-982, copyright (2008). 
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1.3.2 Receptors  
 There are two main types of receptors required for Wnt protein signal transduction: 
Frizzled receptors (Fz) and LDL receptor (LDLR)-related receptor proteins (LRPs) (Wehrli et al., 
2000; Yang-Snyder et al., 1996). Fz are seven-pass transmembrane receptors, which are a common 
component of all three Wnt pathways. All Fz proteins share a highly glycosylated N-terminus 
containing ten invariantly spaced cysteines which is called the cysteine-rich domain (CRD) (Wang 
et al., 1996). Additionally, Fz proteins contain a conserved seven-pass transmembrane domain and 
an intracellular domain with little homology between family members (Wang et al., 1996) (Figure 
1.4). Wnt proteins interact with Fz receptors via their CRD domain (He et al., 1997; Yang-Snyder et 
al., 1996). This interaction has been successfully characterised in Drosophila where Wg binds to 
Drosophila Fz1 (DFz1) and DFz2 with an affinity coefficient of 10-8M and 10-9M respectively 
(Bhanot et al., 1996; Rulifson et al., 2000). The precise mechanism by which Wnt protein signals 
are transduced is not known, but evidence suggests that heterotrimeric G proteins are involved 
(Liu et al., 2001; Slusarski et al., 1997a). This leads to the activation of either of the known Wnt 
signalling pathways (Wnt/PCP, Wnt/Ca2+, Wnt/β-catenin). This is an inherently complicated 
process, not only because of the large diversity of Wnts (19 in mammals) and Fzs (10 in humans 
and mice), but also because of difficulties encountered in attempts to purify Wnt proteins (Willert 
et al., 2003). Furthermore, some Wnt proteins can induce distinct Wnt pathways by interacting 
with different Wnt receptors. For example, Wnt5a can induce the Wnt/β-catenin pathway when it 
interacts with Fz5 or Fz4 (He et al., 1997; Mikels and Nusse, 2006). On the contrary, when the 
same protein interacts with Ror2, an alternative Wnt receptor, it is capable of inducing the 
Wnt/PCP pathway (Mikels and Nusse, 2006). Therefore, the action of Wnt proteins depends on 
the various Wnt protein receptors expressed by cells or tissues. 
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 Whilst Wnt/Fz interaction is sufficient for inducing non-canonical Wnt pathways, 
activation of the Wnt/β-catenin pathway also requires the involvement or LRPs (Semenov et al., 
2001; Wehrli et al., 2000). In Drosophila, the co-receptor is named Arrow (Wehrli et al., 2000) and 
in vertebrates two LRP proteins have been identified; LRP5 and LRP6 (Pinson et al., 2000; Tamai et 
al., 2000). Drosophila mutants lacking Arrow reproduced Wg loss whereas LRP6 knockout mice 
resembled Wnt protein knockout defects (e.g. mid and hindbrain defects, ventralization of limbs 
etc.) (Pinson et al., 2000). Furthermore, truncated LRP5/6 lacking the extracellular domain, but still 
anchored to membrane, where shown to constitutively activate the canonical pathway (Brennan 
et al., 2004; Mao et al., 2001a; Mao et al., 2001b). Whilst the precise method of signal 
transduction is not known, it is thought that trimerisation of Wnt, Fz and LRP may be required 
(Schweizer and Varmus, 2003).   
In addition to Fz and LRP two more types of potential transducers of Wnt signalling have been 
discovered. The first of these is Ror2, a single-pass transmembrane protein of the receptor 
tyrosine kinase (RTK) (Oishi et al., 2003). This receptor interacts with Wnt5a to activate the 
Wnt/JNK pathway (Mikels and Nusse, 2006; Oishi et al., 2003). Ror2 deficient mice exhibit skeletal, 
genital and cardiovascular abnormalities that have been attributed to aberrant convergent 
extension during gastrulation, a process mediated by the Wnt/JNK pathway in vertebrates (Oishi 
et al., 2003). The second type of receptor is Ryk and its Drosophila (Derailed, Drl) and C. Elegans 
(Lin-18) homologues (Hovens et al., 1992; Inoue et al., 2004; Yoshikawa et al., 2003). Studies in 
human embryonic kidney cells (HEK293) have shown that Ryk induces the Wnt/β-catenin pathway 
as a co-receptor with Fz and Wnt proteins (Lu et al., 2004). Functionally, Ryk appears to be 
required for neurite outgrowth, induced by Wnt3a and Wnt1, and for corticospinal tract axon 
repulsion, induced by Wnt1 and Wnt5a (Liu et al., 2005; Lu et al., 2004). Interestingly, Ryk contains 
an extracellular domain similar to the secreted Wnt inhibitor factor-1 (WIF), which is thought to 
mediate Ryk/Wnt interaction (Patthy, 2000). 
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Figure 1.4 Domains of the receptors of the Wnt signalling pathway (not to scale) 
Ryk contains an intracellular tyrosine kinase and an extracellular Wnt inhibitory factor (WIF) domain. Ror2 
contains an intracellular tyrosine kinase and an extracellular Kringle domain, cysteine-rich domain (CRD) and 
an immunoglobulin (IG) domain. Kremen1/2 contains three extracellular kringle domains. LRP5/6 contains 
three low-density lipopropretin receptor (LDLR) domains and four epidermal growth factor-like (EGF) 
domains. Frizzled contains an extracellular CRD domain. 
  
39 | P a g e  
 
1.3.3 Extracellular Antagonists of the Wnt pathway 
Binding of Wnt proteins to receptors is modulated by endogenously-secreted antagonists 
(Bafico et al., 1999; Glinka et al., 1998) (Figure 1.5). These antagonists can be divided into two 
functional classes: secreted frizzled related proteins (sFRPs) and Dickkopf (DKK) proteins (Bafico et 
al., 1999; Semenov et al., 2001). Members of the sFRP group include the sFRP family, WIF-1 and 
Cerberus. There are currently eight known sFRP family members, namely sFRP1 to 5, Sizzled, 
Sizzled2 and Crescent. These can be further sub-divided based on sequence homology: sFRP1, 
sFRP2 and sFRP5 form one group, and sFRP3 and sFRP4 form the second group. SFRP1 to 5 have 
not been identified in invertebrates, and Sizzled, Sizzled2 and Crescent, which make up the final 
subgroup, have not been identified in mammals. Structurally, sFRPs show homology with the Fz 
CRD domain at the N-terminus and with Netrin, an axonal guidance protein, at the C-terminus 
(Banyai and Patthy, 1999; Melkonyan et al., 1997). The antagonistic effect of sFRPs is thought to 
arise from the interaction of their CRD-like domain with Wnt proteins (Lin et al., 1997). However, 
sFRP1 has also been found to interact with Fz (Bafico et al., 1999). Thus, sFRPs might modulate 
Wnt signalling by physically interacting with Wnt proteins or by preventing Wnt proteins from 
binding to Fz. 
However, sFRPs do not always act as antagonists (Melkonyan et al., 1997; Uren et al., 
2000). In vitro experiments with Madin Darby canine kidney (MDCK) cells demonstrated that 
sFRP1 could potentiate Wg signalling at low concentrations (Uren et al., 2000). This potentiation 
was observed with truncated sFRP1 lacking the CRD domain, suggesting that the Netrin-like 
domain (NTR) may serve as a high affinity binding site for Wg (Uren et al., 2000). An alternative 
hypothesis is that at high concentrations sFRP1 could interact with Frizzled, preventing 
Frizzled/Wg interaction. Indeed, sFRP1 was found to interact with human Fz6 (Bafico et al., 1999). 
The obvious caveat with these assays is that they involve Drosophila Wg rather than mammalian 
Wnt. Although there is a high degree of conservation between Wg and Wnt proteins, it is possible 
that they interact differently with sFRPs. Similarly to sFRP1, sFRP2 can also function both as an 
antagonist and as an agonist (Ladher et al., 2000; Melkonyan et al., 1997). Injection of sFRP2 into 
Xenopus embryos blocks the dorsalising activity of Wnt-8 (Ladher et al., 2000). However, sFRP2 
has been shown to block the antagonistic activity of sFRP1 when co-expressed in the metanephric 
kidney (Yoshino et al., 2001). 
Although sFRPs have been postulated to be tumour suppressor genes, no genetic 
mutations have been discovered to date. Nonetheless, sFRP1 is found to be downregulated in 
cervical, kidney, breast and ovary carcinoma (Ko et al., 2002; Ugolini et al., 2001; Zhou et al., 
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1998). Furthermore, chromosome 8p21, where sFRP1 is located, is frequently lost in human 
cancers (Wright et al., 1998). Lastly, sFRP promoters have been shown to be commonly 
hypermethylated in human cancers (Table 1.4 and Table 1.5).  
The other group of antagonists, the Dickkopf (DKK) family, comprises five members: DKK1, 
DKK2, DKK3, DKK4, and a DKK3 related protein called Soggy. The most extensively studied member 
of this family is DKK1. Studies with Dkk1 knockout mice and experiments using injection of Dkk1 
messenger RNA (mRNA) into Xenopus embryos have demonstrated a lack of anterior head 
structures, highlighting the importance of Dkk1 in head formation (Glinka et al., 1998). In a similar 
fashion to sFRP2 and sFRP3, DKK1 can also block Xenopus Wnt-8 effects (XWnt8) (Glinka et al., 
1998). Unlike sFRPs, DKK1 does not inhibit activation of the Wnt signalling pathway by binding to 
Wnt proteins; it binds to LRP5/6 instead (Bafico et al., 2001; Semenov et al., 2001). DKK1 mediates 
the internalisation of LRP5/6 by forming a ternary complex with the single-pass transmembrane 
protein Kremen1 (Krm1) and Krm2 (Mao et al., 2002). As mentioned in section 1.3.2, LRP5 and 
LRP6 are solely required for the activation of the canonical Wnt/β-catenin pathway. This is 
exemplified by the inability of DKK1 and degradation-resistant LRP6 to inhibit the Wnt/PCP 
pathway (Semenov et al., 2001). Moreover, there is also evidence to suggest that DKK1 may be 
able to activate the Wnt/PCP pathway (Caneparo et al., 2007). 
Whereas DKK4 functions in the same manner as DKK1, DKK3 and Soggy have no effect on 
the Wnt signaling pathway (Krupnik et al., 1999; Mao and Niehrs, 2003). DKK2 appears to have 
both antagonistic and agonistic effects on Wnt signaling. DKK2 can bind to LRP6 and Krm2 to 
antagonise Wnt1 and XWnt8 binding (Brott and Sokol, 2002; Mao et al., 2002; Wu et al., 2000). 
However, ectopic expression of DKK2 in Xenopus embryos has shown that it synergises with LRP6 
to potentiate axis duplication, an effect of Wnt/β-catenin pathway activation (Brott and Sokol, 
2002). This synergism was shown to be prevented by co-expression of Krm2, and therefore 
suggests that the relative levels of LRP5/6 and Krm2 dictate whether DKK2 functions as an agonist 
or antagonist (Mao and Niehrs, 2003). 
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Figure 1.5 Mechanism for Wnt protein antagonism 
Wnt proteins interact with Frizzled and Frizzled/LRP to activate the Wnt pathway. Secreted frizzled related 
proteins (sFRPs) inhibit the Wnt pathway by sequestering Wnt proteins. On the other hand Dickkopf (DKK) 
proteins specifically inhibit the Wnt/β-catenin pathway by promoting the internalisation of LRP5/6. 
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1.3.4 The Wnt/PCP or Wnt/JNK pathway 
Cells in tissues are highly coordinated both in terms of their arrangement and function. A 
key feature of this coordination is polarisation. The most common form of polarisation is the 
apical/basal polarisation of epithelial cells [reviewed in (Simons and Fuller, 1985)]. Nevertheless, 
polarisation has also been found to be essential for wing hair and eye photoreceptor orientation in 
Drosophila, mitotic spindle orientation in invertebrates, hair orientation, neural tube closure, 
convergent extension in mammals and ciliogenesis (De Calisto et al., 2005; Gubb and Garcia-
Bellido, 1982; Park et al., 2006; Veeman et al., 2003; Zheng et al., 1995). This polarisation is 
controlled by the Wnt/Planar cell polarity (PCP) pathway in Drosophila, which in vertebrates is 
called the Wnt/JNK pathway (Figure 1.6).  
PCP was first recognised in Oncopeltus fasciatus and studies in Drosophila helped to 
elucidate many of the components of the pathway (Lawrence, 1966). The two most studied PCP 
events in Drosophila are wing hair orientation and the polarity of photoreceptors in ommatidia 
(the units that make up the compound eyes). In the wing, planar cell polarity is dependent on the 
arrangement of six proteins, Fz, Dishevelled (Dsh), Flamingo (Fmi), Diego (Dgo), Strabismus (Stbm) 
and Prickle (Pk) (Chae et al., 1999; Klingensmith et al., 1994; Taylor et al., 1998; Vinson et al., 
1989). These localise proximally or distally in the cells to coordinate actin microfilaments (Chae et 
al., 1999; Klingensmith et al., 1994; Taylor et al., 1998; Vinson et al., 1989). In vertebrates, 
activation is achieved by Wnt11 orWnt5A binding to Fz receptor (Heisenberg et al., 2000; Moon et 
al., 1993). The intracellular domain of Fz interacts with Dsh to activate the Rhodopsin (Rho) 
GTPases ras homolog gene A (RhoA), ras-related C3 botulinum toxin substrate (Rac) and cell 
division cycle 42 (Cdc42) (Fukukawa et al., 2009; Tanegashima et al., 2008). These GTPases 
regulate the activity of Rho kinase (Rok), which activates the mitogen activated protein kinase 
(MAPK) cascade culminating in the activation of Jun kinase (JNK) (Fukukawa et al., 2009; Winter et 
al., 2001). JNK in turn phophorylates c-Jun, which activates gene transcription (Pulverer et al., 
1991; Smeal et al., 1991). The process by which c-Jun promotes cell polarity is not yet fully 
understood.  
43 | P a g e  
 
 
 
Figure 1.6 Schematic representation of the Wnt/PCP pathway in Drosophila
4
 
Induction of the Wnt/Planar cell polarity pathway (Wnt/PCP) activates dishevelled (Dsh in Drosophila). Dsh 
in turn mediates the activation of ras-related C3 botulinum toxin substrate (Rac), cell division cycle 42 
(Cdc42) and Rhodopsin (Rho). Cdc42 and Rho kinase mediate actin cytoskeleton remodelling. On the other 
hand, Rac promotes the activation of Jun Kinase (JNK). JNK phosphorylates c-jun and activates it. Activated 
c-jun promotes the expression of genes required for cell polarity.  Prickle, Strabismus and Flamingo localise 
to the proximal or distal side of the cell, where they help organise PCP. However, the precise mechanism 
remains to be elucidated. 
 
                                                          
4
 Adapted from Seminars in Cell and Developmental Biology, 20, Roszko et al., Regulation of convergence 
and extension movements during vertebrate gastrulation by the Wnt/PCP pathway, pp. 986, 997, copyright 
(2009), with permission from Elsevier. 
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1.3.5 The Wnt/Ca2+ pathway 
The latest pathway to be linked to Wnt proteins is the Wnt/Ca2+ pathway (Figure 1.7). Wnt 
proteins were first linked to calcium signalling ten years ago, following the injection of Xenopus 
Wnt5A and/or rat Fz2 mRNA into early Zebrafish embryos, which resulted in intracellular Ca2+ 
release in a manner dependent on G-protein coupled receptors (GPCRs) and the 
phosphatydilinositol (PI) cycle (Ma and Wang, 2006; Slusarski et al., 1997a; Slusarski et al., 1997b). 
Furthermore, the expression of Pk, Wnt4, Wnt5 and Wnt11 has also been shown to stimulate Ca2+ 
release in Zebrafish embryos (Veeman et al., 2003; Westfall et al., 2003). One of the main classes 
of receptors that activate the PI cycle are G-protein coupled receptors (GPCRs) (Ma and Wang, 
2006; Slusarski et al., 1997a; Slusarski et al., 1997b). These receptors activate PI-specific 
phospholipase C (PLC) that cleaves membrane-bound phosphatidylinositol (4,5) biphosphate 
(PIP2) into membrane-bound diacylglycerol (DAG) and cytoplasmic inositol 1,4,5-triphosphate 
(IP3) [reviewed in (Berridge et al., 2000)]. IP3 subsequently binds to Ca2+ channels in the ER, 
thereby triggering the rapid release of Ca2+ into the cytoplasm [reviewed in (Berridge et al., 2000)]. 
Intracellular Ca2+ ions are rapidly taken up by proteins, which either act as Ca2+ buffers or require 
Ca2+ for activation. Two notable enzymes activated by Ca2+ ions are calmodulin and protein kinase 
C (PKC) (Haiech et al., 1981; Oancea and Meyer, 1998; Sakai et al., 1997). Calmodulin activates 
protein kinases like Ca2+/calmodulin-dependent kinases (CaMK), phosphatases, ion transporters 
and cytoskeletal proteins (Hoeflich and Ikura, 2002). A vital phosphatase activated in this manner 
is calcineurin, which activates the transcription factor nuclear factor of activated T cells (NFAT) 
(Ruff and Leach, 1995). Wnt-induced release of intracellular Ca2+ has since been shown to activate 
PKC, Calmodulin/CaMKII, and Calcineurin/NFAT, suggesting that Wnt proteins can activate the PI 
cycle (Kuhl et al., 2000; Saneyoshi et al., 2002; Sheldahl et al., 1999). Interestingly, the Wnt/Ca2+ 
pathway has been linked with Nemo-like kinase (NLK) activation, which can antagonise the Wnt/β-
catenin pathway (Ishitani et al., 2003). Finally, the Wnt/Ca2+ pathway has also been shown to be 
important for the patterning of embryos, regulation of the Wnt/β-catenin pathway and 
tumourigenesis (Weeraratna et al., 2002). 
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Figure 1.7 Wnt/Calcium pathway 
Activation of the Wnt/Calcium pathway promotes the activation of phospholipase C, which cleaves 
membrane-bound phosphatidylinositol (4,5) biphosphate (PIP2) into membrane-bound diacylglycerol (DAG) 
and cytoplasmic inositol 1,4,5-triphosphate (IP3). IP3 binds to Calcium channels in the endoplasmic 
reticulum (ER), which promotes the release of Calcium ions into the cytoplasm. Three proteins activated by 
calcium ions are Calcineurin, Ca
2+
/calmodulin-dependent kinases (CamKII) and Protein kinase C (PCK). PCK 
additionally can be activated by DAG. Calcineurin promotes transcription, whilst PCK promotes the 
phosphorylation of target genes. CamKII phosphorylates and activates TGFβ activated kinase 1 (TAK1). TAK1 
in turn phosphorylates nemo-like kinase (NLK), which translocates into the nucleus and inhibits β-catenin-
dependent gene transcription. 
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1.3.6 The canonical Wnt/β-catenin pathway  
As the name implies, the key component of the Wnt/β-catenin pathway is β-catenin. β-
catenin is a 780 amino acid (aa) protein, which was originally identified as a component of E-
cadherin junctions, where it links E-cadherin with α-catenin and consequently to the actin 
cytoskeleton (Aberle et al., 1996; Redies and Takeichi, 1996; Takeichi, 1991). However, β-catenin 
was subsequently shown to be a component of the Wnt signalling pathway (Funayama et al., 
1995). As shown in Figure 1.8, in the absence of Wnt proteins (OFF state), cytoplasmic β-catenin is 
efficiently degraded via phosphorylation-dependent ubiquitinylation (Hart et al., 1999; Marikawa 
and Elinson, 1998). However, in the presence of Wnt proteins (ON state) this phosphorylation, and 
thus degradation, is abolished (Liu et al., 2002). Stable cytoplasmic β-catenin translocates into the 
nucleus and interacts with T-cell factor/Lymphoid enhancer factor (TCF/LEF) to promote the 
expression of over thirty genes; including oncogenes such as the cell cycle regulator cyclin D1, the 
transcriptional factor c-myc and the extracellular cell matrix (ECM)-degrading enzyme matrilysin 
(Crawford et al., 1999; He et al., 1998; Shtutman et al., 1999). 
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      OFF State         ON State 
 
Figure 1.8 Schematic representation of the Wnt/β-catenin pathway signalling cascade 
In the absence of Wnt proteins, cytoplasmic β-catenin is phosphorylated by CKIα and GSK3β and targeted 
for degradation by ubiquitination. The interaction of Wnt proteins with Frizzled/LRP stabilises β-catenin by 
disrupting the ‘destruction complex’ (Dvl, Axin, APC, CKIα and GSK3β). Stable cytoplasmic β-catenin 
translocates into the nucleus and activates gene expression by interacting with TCF/LEF. 
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Table 1.2 Nomenclature for genes involved in the Wnt/β-catenin pathway  
Numbers in parentheses represent the number of known homologues 
 
Species Function in Wnt pathway 
Nomenclature (gene) 
Human Mouse Drosophila 
Ck1ε Dvl phosphorylation CKIε Ck1ε dco 
Dvl 
Disrupts the ‘destruction 
complex’ 
DVL (3) Dvl (3) dsh 
Axin Scaffold AXIN (2) Axin (2) daxin  
Gsk3β Phosphorylation GSK3 Gsk3β  sgg 
Ck1α Phosphorylation CKIα Ck1α ck1α 
Apc Scaffold APC, APC2/ APCL Apc (2) dapc, E-apc 
β-catenin Transcriptional factor CTNNB1 Ctnnb1  armadillo 
β-TrCP Ubiquitination β-TrcP (2) β-TrcP (2) slimb  
GBP GSK3β antagonist FRAT (2) Frat (2) - 
TCF/LEF Transcription factor TCF, LEF (4) Tcf/Lef (4) pangolin 
Groucho Transcription repressor TLE1, 2, 3, 4, 6 Tle1, 2, 3, 4, 6 groucho 
CtBP Transcription repressor CTBP (2) Ctbp (2) CtBP 
CBP 
Transcription 
repressor/activator 
CREBBP Crebbp CBP 
Legless Transcription factor BCL9 Bcl9 legless 
Pygopus Transcription factor PYGO (2) Pygo (2) pygopus  
TBP Transcription factor TBP Tbp tbp 
TIP48 Transcription factor RUVBL2/TIP48 Ruvbl2/Tip48 rept 
TIP49 Transcription factor RUVBL1/TIP49 Ruvbl1/Tip49 pont 
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1.3.6.1 OFF state: Absence of Wnt signals 
In the absence of Wnt proteins, β-catenin is phosphorylated and targeted for degradation 
by a complex of proteins designated the ‘destruction complex’; APC, Axin, Glycogen synthase 
kinase 3β (Gsk3β), Casein kinase I α (Ck1α) and Protein phosphatase 2A (PP2A) (Figure 1.9). 
1.3.6.1.1 APC 
APC is a 2843 amino-acid, 312 kDa multifunctional protein that was originally discovered 
as a truncated mutant in FAP (section 1.1). The role of APC in the Wnt/β-catenin pathway is to 
stabilise the ‘destruction complex’ to promote β-catenin phosphorylation (Behrens et al., 1998; 
Rubinfeld et al., 1993; Su et al., 1993b). APC has also been implicated in cell adhesion, cytoskeletal 
integrity, DNA repair/apoptosis and cell migration in a Wnt-independent manner (Balusu et al., 
2007; Barth et al., 1997; Mahmoud et al., 1997; Munemitsu et al., 1994). Additionally, APC has 
been shown to interact with End-binding protein 1 (EB1), which regulates microtubule assembly 
and Discs-large protein (DLG), a tumour suppressor protein that regulates cell cycle progression 
from G0/G1 to S phase (Ishidate et al., 2000; Nakamura et al., 2001b). Structurally, APC contains 
several heptad domains that mediate homodimerisation, followed by seven armadillo repeats 
(Kinzler et al., 1991; Su et al., 1993a). The central part of the protein contains three 15 aa and 
seven 20 aa repeats shown to mediate β-catenin binding (Rubinfeld et al., 1997a; Su et al., 1993b). 
Interspersed within the 20 aa repeats are three Serine-Alanine-Methionine-Proline (SAMP) 
repeats, which have been demonstrated to be vital in Axin binding (Behrens et al., 1998). At the C-
terminus, APC contains a basic domain for microtubule interaction, an EB1 binding domain and a 
DLG binding domain (Matsumine et al., 1996; Munemitsu et al., 1994; Su et al., 1995). APC 
expression is high during development; it is expressed in adult epithelial cells, especially in the 
brain (Midgley et al., 1997; van Es et al., 1999). Its homologue APC2 was identified in 1998 and it 
was found to be highly expressed in the brain (Nakagawa et al., 1998; van Es et al., 1999).  APC2 is 
smaller than APC and does not contain the 15 aa repeats, but retains the 20 aa and two SAMP 
repeat motifs (van Es et al., 1999). This suggests that it may down-regulate β-catenin (van Es et al., 
1999). However, this redundant role may not fully compensate for APC loss during tumourigenesis 
since C-terminal APC truncation mutations are sufficient to induce polyposis in the intestine 
(Andreu et al., 2005; Fodde et al., 1994; Oshima et al., 1995). Recent studies have shown that APC 
can regulate β-catenin-mediated gene transcription at the nucleus (Hamada and Bienz, 2004; 
Sierra et al., 2006). APC bound to β-transducin repeats-containing protein (β-TrCP) and to 
transcription repressors [C-terminal binding protein (CtBP), transducin-like enhancer of split-1(TLE-
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1) and histone deacetylase 1 (HDAC1)+ could interact with β-catenin at the MYC gene and facilitate 
its repression (Hamada and Bienz, 2004; Sierra et al., 2006). Intriguingly, C-terminal truncated APC 
mutants commonly seen in human cancers are missing this CtBP binding domain and may account 
for some of the tumourigenic potential of these mutants (Hamada and Bienz, 2004; Sierra et al., 
2006).  
1.3.6.1.2 Axin 
 Axin is the product of the Fused gene, which was originally identified as an inhibitor of the 
Wnt/β-catenin pathway due to its ability to inhibit axis duplication in Xenopus (Zeng et al., 1997). 
The Axin gene is conserved in mammals, Droshophila and Xenopus and although the protein it 
lacks enzymatic activity, it has been found to play a vital role in organising the ‘destruction 
complex’ (Hart et al., 1998; Hedgepeth et al., 1999; Ikeda et al., 1998; Zeng et al., 1997). It binds 
GSK3β and β-catenin in its centre, physically facilitating their interaction (Behrens et al., 1998; 
Ikeda et al., 1998). Additionally, Axin contains an N-terminal regulator of G protein signalling (RGS) 
domain (that binds to APC) and a C-terminal DIX (acronym of Dishevelled-Axin) domain important 
for binding to Dishevelled and for Axin oligomerisation (Hsu et al., 1999; Kishida et al., 1998; 
Kishida et al., 1999). These domains are critical, and loss of the DIX domain has been shown to 
severely disrupt β-catenin down-regulation (Kawahara et al., 2000; Sakanaka and Williams, 1999). 
Regardless, Axin mutations are relatively rare in human cancers and have been mainly identified in 
hepatocellular carcinomas and medulloblastomas (Table 1.5). Similar to APC, Axin has also been 
found to interact with many Wnt-independent partners (Cowan and Henkemeyer, 2001; Zhang et 
al., 1999). These include MAPK kinase kinase 1 (MAPKKK1) and MAPKKK4 and Smad3 [a member 
of the tumour growth factor β (TGF-β) pathway+ (Furuhashi et al., 2001; Luo et al., 2003; Zhang et 
al., 1999). Additionally, it can interact with NCK adaptor protein 2 (Nck2), an enzyme which 
modulates Ephrin B1 involved in axon growth (Cowan and Henkemeyer, 2001). These pathways 
have been implicated in cell proliferation, differentiation and apoptosis, suggesting that Axin may 
be a vital scaffold protein for regulating these processes (Furuhashi et al., 2001; Luo et al., 2003; 
Zhang et al., 1999). A homologue of Axin, named Axin2, was identified by its interaction with 
GSK3β using a yeast two-hybrid screen (Yamamoto et al., 1998). Axin2 shares 44 % identity with 
Axin and can also promote β-catenin degradation (Behrens et al., 1998; Yamamoto et al., 1998). 
Interestingly, Axin2 is up-regulated by β-catenin, suggesting that it may serve as a feedback loop to 
modulate the duration and intensity of the active Wnt/β-catenin pathway (Jho et al., 2002; Lustig 
et al., 2002; Yan et al., 2001). 
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Figure 1.9 Schematic representation of Wnt/β-catenin pathway intracellular members (not to scale) 
APC contains an oligomerisation domain, eight armadillo repeats, three 15 amino acid (aa) and seven 20 aa 
repeats that mediate β-catenin binding, three SAMP repeats important for binding to Axin, a microtubule 
association domain, an End-binding protein 1 (EB1) binding domain and a Discs-large protein (DLG) binding 
domain. Axin contains an RGS domain for binding to APC and a C-terminal DIX domain important for binding 
to Dishevelled and for Axin oligomerisation. Axin binds to β-catenin and Gsk3β at the centre. The N-terminus 
of β-catenin is phosphorylated by Gsk3β and Ck1α. Phosphorylation allows β-TrCP to bind to β-catenin and 
promote its degradation. Additionally, β-catenin contains twelve armadillo repeats. These repeats mediate 
the interaction of β-catenin with APC, TCF, E-cadherin, TIP48/49 and CBP among other binding partners. TCF 
interacts with β-catenin and Groucho at the N-terminus, a central HMG domain for binding to DNA and a 
CtBP binding domain at the C-terminus. Finally, Dvl contains a DIX domain, which mediates binding with 
Axin, a GBP binding domain and a PDZ and DEP domain, which are important for binding to proteins 
involved in the Wnt/PCP and Wnt/Ca
2+
 pathway.  
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1.3.6.1.3 The destruction complex kinases: Gsk3β and Ck1α 
β-catenin degradation is dependent on the phosphorylation of four key serine/threonine 
residues at its C-terminus domain (Aberle et al., 1997; Morin et al., 1997; Yost et al., 1996) (Figure 
1.10). The two kinases responsible for this are Ck1α and Gsk3β (Amit et al., 2002; Yost et al., 
1996). Both of these enzymes are unable to bind to β-catenin directly and require Axin and APC for 
interaction (Behrens et al., 1998; Ikeda et al., 1998; Rubinfeld et al., 1996). The Ck1 family of 
protein kinases is highly conserved across species and regulates many critical processes such as 
Wnt signalling, nuclear import (Fish et al., 1995; Vielhaber et al., 2000). Ck1α interacts with Axin 
and enhances β-catenin degradation by phosphorylating it at Serine45, priming it for subsequent 
phosphorylation by Gsk3β (Amit et al., 2002; Zhang et al., 2002). Gsk3β is an essential protein 
kinase that is involved in many cellular processes [reviewed in(Forde and Dale, 2007)]. It was 
originally identified by its ability to regulate glycogen synthase (Embi et al., 1980). Subsequently, it 
has been implicated in microtubule dynamics, transcription factor regulation and many other 
cellular events (Lovestone et al., 1996; Sears et al., 2000)[reviewed in (Forde and Dale, 2007)]. In 
the Wnt/β-catenin pathway, its main role is to sequentially phosphorylate β-catenin at 
Threonine41, Serine37 and Serine33, following priming (Liu et al., 2002). Gsk3β also 
phosphorylates Axin and APC, thereby increasing their stability and affinity for β-catenin (Hart et 
al., 1998; Yamamoto et al., 1999b). Phosphorylated Serine33/37 forms a docking site for β-
TrCP1/2, a component of the SCF (acronym of Skp1-Cullin1-F-box protein) E3 ubiquitin ligase, which 
recognises Aspartic acid-Serine (phosphorylated)-Glycine-X-X-Serine (phosphorylated) 
[DS(p)GXXS(p)] motifs (Alkalay et al., 1995; Fuchs et al., 1999; Winston et al., 1999). 
Phosphorylation at both residues in absolutely required and disruption of this motif inhibits the 
degradation of β-catenin (Miyoshi et al., 1998a; Morin et al., 1997). The SCF E3 ubiquitin ligase 
interacts with an E2 enzyme and sequentially transfers ubiquitin from E2 to the bound protein, in 
this case β-catenin [reviewed in (Krek, 1998)]. Polyubiquitinated β-catenin is then degraded by the 
26S proteasome (Fuchs et al., 1999; Hart et al., 1999; Winston et al., 1999). 
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Paradoxically, CKIα and GSK3β appear to perform opposite functions at the cell 
membrane. There, they have been shown to phosphorylate Proline-Proline-Proline-Serine-Proline 
(PPPSP) motifs in the intracellular domain of LRP6 (Brennan et al., 2004). LRP5 contains three of 
these motifs and interaction with GSK3β promotes its binding to Axin (Mao et al., 2001b). The 
outcome of this interaction remains to be fully determined. However, a study in Drosophila using 
Arrow (homolog of LRP5/6), suggests that it may result in Axin degradation (Tolwinski et al., 2003). 
As mentioned previously, LRP5/6 truncated mutants lacking the extracellular domain can 
constitutively activate the Wnt/β-catenin pathway (Brennan et al., 2004; Mao et al., 2001a; Mao 
et al., 2001b). Interestingly, LRP5 mutants-containing the intracellular and transmembrane domain 
were shown to activate the pathway more than mutants containing only the intracellular domain, 
indicating that membrane localisation of Axin may be important for activation (Mao et al., 2001b). 
Recently, a role for caveolin in β-catenin stabilisation was also reported (Yamamoto et al., 2006). 
In this study, Wnt3a protein promoted the internalisation of LRP6 by its interaction with caveolin in 
the human embryonic kidney cell line HEK293 (Yamamoto et al., 2006). Furthermore, 
immunoprecipitation analysis of LRP6/GSK3β/Axin/β-catenin showed that caveolin inhibits the 
binding of β-catenin to Axin (Yamamoto et al., 2006). Even though the exact method by which 
caveolin acts remains to be elucidated, it is possible that it accounts for the importance of 
membrane localisation of Axin in activation of the Wnt/β-catenin pathway. In conclusion, it 
appears that CKIα and GSK3β promote the degradation of β-catenin in the absence of Wnt, but 
promote its stability during Wnt/β-catenin signalling by promoting the interaction between LRP5/6 
and Axin.  
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Figure 1.10 Wnt/β-catenin pathway OFF state 
In the absence of Wnt proteins, an efficient complex made up of Axin, Gsk3β, APC, Ck1α and PP2A promotes 
the hyperphosphorylation of β-catenin. Phosphorylated β-catenin is recognised by β-TrCP, wich targets it for 
ubiquitination and degradation by the 26S proteasome. In the absence on nuclear β-catenin, Wnt responsive 
genes are inhibited by Groucho, histone deacetylases (HDAC) and C-terminal binding protein (CBP). 
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1.3.6.2 ON state: Presence of Wnt signals 
Activation of the Wnt/β-catenin pathway recruits Dishevelled (Dvl in vertebrates) to the 
cell membrane, where it is hyperphosphorylated by membrane-bound Ck1 and thereby activated 
(Hino et al., 2003; Kishida et al., 2001; Peters et al., 1999) (Figure 1.11). Dvl contains an N-terminal 
DIX domain, a central PDZ domain (acronym of post synaptic density protein [PSD95], Drosophila 
disc large tumor suppressor [DlgA], zonula occludens-1 protein [zo-1]) and a C-terminal DEP 
domain (acronym of Dishevelled, egl-10 and Pleckstrin). Hyperphosphorylated Dvl interacts with 
Axin via its DIX and PDZ domain (Kishida et al., 1999; Li et al., 1999). This interaction inhibits 
Gsk3β-mediated phosphorylation of β-catenin (Kishida et al., 1999). The mechanism of inhibition is 
not fully understood, but it may involve conformation changes in axin leading to a decreased 
affinity between Gsk3β and β-catenin. Alternatively, Dvl has been shown to bind Gsk3β binding 
protein (GBP) via its PDZ domain and recruit it to the ‘destruction complex’ (Li et al., 1999). GBP 
can therefore interact with the C- terminus of GSK3β and inactivate it (Li et al., 1999).  
 Once Gsk3β is inactivated, β-catenin is no longer phosphorylated and cannot be 
recognised by β-TrCP (Yost et al., 1996). Nevertheless, β-catenin still needs to dissociate from Axin 
and APC before it can translocate into the nucleus. As abovementioned, GSK3β phosphorylates 
Axin and APC to enhance their affinity to β-catenin (Hart et al., 1998; Yamamoto et al., 1999b). 
Therefore, they need to be de-phosphorylated. This is mediated by PP2A, one of the four major 
serine/threonine phosphatases (Cohen, 1989). PP2A is a heterotrimeric protein comprised of a 
catalytic subunit (C), a regulatory subunit (A), and one of variable regulatory subunits (B), which 
modulate its activity (Cohen, 1989). Axin directly interacts with PP2A C, and its inhibition (by 
okadaic acid) has been shown to prevent the de-phosphorylation of Axin and APC (Hsu et al., 
1999; Ikeda et al., 2000a; Willert et al., 1999). Interestingly B56, a regulatory subunit of PP2A, binds 
to APC and its over-expression promotes β-catenin down-regulation, probably by inhibiting PP2A C 
(Seeling et al., 1999). On the other hand, the process by which Wnt proteins mediate a change 
from inactive to active PP2A remains to be elucidated. 
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1.3.6.3 Nuclear translocation of β-catenin and gene transactivation  
β-catenin lacks any obvious nuclear localisation signal (NLS) and two different mechanisms 
for its translocation into the nucleus have been proposed. Microinjection or expression of TCF in 
Xenopus embryos promotes translocation of β-catenin indicating that they may translocate as a 
complex (Behrens et al., 1996; Huber et al., 1996; Molenaar et al., 1996). However, deletion of the 
β-catenin TCF binding site did not prevent β-catenin translocation, suggesting a TCF independent 
mechanism (Orsulic and Peifer, 1996; Prieve and Waterman, 1999). This was further substantiated 
in vitro, where β-catenin was able to enter the nucleus independent of importins, a family of 
proteins involved in recognising proteins with NLS (Fagotto et al., 1998; Yokoya et al., 1999). 
Interestingly, the central armadillo repeats appear to be required for translocation (Funayama et 
al., 1995). These repeats can also be found in importin-α and are structurally related to the 
importin-β HEAT repeats (acronym for Huntingtin, elongation factor 3 [EF3], PP2A, and TOR1) 
which bind to the nuclear pore complex (Gorlich et al., 1995; Kutay et al., 1997; Malik et al., 1997). 
Once in the nucleus, β-catenin is either anchored to DNA by interacting with TCF/LEF or exported 
from the nucleus by interacting with nuclear Axin or APC (Cong and Varmus, 2004; Rosin-Arbesfeld 
et al., 2000). 
There are at least four mammalian TCF/LEF members; LEF1, TCF1, TCF2 and TCF4 (Korinek 
et al., 1997; Travis et al., 1991; van de Wetering et al., 1991; Waterman et al., 1991). They bind to 
the minor groove of DNA via a high motility group (HMG) box and induce a sharp bend (Giese et 
al., 1992). However, they do not possess any transactivation activity (Giese et al., 1992; Molenaar 
et al., 1996). This activity is provided by the N- and C-terminus transactivation domains of β-
catenin (Hecht et al., 1999; Hsu et al., 1998; van de Wetering et al., 1997). In the absence of Wnt 
proteins, Groucho and CtBP interacts with TCF/LEF and represses gene expression by in/directly 
modifying chromatin structure (Brannon et al., 1999; Cavallo et al., 1998; Roose et al., 1998). 
Groucho inhibits expression by recruiting HDAC2, which condenses chromatin by deacetylating 
histones (Chen et al., 1999). On the other hand, the CtBP complex contains both HDAC and histone 
methyltransferase (HMT) activities which deacetylate and methylate histones to condense the 
structure of chromatin (Shi et al., 2003). A further level of repression is observed in Drosophila, 
where cyclic Adenosine monophosphate (cAMP) response element binding protein (CBP) interacts 
with TCF/LEF and acetylates it at the β-catenin-binding domain weakening its interaction for the 
armadillo repeats (Waltzer and Bienz, 1998). Interaction of β-catenin with TCF/LEF displaces 
Groucho and CtBP from TCF/LEF and recruits transcriptional coactivators (Chen et al., 1999). 
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Interestingly, the vertebrate CBP is recruited in this way and acetylates β-catenin to promote its 
transactivation activity (Hecht et al., 2000; Takemaru and Moon, 2000). Furthermore, it binds to 
the TATA-binding protein (TBP), TATA-interactive protein 48 (TIP48) and TIP49, which are 
proposed to form a bridge between β-catenin and RNA polymerase II (Bauer et al., 1998; Hecht et 
al., 1999). In summary, binding of β-catenin to TCF/LEF promotes the organisation of an efficient 
complex that activates the expression of canonical Wnt pathway target genes. 
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Figure 1.11 Wnt/β-catenin pathway ON state 
In the presence of Wnt proteins, Gsk3β and Ck1α phosphorylate the intacellular domain of LRP5/6 at PPPSP 
motifs. Phosphorylated LRP5/6 binds to Axin and disrupts the ‘destruction complex’. Additionally, 
dishevelled (Dvl) becomes hyperphosphorylated by casein kinases. Phosphorylated Dvl promotes Gsk3β 
inactivation by binding to Gsk3β binding protein (GBP). PP2A dephosphorylates Axin and APC to decrease 
their affinity for β-catenin. These three events de-stabilise the ‘destruction compplex’, thereby inhibiting β-
catenin degradation. Stable β-catenin translocates into the nucleus where is promotes transcription by 
displacing the transcriptional repressors Groucho and C-terminal binding protein (CtBP) and binding to the 
transcriptional activator cAMP response element binding protein (CBP). Additionally, β-catenin binds to 
TIP48 and TIP49, which are thought to form a bridge β-catenin and RNA polymerase II.  
  
59 | P a g e  
 
1.3.6.4 Wnt/β-catenin target genes 
More than 30 genes are regulated by β-catenin. Among these, cyclin D1, c-myc and 
matrilysin stand out for their oncogenic potential (Crawford et al., 1999; He et al., 1998; Mann et 
al., 1999; Shtutman et al., 1999; Tetsu and McCormick, 1999). Cyclin D1 is a critical regulator of 
the cell cycle and is frequently activated in human cancers [reviewed in (Baldin et al., 1993; 
Donnellan and Chetty, 1998)]. This activation can occur by chromosomal translocation of the cyclin 
D1 gene, gene amplification and deregulation of the Ras or Wnt/β-catenin pathways [reviewed in 
(Donnellan and Chetty, 1998)]. Cyclin D1 is expressed during early to mid G1 phase and is involved 
in promoting cell cycle progression (Baldin et al., 1993) (Figure 1.12). It functions as a regulatory 
subunit for cyclin-dependent-kinase 4 (CDK4) and CDK6 holoenzyme complex (Matsushime et al., 
1992; Meyerson and Harlow, 1994).  One of the main targets of cyclin D1/CDK4 is the 
retinoblastoma (Rb) protein (Ewen et al., 1993; Kato et al., 1993; Matsushime et al., 1992). 
Hypophosphorylated Rb suppresses cell cycle progression by sequestering E2 transciption factor 
proteins (E2F), an important family of transcription factors implicated in cell cycle progression 
(Ross et al., 2001; Wu et al., 2001a). Cyclin D1/CDK4 partially phosphorylates Rb, but it does not 
disrupt its interaction with E2F (Lundberg and Weinberg, 1998). Additionally, cyclin D1 and CDK4 
have been shown to promote the expression of the transcriptional factor Sp1 (Tapias et al., 2008). 
Mutation of Sp1 binding sequences in the cyclin E promoter prevents full expression of the gene 
(Kim et al., 2006). These results suggest that Cyclin D1/CDK4-mediated expression of Sp1 may 
promote cyclin E expression. Cyclin E/CDK2 complexes fully phosphorylate Rb, disrupting its 
interaction with E2F (Lundberg and Weinberg, 1998). This prompts the cell to progress to S phase 
(Muller et al., 2001). Overexpression of cyclin D1 in vitro shortens the G1 phase but requires co-
operation with other proto-oncogenes to promote cell transformation (Jiang et al., 1993; 
Musgrove et al., 1994; Zhou et al., 1995). Cyclin D1 can transform rat kidney cells and rat embryo 
fibroblasts in conjunction with Ras and can co-operate with c-myc to induce B cell lymphomas in 
transgenic mice (Lovec et al., 1994a; Lovec et al., 1994b). Interestingly, studies in human cancers 
have shown that cyclin D1 overexpression can promote carcinogenesis independently of CDKs 
(Lamb et al., 2003; Oyama et al., 1998; Zukerberg et al., 1996). To ascertain the significance of this 
activity, a comprehensive analysis of deregulated genes in breast cancer was undertaken (Lamb et 
al., 2003). This study showed that in breast cancer, overexpression of cyclin D1 did not correlate 
with Rb disruption and cell cycle deregulation. In oestrogen sensitive tissues, cyclin D1 has been 
shown to regulate growth by activating the oestrogen receptor (ER) (Neuman et al., 1997; Zwijsen 
et al., 1997). Cyclin D1 can bind to ER and promote ER-mediated transcription in the absence of 
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oestrogen ligand (Neuman et al., 1997; Zwijsen et al., 1997). This may underlie the oncogenic role 
of cyclin D1 in ER-positive breast cancer. Cyclin D1 can therefore promote tumourigenesis by 
shortening cell cycle progression or by CDK-independent gene transcription. 
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Figure 1.12 Activation of the cell cycle by cyclin D1 
At G0, the Retinoblastoma protein (Rb) binds to E2 trasncription factors (E2F) and prevents their 
transcription activity. At mid-G1 phase cyclin D1 binds to cyclin dependent kinases 4 or 6 (CDK4/6) and 
phosphorylates Rb. This phosphorylation event induces a conformation change in Rb, but it does not disrupt 
Rb-E2F interaction. Cyclin D1-CDK4/6 promote the expression of the transcription factor Sp1 by an unkown 
mechanism. Inhibition of histone deacetylases promotes the expression of cyclin E. Expression of cyclin E 
depends on Sp1. Cyclin E interacts with CDK2 and phosphorylates Rb in a site exposed by the conformation 
change induced by cyclin D1-CDK4/6 phosphorylation. Phosphorylation at this site disrupts the interaction 
between Rb and E2F. Subsequently, E2F mediates the expression of genes required for G1 to S phase 
transition. 
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C-myc is a member of the MYC family of helix-loop-helix leucine zipper (HLH-LZ) 
transcriptional factors (Kato et al., 1990; Murre et al., 1989). It dimerizes with Max to bind specific 
DNA sequences, such as the E-box sequences (CACGTC) to promote target gene expression 
(Blackwood and Eisenman, 1991; Prendergast and Ziff, 1991). C-myc/Max dimers promote gene 
transcription by modulating chromatin condensation (McMahon et al., 2000). This process is 
dependent on recruited factors like TIP48/49/60, General control nonderepressible 5 (GCN5) and 
transformation/transcription domain-associated protein (TRRAP) (Bellosta et al., 2005; Bouchard 
et al., 2001; McMahon et al., 1998; McMahon et al., 2000). TRRAP is a protein that interacts with 
c-myc during chromatin binding and is believed to bridge c-myc to histone acetyltransferases 
(HATs) (McMahon et al., 1998). TIP60 and GCN5 are HATs, which interact with c-myc to acetylase 
histone 3 (H3) and H4 to relax chromatin condensation and promote gene transcription (Allard et 
al., 1999; McMahon et al., 2000; Xu et al., 1998). C-myc promotes proliferation and aberrant 
expression is associated with aggressive, poorly differentiated tumours (Fults et al., 2002; Lamont 
et al., 2004). C-myc induces G1S phase transition by several mechanisms. C-myc promotes the 
activity of cyclin E/CDK2 (Berns et al., 1997; Steiner et al., 1995). It also directly promotes the 
expression of cyclin D2 and CDK4 (Bouchard et al., 1999; Hermeking et al., 2000). Furthermore, c-
myc promotes the degradation of p27, and inhibitor of cyclin E/CDK4 (O'Hagan et al., 2000). 
Inhibitor-free cyclin/CDK complexes are subsequently activated by cyclin activating kinase (CAK) 
and promote cell cycle progression by hyperphosphorylating Rb (Kato et al., 1993; Russo et al., 
1996). C-myc also induces proliferation by up-regulating RNA polymerase III, an enzyme involved 
in generating  transfer RNA (tRNA) and 5S ribosomal RNA (rRNA), which is required for protein 
synthesis during cell growth (Gomez-Roman et al., 2003). Whilst being a potent inducer of cell 
proliferation, c-myc can also induce apoptosis. This can be achieved in several ways. In certain cell 
lines, c-myc has been shown to increase the expression of B-cell lymphoma 2 (Bcl-2) associated X 
protein (Bax), an inducer of mitochondrial outer membrane permeabilisation (MOMP) (Juin et al., 
2002; Mitchell et al., 2000). This releases cytochrome c from mitochondria, which associates with 
apoptotic protease-activating factor 1 (APAF-1) to induce activation of Caspase-9 and promote 
apoptosis (Acehan et al., 2002). C-myc can also down-regulate members of the anti-apoptotic Bcl-
2 protein family (Eischen et al., 2001; MacLean et al., 2003). Finally, c-myc can promote apoptosis 
by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) and indirect 
activation of p53 via Adenosine diphosphate ribose (ADP) ribosylation factors (ARFs) (Klefstrom et 
al., 1997; You et al., 2002; Zindy et al., 1998). The decision between proliferation and apoptosis is 
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likely to be dependent on the cell type, the presence or absence of additional mutations and the 
presence of mitogenic signal and nutrients. 
Matrix metalloproteinase-7 (MMP-7, also known as matrilysin) is an enzyme that belongs 
to a family of zinc dependent endopeptidases which cleave ECM components [reviewed in (Roy et 
al., 2009)]. Matrilysin recognises many components of the ECM including elastin, type IV collagen, 
fibronectin, vitronectin, aggrecan and proteoglycans (Miyazaki et al., 1990; Wilson and Matrisian, 
1996; Woessner, Jr. and Taplin, 1988). Tumour metastasis is dependent on ECM degradation so 
MMPs are commonly up-regulated in malignant tumours [reviewed in (Roy et al., 2009)]. 
Matrilysin is no exception and its over-expression has been identified in oesophageal, colon, 
pancreatic, liver and stomach invasive tumours among others (Aihara et al., 2005; Jones et al., 
2004; Yamamoto et al., 1997; Yamamoto et al., 1999a; Yamamoto et al., 2001; Yamamoto et al., 
2003). Apart from degrading ECM components, matrilysin has also been shown to promote 
tumourigenesis by indirectly inhibiting E-cadherin junctions, activating the Oestrogen receptor β4 
(ErB4) receptor and inhibiting apoptosis (Noe et al., 2001; Yu et al., 2002).  
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1.3.6.5 Wnt/β-catenin pathway mutations in human cancers 
The Wnt/β-catenin pathway is de-regulated in many types of cancer (Table 1.3 and Table 
1.5). The most commonly mutated proteins in the Wnt/β-catenin pathway in tumours are β-
catenin, APC and Axin1 (Table 1.3 and Table 1.5). Activating β-catenin mutations occur mostly at 
exon 3, which corresponds to the CKIα/GSK3β phosphorylation site (Wright et al., 1999). 
Mutations in this region tend to be missense mutations either adjacent to (Asparagine32, 
Glycine34) or on codons (Serine33, Serine37, Threonine41, Serine45) which are phosphorylation 
sites of β-catenin (Garcia-Rostan et al., 2001). These mutations interfere with β-catenin 
phosphorylation resulting in protein stabilisation (Miyoshi et al., 1998a). In contrast, most 
mutations in APC are either nonsense mutations (C-terminal truncation) or frameshift mutations 
[reviewed in (Beroud and Soussi, 1996)]. Around 68-77 % of somatic mutations fall on a region 
called the mutation cluster region (MCR) which corresponds to 8 % of the gene (codons 1286-
1513) (Nishisho et al., 1991). Whilst APC truncation products generally retain the β-catenin binding 
domain, they lose the Axin-binding domain, highlighting the importance of Axin-APC interaction in 
β-catenin down-regulation [reviewed in (Beroud and Soussi, 1996)]. Interestingly, complete 
deletion of both APC alleles has not been observed in human cancers. The N-terminal part of the 
APC protein contains proline-free blocks with heptad repeats of hydrophobic residues (Joslyn et 
al., 1993; Su et al., 1993b). This pattern is characteristic of coiled coils and has been shown to 
mediate APC homodimerisation in vitro (Joslyn et al., 1993; Su et al., 1993a). Dimerisation suggests 
that truncated APC may negatively affect full length APC. Indeed, expression of truncated APC in 
enterocytes increases β-catenin activity and extends proliferation (Mahmoud et al., 1997). 
Furthermore, the ability of wild-type APC in controlling β-catenin transcription is strongly 
attenuated when a mutant APC truncated at codon 1309 is present (Dihlmann et al., 1999).  
Colorectal cancers (CRCs) with truncated APC retaining one or two β-catenin binding sites seem to 
have an increased selective advantage (Albuquerque et al., 2002; Smits et al., 2000). These APC 
species can partially regulate β-catenin mediated transcription (Dihlmann et al., 1999; Munemitsu 
et al., 1995; Rubinfeld et al., 1997a). Therefore N-terminal APC seems to promote tumourigenesis 
by retaining optimal control over β-catenin. This has been named the ‘just-right’ hypothesis. 
AXIN1 plays a central role in the ‘destruction complex’ by interacting with all of its 
members (Amit et al., 2002; Behrens et al., 1998; Ikeda et al., 1998). However, AXIN1 mutations 
are unexpectedly rare in cancer and are mostly restricted to CRC, medulloblastoma and 
hepatocellular carcinoma (HCC) (Table 1.3 and Table 1.5). By far the most common types of 
mutations in AXIN1 are missense mutations (Satoh et al., 2000; Taniguchi et al., 2002; Wu et al., 
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2001b). These are predominantly found in the APC-GSK3β binding domains, which are 
hypothesised to disrupt the ‘destruction complex’ (Satoh et al., 2000; Taniguchi et al., 2002; Wu et 
al., 2001b). Indeed, Leucine396Methionine mutation in the GSK3β binding domain has been 
shown to disrupt Axin-GSK3β interaction (Webster et al., 2000). Interestingly, in medulloblastoma, 
AXIN1 deletions are much more frequent than missense mutations (Dahmen et al., 2001; Yokota 
et al., 2002). These can occur at the C-terminus, ablating the APC-GSK3β-β-catenin binding 
domains or at the N-terminus, deleting the DIX domain essential for AXIN1 oligomerisation and 
down-regulation of β-catenin (Dahmen et al., 2001; Yokota et al., 2002). Mutations in β-catenin, 
APC and AXIN1 promote β-catenin stabilisation and are mostly mutually exclusive; e.g. a tumour 
with an APC mutation will be likely to be wild-type for β-catenin or AXIN1 (Sparks et al., 1998; 
Yokota et al., 2002). 
By contrast, GSK3β mutations have not been found in human cancers to date. GSK3β is 
involved in glycogen metabolism, transcription, translation, cytoskeletal regulation, 
differentiation, proliferation and apoptosis so inactivating mutations are likely to be detrimental 
for survival [reviewed in(Forde and Dale, 2007)+. Instead, tumours seem to control GSK3β through 
phosphorylation. Phosphorylation at Ser9 inhibits GSK3β whereas phosphorylation at Tyr216 fully 
activates the enzyme (Hughes et al., 1993; Sutherland et al., 1993). GSK3β negatively regulates 
many oncogenic proteins and cell cycle regulators so it was predicted to act as a tumour 
suppressor (de Groot et al., 1993; Nikolakaki et al., 1993). Indeed, in a mouse model for skin 
carcinogenesis phosphorylation and Ser9 is increased whilst phosphorylation at Tyr216 is 
decreased (Leis et al., 2002). Furthermore, a recent study found that pGSK3β(Ser9) was strongly 
expressed in squamous cell carcinomas and basal cell carcinomas (Ding et al., 2007b; Ma et al., 
2007). This also appears to be the case for mammary tumours (Farago et al., 2005). Expression of 
inactive degradation-resistant GSK3β in mammary glands promotes tumourigenesis (Farago et al., 
2005). Interestingly, this transformation was accompanied by cytoplasmic/nuclear accumulation of 
β-catenin and cyclin D1, suggesting that tumourigenesis was mediated by the activation of the 
Wnt/β-catenin pathway (Farago et al., 2005). Mutagenesis studies with primary breast tumours 
have shown that β-catenin and APC mutations are rare events (Table 1.3 and Table 1.5). However, 
nuclear accumulation of β-catenin and cyclin D1 are frequent and are associated with poorer 
prognosis (Table 1.3). Studies in breast cancer cell lines show that expression GSK3β or 
constitutively active GSK3β (Serine9Alanine mutant) can induce cell cycle arrest or apoptosis (Ding 
et al., 2007b; Wang et al., 2006). This implicates GSK3β as a tumour suppressor in breast 
tumourigenesis. In contrast, GSK3β protein appears to play an oncogenic role in human ovarian, 
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colon and pancreatic carcinomas, suggesting an oncogenic role (Cao et al., 2006; Ougolkov et al., 
2006). Pharmacological inhibition of GSK3β suppresses proliferation of ovarian cancer cells in vitro 
and prevents tumour formation after injection of these cells into nude mice (Cao et al., 2006). 
Similarly, inhibition of GSK3β decreases survival and proliferation of colon and pancreatic cancer 
cells (Ougolkov et al., 2005; Ougolkov et al., 2006; Shakoori et al., 2005; Shakoori et al., 2007). An 
oncogenic role of GSK3β in hepatocellular, prostate, lymphocytic leukaemia and medullary thyroid 
cancer cells have also been suggested (Erdal et al., 2005; Kunnimalaiyaan et al., 2007; Liao et al., 
2003; Mazor et al., 2004; Ougolkov et al., 2007). However, these effects may not be related to 
activation of the Wnt/β-catenin pathway. For example, GSK3β-induced suppression of mammary 
tumours has been suggested to be mediated by myeloid cell leukaemia-1 (Mcl-1) (Ding et al., 
2007a; Ding et al., 2007b). Mcl-1 is an anti-apoptotic member of the Bcl-2 family, which is related 
to high grade breast cancer and poor survival (Ding et al., 2007b). Inactivation of GSK3β promotes 
accumulation of Mcl-1 which has been linked with increased mammary tumour chemoresistance 
(Ding et al., 2007a; Ding et al., 2007b).  
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Table 1.3 Mutations of the Wnt/β-catenin pathway in selected human cancers 
Cancer type Gene Mutation 
frequency 
Comments References 
Primary Breast 
Cancer 
β-catenin 0/177 Mutations in components of the Wnt/β-catenin pathway 
are rare but nuclear β-catenin and nuclear cyclin D1 are 
associated with poor prognosis 
(Jonsson et al., 2000; Lin et al., 2000) 
APC 4/271 (Jonsson et al., 2000; Sorlie et al., 1998) 
Nuclear β-catenin 74/123 (Lin et al., 2000) 
Nuclear cyclin D1 49/123 
Breast Fibromatosis β-catenin 15/33 Breast fibromatosis are rare non-metastasing tumours (Abraham et al., 2002b) 
APC 11/33 
Nuclear β-catenin 27/33 
Desmoid tumours β-catenin 39/85  Desmoid tumours are a locally invasive soft tissue tumour 
composed of spindle cells 
(Miyoshi et al., 1998b; Saito et al., 2001; Saito et al., 
2002; Tejpar et al., 1999) 
APC 12/48 (Alman et al., 1997; Tejpar et al., 1999) 
Nuclear β-catenin 19/38 (Saito et al., 2001) 
Colorecetal 
carcinoma 
APC 128/164 The 27 samples tested for β-catenin mutations 
corresponded to APC wild-type tumours. 
(Jen et al., 1994; Powell et al., 1993; Samowitz et al., 
2007) 
β-catenin 13/27 (Sparks et al., 1998) 
Gastric carcinoma β-catenin 26/161 Reduced expression of β-catenin is associated with 
metastasis and larger tumours. Of the 90 tumours with 
nuclear β-catenin only 19 possessed mutations in β-
catenin  
(Clements et al., 2002; Kim et al., 2009; Woo et al., 
2001; Yoon et al., 2008) 
Nuclear β-catenin 90/311 (Clements et al., 2002) 
Gastric Adenoma 
without associated 
Adenocarcinoma 
β-catenin 0/96 Gastric Adenomas are rare gastric polyps that often 
progress to Gastric Carcinoma 
(Abraham et al., 2003; Lee et al., 2002) 
Gastric intestinal-
type 
Adenocarcinoma 
 
β-catenin 7/26 40 of the 41 tumours with nuclear β-catenin were early 
gastric cancer suggesting that de-regulation of the 
Wnt/β-catenin pathway may play a role in 
tumourigenesis 
(Park et al., 1999) 
Nuclear β-catenin 41/154 (Miyazawa et al., 2000; Song et al., 2004) 
APC 67/96 (Park et al., 1999) (Miyazawa et al., 2000; Song et al., 
2004) 
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Cancer type Gene Mutation 
frequency 
Comments References 
Hepatocellular 
carcinoma 
β-catenin 91/223 Hepatocellular carcinoma is one of the most common 
types of cancers worldwide and has poor prognosis 
(De La et al., 1998; Legoix et al., 1999; Miyoshi et al., 
1998a; Nhieu et al., 1999; Satoh et al., 2000; Taniguchi 
et al., 2002; Wong et al., 2001) 
AXIN1 15/179 (Satoh et al., 2000; Taniguchi et al., 2002) 
AXIN2 2/73 (Taniguchi et al., 2002) 
Hepatoblastoma β-catenin 125/223 Hepatoblastoma is a malignant childhood neoplasm and 
represents the most common malignant liver tumour in 
childhood 
(Blaker et al., 1999; Jeng et al., 2000; Koch et al., 1999; 
Park et al., 2001; Takayasu et al., 2001; Taniguchi et 
al., 2002; Udatsu et al., 2001; Wei et al., 2000) 
APC 0/68 (Takayasu et al., 2001) 
APC 9/13 (Oda et al., 1996) 
AXIN1 2/27 (Taniguchi et al., 2002) 
Lung 
Adenocarcinoma  
β-catenin 3/137 Patients with low β-catenin expression have significantly 
poorer prognosis 
(Nozawa et al., 2006; Shigemitsu et al., 2001; Sunaga 
et al., 2001) 
Solid-
pseudopapillary 
tumours (SPTs) 
β-catenin 18/20 SPTs account for around 1 % of pancreatic cancers have a 
low malignant potential. These tumours mostly arise in 
young women 
(Abraham et al., 2002a) 
Nuclear β-catenin 19/20 (Abraham et al., 2002a) 
Wilms Tumour β-catenin 39/286 Wilms tumour is a paediatric kidney cancer that affects 1 
in 100,000 children 
(Koesters et al., 1999; Kusafuka et al., 2002; Maiti et 
al., 2000; Zirn et al., 2006) 
WTX 15/51  Wilms tumour gene on the chromosome X (WTX) is a 
protein that has been recently linked with promoting β-
catenin degradation 
(Rivera et al., 2007)Rivera at al 2007 Science, Major et 
al, 2007 Science 
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Cancer type Gene Mutation 
frequency 
Comments References 
Prostate cancer β-catenin 14/264  - (Chesire et al., 2000; Gerstein et al., 2002; Voeller et 
al., 1998) 
APC 2/22 (Gerstein et al., 2002) 
β-TrCP 2/22 (Gerstein et al., 2002) 
Uterine endometrial β-catenin 33/182 Nuclear β-catenin generally corresponds to type I 
endometrial tumours, which have a improved prognosis 
(Ashihara et al., 2002; Fukuchi et al., 1998; Ikeda et al., 
2000b; Mirabelli-Primdahl et al., 1999; Moreno-Bueno 
et al., 2001b; Nei et al., 1999) 
Nuclear β-catenin 74/319 (Machin et al., 2002; Ng et al., 2005; Scholten et al., 
2003) 
Ovarian Carcinoma 
(emdometrial type) 
β-catenin 47/153 Common ovarian cancer  (Moreno-Bueno et al., 2001b; Palacios and Gamallo, 
1998; Wright et al., 1999; Wu et al., 2001b) 
APC 1/47 (Wu et al., 2001b) 
AXIN1 2/47 (Wu et al., 2001b) 
AXIN2 1/47  (Wu et al., 2001b) 
Malignant 
melanoma 
β-catenin 11/221 The Wnt/β-catenin pathway plays an important role in 
melanocyte development. However nuclear β-catenin is 
associated with improved prognosis. De-regulation of the 
Wnt/β-catenin pathway is hypothesised to be important 
for the early stages of melanoma development, but not 
for later stages 
(Omholt et al., 2001; Pollock and Hayward, 2002; 
Reifenberger et al., 2002; Rimm et al., 1999; Rubinfeld 
et al., 1997b) 
APC 3/63  (Reifenberger et al., 2002; Rubinfeld et al., 1997b) 
Nuclear β-catenin 28/111 (Chien et al., 2009; Omholt et al., 2001; Rimm et al., 
1999) 
Pilomatrixoma β-catenin 36/57 Pilomatrixoma is a common skin tumour arising from the 
hair follicles 
(Chan et al., 1999; Kajino et al., 2001; Moreno-Bueno 
et al., 2001a; Xia et al., 2006) 
Thyroid carcinoma β-catenin 26/57 Nuclear β-catenin or mutations are associated with poor 
prognosis in these tumours 
(Garcia-Rostan et al., 2001) 
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Cytoplasmic and nuclear β-catenin accumulation is associated with activation of the 
Wnt/β-catenin pathway and is commonly used as a diagnostic marker in cancer (Eberhart et 
al., 2000; Terris et al., 1999). Interestingly, nuclear β-catenin is observed more frequently than 
mutations, suggesting the presence of undiscovered mutations and alternative mechanisms 
for Wnt/β-catenin pathway activation. For example, the Wilms tumour gene on the 
chromosome X (WTX) is a recently discovered gene that is mutated in Wilms tumour, a 
paediatric cancer of the kidney (Rivera et al., 2007). WTX protein has been suggested to form 
a complex with β-catenin, AXIN1, β-TrCP, and APC and promote β-catenin ubiquitination and 
degradation (Major et al., 2007). Alternative tumour mechanisms of activating the Wnt/β-
catenin pathway include promoter hypermethylation of Wnt protein antagonists, Wnt protein 
up-regulation and down-regulation of E-cadherin. Promoter hypermethylation of SFRP and 
DKK silences their expression and is a common event in tumourigenesis (Table 1.4). Up-
regulation of Wnt5a mRNA occurs in gastric, colorectal and uterine cancer and the Wnt2 
proto-oncogene is up-regulated in breast, uterine, colorectal and kidney cancer (Katoh, 2001; 
Saitoh et al., 2002; Taki et al., 2003). β-catenin associates with E-cadherin to mediate 
epithelial cell-cell adhesion (Rimm et al., 1995). Down-regulation of E-cadherin in the absence 
of Wnt/β-catenin pathway mutations does not promote tumourigenesis (Caca et al., 1999; van 
de Wetering et al., 2001), but down-regulation in the presence of APC mutations has been 
reported in colorectal tumours and exacerbates pathway activation (Gottardi et al., 2001; 
Kuphal and Behrens, 2006). 
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Table 1.4 Hypermethylation of Wnt antagonists in selected human cancers 
Cancer type 
Gene 
involved 
Mutation 
Frequency 
Comments References 
Hepatocellular 
carcinoma 
SFRP1 9/19 Hypermethylation is also detected in liver 
cirrhosis. This suggests that 
hypermethylation could be an early event in 
liver carcinogenesis 
(Takagi et al., 
2008) 
SFRP2 12/19 
SFRP5 8/19 
Acute myeloid 
leukaemia 
SFRP1 29/100 No activating mutations in the Wnt/β-
catenin identified have been indentified in 
acute myeloid leukaemia to date 
(Jost et al., 2008) 
SFRP2 19/100 
SFRP4 0/100 
SFRP5 9/100 
Pancreatic 
cancer 
SFRP1 42/60 Hypermethylation and subsequent loss of 
expression of sFRPs appears to be an early 
event in the pathogenesis of pancreatic 
cancer 
(Bu et al., 2008) 
SFRP2 29/60 
SFRP4 36/60 
SFRP5 46/60 
Oral 
squamous Cell 
carcinoma 
SFRP1 7/17 No mutations have been identified in β-
catenin or APC in these tumours to date. 
These hypermethylation events were found 
in cell lines grown from tumours 
(Sogabe et al., 
2008) 
SFRP2 16/17 
SFRP5 14/17 
Breast cancer 
SFRP1 31/78  Methylation of SFRP5 is associated with 
reduced survival 
 (Suzuki et al., 
2008; Veeck et 
al., 2008) SFRP2 60/78 
DKK1 15/78 
SFRP5 123/168 
Gastric cancer 
SFRP1 42/46 -  (Nojima et al., 
2007) 
SFRP2 44/46 
SFRP5 30/46 
 
 
As mentioned in section 1.1 aberrant activation of the Wnt/β-catenin pathway has 
been implicated in CNS tumours, including medulloblastomas, CNS PNET, NOS and 
glioblastomas (Table 1.5). However not much is known about the role the Wnt/β-catenin 
pathway plays in these tumours. In order to address these issues transgenic mouse models are 
necessary to study the role of β-catenin in CNS tumourigenesis. 
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Table 1.5 De-regulation of the Wnt/β-catenin pathway in CNS tumours 
Tumour Abnormality Mutation     
frequency 
Description References 
Diffuse astrocytoma  
WHO grade II 
β-catenin mutations 0/16 - (Gotze et al., 2009) 
APC allelic imbalance 1/5 - (Nikuseva-Martic et al., 2007) 
Increased levels of Dvl3 mRNA - Dvl3 de-stabilises of the 'destruction complex' (Sareddy et al., 2009b) 
 Increased levels of β-catenin mRNA and 
protein 
- Higher expression of these targets correlates with 
increased malignancy 
 Increased expression of TCF4, LEF1, c-myc, 
cyclin D1 
- 
NKD2 promoter hypermethylation 1/16 Promoter hypermethylation correlates with 
decreased expression of the target genes  
(6/16 tumours possessed Wnt antagonist promoter 
hypermethylation) 
(Gotze et al., 2009) 
 SFRP1 promoter hypermethylation 1/16 
SFRP2 promoter hypermethylation 2/16 
SFRP4 promoter hypermethylation 1/16 
SFRP5 promoter hypermethylation 1/16 
Anaplastic astrocytoma  
WHO grade III 
β-catenin mutations 1/19 - (Gotze et al., 2009; Nikuseva-Martic et al., 2007) 
Increased levels of Dvl3 mRNA - Dvl3 de-stabilises of the 'destruction complex' (Sareddy et al., 2009b) 
 
 
Increased levels of β-catenin mRNA and 
protein 
- Higher expression of these targets correlates with 
increased malignancy 
 Increased expression of TCF4, LEF1, c-myc and 
cyclin D1 
- 
Patients with Turcot's syndrome type 2 4/24 - (Attard et al., 2007) 
DKK1 promoter hypermethylation 1/14 Promoter hypermethylation correlates with 
decreased expression of the target gene 
(Gotze et al., 2009) 
 SFRP1 promoter hypermethylation 2/14 
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Tumour Abnormality Mutation     
frequency 
Description References 
SFRP4 promoter hypermethylation 1/14 (4/16 tumours possessed Wnt antagonist promoter 
hypermethylation) 
SFRP5 promoter hypermethylation 1/14 
Glioblastoma (GBM)  
WHO grade IV 
APC loss of heterozygosity or allelic imbalances 6/18 - (Nikuseva-Martic et al., 2007) 
β-catenin mutations 1/58 - (Gotze et al., 2009; Nikuseva-Martic et al., 2007) 
Glioblastoma cell lines (T98G, GO-G-CCM, 
U373 and C6) overexpress β-catenin protein 
- Inhibition of Wnt signalling in these cell lines 
decreases proliferation 
(Sareddy et al., 2009b) 
 
Increased levels of β-catenin mRNA and 
protein 
- Higher expression of these targets correlates with 
increased malignancy 
 Increased expression of TCF4, LEF1, c-myc, 
cyclin D1 
- 
Primary GBM NKD2 promoter hypermethylation 13/20 Promoter hypermethylation correlates with 
decreased expression of the target gene 
(23/30 tumours possessed Wnt antagonist promoter 
hypermethylation) 
(Gotze et al., 2009) 
SFRP1 promoter hypermethylation 16/30 
SFRP2 promoter hypermethylation 13/30 
SFRP4 promoter hypermethylation 2/30 
SFRP5 promoter hypermethylation 1/30 
Secondary GBM NKD2 promoter hypermethylation 2/10 Promoter hypermethylation correlates with 
decreased expression of the target gene 
(7/10 tumours possessed Wnt antagonist promoter 
hypermethylation) 
(Gotze et al., 2009) 
 DKK1 promoter hypermethylation 5/10 
DKK3 promoter hypermethylation 2/10 
SFRP1 promoter hypermethylation 1/10 
SFRP2 promoter hypermethylation 2/10 
SFRP5 promoter hypermethylation 2/10 
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Tumour Abnormality Mutation     
frequency 
Description References 
CNS PNET, NOS 
WHO grade IV 
β-catenin mutations 2/30 - (Koch et al., 2001; Rogers et al., 2009) 
 APC mutations 0/24 - 
Nuclear β-catenin 10/28 - (Rogers et al., 2009) 
 
 
Nuclear Cyclin D1 12/28 8 of the 12 tumours positive for cyclin D1 were also 
positive for nuclear β-catenin. However, no 
correlation was found between proliferation and 
cyclin D1 overexpression 
Medulloblastoma 
WHO grade IV 
β-catenin mutations 16/253 - (Huang et al., 2000; Koch et al., 2001; Rogers et al., 
2009; Yokota et al., 2002; Zurawel et al., 1998) 
APC mutations 4/162 - (Dahmen et al., 2001; Huang et al., 2000; Rogers et 
al., 2009) 
Axin1 mutations 9/109 - (Dahmen et al., 2001; Yokota et al., 2002) 
Nuclear β-catenin 51/220 - (Eberhart et al., 2000; Ellison et al., 2005; Rogers et 
al., 2009; Yokota et al., 2002) 
Nuclear Cyclin D1 12/28 There was no significant correlation between nuclear 
β-catenin and cyclin D1 overexpression. Additionally, 
no correlation was found between proliferation and 
cyclin D1 overexpression 
(Rogers et al., 2009) 
Patients with Turcot's syndrome type 2 17/26 Turcot's syndrome arises from APC germline 
mutations 
(Attard et al., 2007) 
Ependymoma Patients with Turcot's syndrome type 2 3/28 Turcot's syndrome arises from APC germline 
mutations 
(Attard et al., 2007) 
β-catenin mutations 0/77 - (Onilude et al., 2006) 
 APC mutations 0/77 - 
Germinoma β-catenin mutations 1/1 - (Nikuseva-Martic et al., 2007) 
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Tumour Abnormality Mutation     
frequency 
Description References 
Meningioma  
WHO grade II 
APC loss of heterozygosity 4/16 - (Nikuseva-Martic et al., 2007) 
β-catenin mutations 2/16 - 
miRNA-200a downregulation 10/14 miRNA-200a downregulation results in 
downregulation of E-cadherin and upregulation of β-
catenin 
(Saydam et al., 2009) 
Neurinoma APC loss of heterozygosity 1/6 - (Nikuseva-Martic et al., 2007) 
Oligoastrocytoma APC loss of heterozygosity 1/1 - (Nikuseva-Martic et al., 2007) 
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1.4 Mouse models 
1.4.1 Conventional loss-of-function/knockout Models 
Mice are widely used to model human diseases due to their genetic similarity and 
genetic techniques available. One of the greatest breakthroughs in disease modelling was the 
cellular targeting of genes to introduce mutations (Folger et al., 1985). This was achieved by 
‘homologous recombination’, which involves the recombination between two homologous 
DNA sequences (Folger et al., 1982). 
Another breakthrough in disease modelling was the development of techniques that 
allowed embryonic stem (ES) cells to be cultured in vitro (Evans and Kaufman, 1981; Martin, 
1981). These cells remain undifferentiated in vitro, but retain the ability to differentiate into all 
cell types, including germ cells, when returned to the environment of the early embryo 
(Bradley et al., 1984). ES cells carrying genetic mutations can be generated using homologous 
recombination (Thomas and Capecchi, 1987). Subsequently, these cells can be injected into the 
inner cell mass of blastocysts, where they can differentiate and contribute to the development 
of the embryo (Figure 1.13) (Bradley et al., 1984). To generate a stable transgenic mouse line, 
the mutant ES cells need to incorporate into the germline so the null mutations can be 
inherited (Bradley et al., 1984). In this manner, mice carrying null mutations for specific genes 
could be generated (Koller and Smithies, 1989; Thomas and Capecchi, 1990). These mice were 
named knockout mice.  
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Figure 1.13 Generation of knockout mice 
Embryonic stem cell cultures are established from inner cell mass cells. Once in culture, these cells are 
electroporated with vectors containing the null allele and a drug resistant gene. In the example above, 
the Neo
R
 gene confers resistance to neomycin. Electroporation results in a mixed culture containing 
recombined and non-recombined cells. The recombined cells are positively selected by administering 
neomycin. Only the recombined cells will survive the treatment. Recombined ES cells are subsequently 
injected into blastocyts, which are transplanted into a surrogate mother. The ES cells are derived from 
mice with agouti (brown) fur whilst the surrogate mother is non agouti. In the image above, the agouti 
patches are derived from the ES knockout cells. This allows for chimaeric mice to be identified. If the ES 
cells were incorporated into the germline, the null allele can be transmitted to the offspring of the 
chimaeric mice. 
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There are two major draw-backs to knockout mice. First, many genes are essential for 
embryonic development and ablation can result in embryonic lethality (Thomas and Capecchi, 
1990). Hence, only the first vital function of a developmentally important gene can be studied. 
Second, if a gene knockout is not embryonic lethal, null expression occurs in all tissues of the 
body. This often results in complex phenotypes, which can complicate the interpretation. The 
Wnt pathway plays a very important role during development and ‘conventional’ knockout 
models of many its components result in embryonic lethality (Table 1.6, Table 1.7 and Table 
1.8).  
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Table 1.6 Phenotypes of Wnt protein ‘conventional’ knockout mice 
 
Gene Phenotype References 
Wnt1 Severe mid-hindbrain abnormalities  (Mcmahon and Bradley, 
1990; Thomas and Capecchi, 
1990) 
Wnt2 Placental defects  (Monkley et al., 1996) 
Wnt3 Lack of Anterior-Posterior patterning, no primitive streak 
formed 
(Liu et al., 1999) 
Wn3a 
  
  
  
  
Disruption of notochord, no tailbud or caudal somites (Takada et al., 1994) 
Paraxial mesoderm defects (Yoshikawa et al., 1997) 
Underproliferation of hippocampal progenitors (Lee et al., 2000) 
Abnormalities in left-right body symmetry (Nakaya et al., 2005) 
Truncation of rostral hindlibms and absence of tail bud (Greco et al., 1996) 
Wnt4 
  
  
Failure to form Kidney tubules (Stark et al., 1994) 
Ectopic testosterone synthesis in female mice and absence 
of Mullerian duct 
(Vainio et al., 1999) 
Role in male gonad development (Jeays-Ward et al., 2004) 
Wnt5a 
  
  
  
Truncation of Anterior-Posterior axis (Yamaguchi et al., 1999) 
Abnormalities in distal lung morphogenesis (Li et al., 2002) 
Abnormal pituitary gland development (Cha et al., 2004) 
Required for pancreatic insulin-cell migration (Kim et al., 2005) 
Wnt7a 
  
  
  
Dorsal-Ventral defects, lack of posterior digits (Parr and Mcmahon, 1995) 
Role in Anterior-Posterior patterning, defects in uterus and 
vagina 
(Miller and Sassoon, 1998) 
Mullerian duct regression failure in males (Parr and Mcmahon, 1998; 
Stevens et al., 1991) 
Delayed synaptic maturation in cerebellum (Hall et al., 2000) 
Wnt7b 
  
Placental abnormalities (Parr et al., 2001) 
Defects in pulmonary vessels (Shu et al., 2002) 
Wnt9a Defects in skelotogenesis, loss of synovial chondroid 
metaplasia 
(Spater et al., 2006) 
Wnt9b Essential for caudal extension of Mullerian duct in females (Carroll et al., 2005) 
Wnt10A Unknown - 
Wnt10b Excess lipid accumulation in regenerating muscle (Vertino et al., 2005) 
Wnt11 Kidney hypoplasia from ureteric branching defects (Majumdar et al., 2003) 
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Table 1.7 Phenotypes of Fzd and Lrp ‘conventional’ knockout mice 
 
Gene Phenotype References 
Fzd3 Defects in axon tracts in the forebrain (Wang et al., 2002) 
Fzd4 Progressive cerebellar, auditory and oesophageal 
dysfunction 
(Wang et al., 2001) 
Infertility due to impaired formation of corpora lutea (Hsieh et al., 2005) 
Fzd5 Yolk sac and placental angiogenesis defects (Ishikawa et al., 2001) 
Fzd6 Hair patterning defects (Guo et al., 2004) 
Fzd9 Defects in B-cell development (Ranheim et al., 2005) 
Hippocampal and visuospatial learning defects (Zhao et al., 2005) 
Fzd10 Unknown - 
Lrp5 Low bone mass as a result of decreased osteoblast 
proliferation, impaired vascular regression 
(Kato et al., 2002) 
Increased plasma cholesterol and decreased glucose-
induced insulin secretion 
(Fujino et al., 2003) 
Lrp6 Truncated Anterior-Posterior axis, neural tube closure, 
mid-hindbrain and dorsal-ventral patterning defects 
(Pinson et al., 2000) 
Small eyes and aberrant lenses (Stump et al., 2003) 
Reduced dentate granule neurone production, 
abnormalities of the radial glia scaffolding 
(Zhou et al., 2004b) 
Smaller and severely disorganized dorsal thalamus (Zhou et al., 2004a) 
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Table 1.8 Phenotypes of Wnt/β-catenin downstream component ‘conventional’ knockout 
mice 
 
Gene Phenotype References 
Dvl1 Abnormal social interaction (Lijam et al., 1997; Long et al., 
2004) 
Dvl2 Cardiovascular outflow tract defect, vertebral and rib 
malformations, neural tube closure defects 
(Hamblet et al., 2002) 
Dvl3 Cardiac outflow tract abnormalities (Etheridge et al., 2008) 
GBP1-2-3 No obvious defects in Wnt signal transduction (van Amerongen et al., 2005) 
Axin1 No knockout generated. Fused mutant allele results in 
Anterior-Posterior duplication, neuroectodermal and 
cardiac abnormalities 
(Zeng et al., 1997) 
Axin2 Malformation of skull due to increased osteoblast 
proliferation and differentiation 
(Yu et al., 2005) 
Gsk3β Liver degeneration due to defects in NFκB signalling (Hoeflich et al., 2000) 
Hypertrophic cardiomyopathy and cardiomyoblast 
hyperproliferation 
(Kerkela et al., 2008) 
Apc1 Development of primitive ectoderm fails before 
gastrulation 
(Moser et al., 1995) 
Apc2 Unknown - 
β-catenin Failure in Anterior-Posterior formation (Huelsken et al., 2000) 
Defects in the embryonic ectoderm cell layer (Haegel et al., 1995) 
Lef1 Defects in pro-B-cell proliferation and survival (Reya et al., 2000) 
Defects in the formation of organs that require 
inductive tissue interaction 
(van Genderen et al., 1994) 
Varying degrees of hippocampal abnormalities (Galceran et al., 2000) 
Tcf1 Defects in thymocyte proliferation and differentiation (Schilham and Clevers, 1998; 
Verbeek et al., 1995) 
Tcf3 Failure in Anterior-Posterior axis formation (Merrill et al., 2004) 
Tcf4 Depletion of epithelial stem cell compartments in the 
intestine 
(Korinek et al., 1998) 
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1.4.2 Mouse models of conditional gene inactivation (Cre-loxP system)  
Conditional gene inactivation allows for inactivation of genes in a time- and/or tissue-
specific manner (Gu et al., 1993). This relies on enzymes that can recombine specific DNA 
sequences with high fidelity. The most common system for conditional gene inactivation is the 
Cre-loxP system. Cre-recombinase is a bacteriophage P1 enzyme that belongs to a large family 
of DNA recombinases (Sternberg and Hamilton, 1981). It recognises sequences called locus of 
crossover (x) in P1 (loxP), which consist of two 13bp inverted repeats separated by an 8bp 
asymmetric spacer (Hoess and Abremski, 1984; Sternberg and Hamilton, 1981). Cre-
recombinase accomplishes recombination by binding to two loxP sites and mediating strand 
cleavage, exchange and ligation at the asymmetric spacer (Sadowski, 1995, Hoess 1985). In this 
manner, Cre-recombinase can mediate the excision or inversion of DNA flanked by loxP sites 
(Figure 1.14). Furthermore, it can also mediate the insertion of circular DNA molecules into 
linear molecules or the exchange of DNA between two linear molecules as long as each one 
contains a loxP site (Figure 1.14). 
By flanking a gene with loxP sites its excision can be triggered in the presence of Cre-
recombinase (Gu et al., 1994). Therefore, by controlling Cre-recombinase expression it is 
possible to conditionally inactivate gene function (Gu et al., 1994). The most common method 
for controlling Cre-recombinase is by generating mice that express the enzyme under the 
control of a specific promoter (Orban et al., 1992). As a result, only the cells in which the 
promoter is active will express Cre-recombinase and be recombined (Orban et al., 1992). The 
limitation of this approach is the need of multiple Cre-recombinase-expressing mice to study 
the effect of a gene in different cell populations. 
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Figure 1.14 Cre-recombinase recombination events 
Cre-recombinase can mediate excision/insertion (A) inversion (B) and translocation between 
chromosomes (C) depending of the location and the direction of the loxP sites. The arrows represent the 
direction of recombination and the thickness represents the likelihood of the recombination event 
taking place. 
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Cre-recombinase expression can also be controlled by inducible systems. An example 
of this is the Cre-Tamoxifen system (Metzger et al., 1995). Tamoxifen is a synthetic drug which 
competes with oestrogen for binding to the oestrogen receptor (ER) (Wakeling et al., 1984). In 
the Cre-Tamoxifen inducible system, transgenic mice, which express a Cre-Oestrogen receptor 
binding-domain fusion protein (Cre-ER), are used (Feil et al., 1996). When tamoxifen binds to 
the oestrogen receptor it translocates from the cytosol into the nucleus (Dix and Jordan, 
1980). Therefore, in the presence of Tamoxifen, the Cre-ER fusion protein is translocated into 
the nucleus where it can mediate loxP site recombination (Metzger et al., 1995). This method 
is highly versatile as Tamoxifen can be administered to localised areas within tissues via 
postnatal injection (Andersson et al., 2010). Alternatively, it can be delivered orally to pregnant 
mice for recombination during embryonic development (Andersson et al., 2010). 
Finally, Adenoviral vectors expressing Cre-recombinase can also be used to mediate 
loxP site recombination (Anton and Graham, 1995; Sakai et al., 1995). In this system, all 
infected cells transiently express Cre-recombinase and are irreversibly recombined.  
The nature of the scientific investigation determines which of the methods for Cre-
mediated recombination is most appropriate. Cre-recombinase-expressing mouse lines are 
useful for studying gene inactivation in specific cell populations. On the other hand, inducible 
and Adenoviral systems are useful for studying the effect of null mutations in targeted areas.   
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1.4.3 Conditional Models for studying the Wnt/β-catenin pathway in CNS 
tumours 
De-regulation of the Wnt/β-catenin pathway has been observed in CNS tumours 
(Table 1.5). However, the role of the Wnt/β-catenin pathway in the development and 
maintenance of these tumours is poorly understood. To study this role, mouse models in 
which the pathway is constitutively active are necessary. The most common method used to 
achieve this is mutating the four phosphorylation residues of β-catenin. As discussed in section 
1.3.6, phosphorylation at those residues is necessary for β-catenin degradation. Hence, 
abolishing their phosphorylation prevents β-catenin from being degraded, resulting in 
constitutive activation of the pathway.  
Several β-catenin gain-of-function conditional mouse models have been generated. 
The first of these models expressed Serine37Alanine (S37A) β-catenin under the control of the 
prion protein (PrP) promoter (E11.5) (Kratz et al., 2002). PrP is a GPI-anchored membrane 
protein predominantly expressed in neurones (Bailly et al., 2004). Although a doubling in 
nuclear S37A β-catenin was observed in the cerebella of transgenic mice, no brain tumours 
were detected. In this model S37A β-catenin was expressed in neuronally committed cells. 
However, evidence suggests that stem/progenitor cells are the cell of origin of CNS tumours 
(Jacques et al., 2010; Sanai et al., 2005). Therefore, degradation-resistant β-catenin may need 
to be expressed in neural stem cells for tumourigenesis to take place. This possibility was 
explored by Holland’s group (Fults et al., 2002; Momota et al., 2008). In the first study, 
transgenic mice were infected with an avian leukosis virus (ALV) expressing S37A β-catenin 
(ALV-S37A-β-catenin) (Fults et al., 2002). Murine cells are not susceptible to AVL. However, the 
transgenic mice used in this study expressed TVA, the avian receptor for ALV, in Nestin-
expressing cells (Nestin-TVA mice). This allowed for Nestin-expressing cells to be specifically 
infected with ALV-S37A-β-catenin. These mice did not develop tumours within eight weeks, 
the endpoint of the experiment. However, this is unsurprising since inactivation of two tumour 
suppressor genes in the SVZ results in the development of tumours after up to thirty weeks 
(Jacques et al., 2010). Additionally, infection of Nestin-TVA mice with an avian leukosis virus 
(AVL) expressing the potent oncogene c-myc (ALV-c-myc) did not yield any tumours (Fults et 
al., 2002). Hence, the lack of tumours may be explained by the lack of additional mutations 
and/or short follow-up of the experiment. In their second study, Holland’s group addressed 
the issue of additional mutations by using mice expressing TVA under the control of the GFAP 
promoter (GFAP-TVA) on a p53-/- genetic background (Momota et al., 2008). GFAP-TVA; p53-/- 
mice infected with ALV-c-myc, but not with ALV-S37A-β-catenin, formed tumours (Momota et 
al., 2008). However, the endpoint of the experiment was at three months due to the 
development of lymphomas and sarcomas, a known phenotype of p53 knockout mice (Harvey 
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et al., 1993). Interestingly, combined infection with ALV-c-myc and ALV-S37A-β-catenin 
increased the phenotypic diversity and halved the tumour latency in GFAP-TVA; p53-/- mice 
without increasing tumour incidence in comparison to ALV-c-myc infected mice (Momota et 
al., 2008). These results suggest that constitutive activation of the Wnt/β-catenin pathway 
does not promote tumourigenesis. Instead, it appears to influence tumour phenotype and 
behaviour. However, the possibility that degradation-resistant β-catenin may promote 
tumourigenesis in the long-term can not be ruled out.  
In order to address these unresolved issues and investigate further, a conditional 
mouse model, which expresses a degradation-resistant form of β-catenin (GSK-β-catenin) 
was generated (Figure 3.1). GSK-β-catenin contains point mutations at the four 
phosphorylation sites required for β-catenin down-regulation (S33A, S37A, T41A and S45A). 
These mutations abolish GSK3β and CKIα mediated phosphorylation and therefore prevent 
GSK-β-catenin from being degraded (section 1.3.6). Expression of GSK-β-catenin in 
embryonic stem (ES) cells up-regulated the expression of the Wnt/β-catenin downstream 
targets (Haegele et al., 2003). This phenotype was reproduced by the expression of a truncated 
form of APC (Haegele et al., 2003). These results confirmed that this GSK-β-catenin construct 
can effectively activate the Wnt/β-catenin pathway. Therefore, transgenic mice expressing this 
construct (Figure 3.1) were generated to study the Wnt/β-catenin pathway in the CNS. 
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2 Materials and methods 
2.1 Mice 
All mice were housed and maintained under specific pathogen-free conditions in 
accordance with Institutional and UK Home Office guidelines (Project license 70/6603). They 
were kept on a 12 hour light-dark cycle and given food and water ad libitum. All procedures, 
including culling of the mice, were carried out in accordance with Home Office regulations. 
2.1.1 Genotyping 
Mice were assessed for the presence of transgenes by ear biopsies, which were used 
for DNA extraction and subsequent analysis by polymerase chain reaction (PCR) (section 2.7). 
2.1.2 Embryonic LacZ expression 
After timed matings, embryos were harvested at embryonic day 10.5, 12.5, or 16.5 and 
β-galactosidase-stained (section 2.2.2). They were then photographed using a Nikon Coolpix 
995 camera mounted on a Zeiss Stemi SV11 microscope and paraffin-embedded. 
2.1.3 BrdU injection of mice 
5-Bromo-2-deoxyuridine (BrdU) (Sigma; 5 mg/ml or 10 mg/ml) was made in distilled 
water and dissolved using a sonicator (Fisherbrand FP11002). To label proliferating cells, mice 
were given intraperitoneal injections of BrdU at a concentration of 50 μg per gram of body 
weight. As a base analogue of thymidine, BrdU substitutes for thymidine during DNA synthesis 
and incorporates into the newly synthesized DNA. Therefore, by BrdU administration, dividing 
(stem) cells are labelled. BrdU-positive cells can be detected on brain sections by 
immunohistochemical techniques. 
2.1.4 Adenovirus-Cre intraventricular injection 
Viral infection of SVZ cells was achieved by unilateral stereotaxic injections of 109 
plaque-forming units of Adenovirus-Cre in phosphate buffered saline (PBS) into anaesthetized 
mice placed in a Narishige SR 6N stereotaxic frame. The injection in relation to bregma was 
anterior 0 mm; lateral 0.5 mm and ventral 2.5 mm. Injections (usually of 2-4 µL volume) were 
administered with a Hamilton syringe 1701RN and a 26 gauge needle (Hamilton). 
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2.2 Tissue harvesting and preparation 
2.2.1 Brain and peripheral organ harvesting 
For histology (section 2.5) and β-galactosidase staining (section 2.2.2), the mice were 
killed by increasing concentration of CO2 in order to retain the structural integrity of the entire 
brain. For primary cell cultures (section 2.4), mice were killed by cervical dislocation and their 
brains removed under sterile conditions, to minimise cell death.  
For Western blotting (section 2.6) brains were sagittally cut with one hemisphere used 
for β-galactosidase staining (section 2.2.2). The other hemisphere was sub-divided into 
forebrain and cerebellum, which were further sub-divided into halves. The pieces were then 
submerged in isopentane (Sigma) and snap-frozen in liquid nitrogen. Excess isopentane was 
blotted out and the samples were stored at -80°C until use. Peripheral organs such as heart, 
kidney, lung, liver, spleen, and testis of mice were removed for β-galactosidase staining 
(section 2.2.2). 
2.2.2 β-galactosidase staining assay 
Brains were incubated in formalin (Pioneer Research) for 30 min at room temperature 
(RT), cut sagittally and then incubated for a further 30 min in formalin. They  were then 
permeabilised (by shaking) in permeabilisation buffer, which consisted of β-gal staining 
solution (10 mM Phosphate buffer [pH: 7-7.2][Fisher Chemicals], 150 mM NaCl [Fisher 
Chemicals], 1 mM MgCl2 [Sigma], 3.3 mM K4Fe(CN)6 x 3H2O [Sigma], 3.3 mM K3Fe(CN)6 
[Sigma]), 1 % MgCl2 [w/v] [Sigma], 0.02 % Igepal (v/v) (Fluka BioChemika) and 0.01 % Sodium 
Deoxycholate (w/v) (Sigma). The brains were then incubated overnight at 37°C (shaking) in 
permeabilisation buffer and 1 % X-Gal (w/v) (Merck; dissolved in N,N-Dimethylformamide 
[Sigma]). X-Gal is cleaved by β-galactosidase, when the latter is expressed by the LacZ gene, 
yielding galactose and 5-bromo-4-chloro-3-hydroxyindole. The resulting compound is then 
oxidised into 5,5'-dibromo-4,4'-dichloro-indigo, an insoluble blue product. The brains were 
subsequently photographed using a Nikon Coolpix 995 camera mounted on a Zeiss Stemi SV11 
microscope to record the staining pattern of β-galactosidase. Somatic organs were prepared in 
exactly the same way, but they were not sectioned. When staining for embryos, 
permeabilisation was not required. 
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2.3 Generation of the pcall2-GSK-β-catenin-IRES-GFP vector 
2.3.1 Restriction enzyme digestion and ligation 
The pUHD10-3/GSK-β-catenin vector containing GSK-β-catenin was a kind gift from 
Dr Nelson, Department of Molecular and Cellular Physiology, Stanford University School of 
Medicine, Stanford, California, United States of America (Barth et al., 1999). A BamH I 
restriction enzyme site (GGATCC) was inserted upstream of GSK-β-catenin cDNA sequence by 
doing a PCR with the pUHD10-3/GSK-β-catenin vector and primers TJ1 and TJ3 (section 
2.7.2). The PCR product and pUHD10-3/GSK-β-catenin vector were digested with 0.5 U/µl Sac 
II and 0.5 U/µl Sph I (both from New England Biolabs), NE buffer 4 (New England Biolabs) for 
three hours at 37°C. The digests were run on a 2 % agarose gel (w/v) (Sigma) containing 75 
ng/ml ethidium bromide (Sigma) for 30 min. The bands were briefly visualised under UV light, 
cut out of the gel and purified using the QIAquick gel purification kit (QIAGEN). The digested 
PCR product and the digested pUHD10-3/GSK-β-catenin vector were subsequently ligated 
with T4 DNA ligase (20 U/ml, New England Biolabs) in T4 DNA ligase buffer (New England 
Biolabs) overnight at 16°C.  
The modified pUHD10-3/GSK-β-catenin vector was restriction enzyme digested with 
0.5 U/µl BamH I (New England Biolabs), NE Buffer 2 (New England Biolabs) supplemented with 
100 µg/ml bovine serum albumin (BSA) (Sigma) and incubated at 37°C for three hours. The 
digest was run on gel and purified as mentioned above to obtain the GSK-β-catenin cDNA. 
Subsequently, the pcall2-updated-IRES-GFP vector was digested with 0.5 U/µl Bgl II (New 
England Biolabs), NE Buffer 3 (New England Biolabs) at 37°C for three hours. The pcall2-
updated-IRES-GFP digest was gel purified as mentioned above. Both BamH I and Bgl II leave 
the same overhang so the digested GSK-β-catenin cDNA and pcall2-updated-IRES-GFP can be 
ligated together. For ligation, the DNA digests were incubated with 20 U/ml T4 DNA ligase 
(New England Biolabs) in T4 DNA ligase buffer (New England Biolabs) overnight at 16°C. 
2.3.2 Bacterial transformation and purification 
Prior to bacterial transformation, Luria Bertani (LB) agar plates containing neomycin 
were prepared. For this purpose, 37 g/L LB agar (Sigma) was made and autoclaved. 
Subsequently, Isopropyl β-D-1-thiogalactopyranoside (IPTG) (100 µM final concentration) 
(Promega), Neomycin (100 μg/ml final concentration) (Sigma) and X-gal (20 mg/ml final 
concentration) (Merck; dissolved in N,N-Dimethylformamide [Sigma]) were added. This 
mixture was poured into 10 cm tissue culture plates and allowed to cool and solidify. 
For transformation, 2 μl of ligation product was added to 90 μl of thawed JM109 
competent cells (Promega). This mixture was incubated on ice for 20 min. Following 
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incubation, the cells were heat-shocked by heating  for 45 seconds at 42°C followed by 
incubation on ice for 5 min. 1 mL of LB broth (25 g/L, sterile) (Sigma) was added and the cells 
were incubated at 37°C for one hour (shaking). After incubation, cells were pelleted for 10 min 
at 3000 x g and re-suspended in 100 μl of LB broth. The cells were plated on an LB agar plate 
and incubated at 37°C overnight. The following day, single colonies were picked with a pipette 
tip and transferred to a 15 mL Falcon tube containing 2 mL of LB broth supplemented with 
neomycin 100 μg/ml (Sigma) and incubated at 37°C overnight (shaking). The cells were 
pelleted for 10 min at 3000 x g. The DNA from the pellet was harvested using the QIAprep spin 
miniprep kit (QIAGEN). Finally, the plasmid DNA was linearised by restriction enzyme digestion 
with 0.5 U/µl Sca I (New England Biolabs), NE Buffer 3 (New England Biolabs) incubated at 37°C 
for three hours and purified using the QIAquick PCR purification kit (QIAGEN). 
2.3.3 ES cells electroporation 
The ES cell medium (Dulbecco’s modified Eagle’s medium *DMEM+ *Sigma+, 20 % foetal 
calf serum (v/v) [FCS] [Invitrogen], 1 mM Na pyruvate [Sigma], 2 mM L-glutamine [Sigma], 0.1 
mM non-essential amino acids [Sigma], 0.1 mM 2-mercaptoethanol [Sigma], 103 units/ml 
ESGRO murine LIF [Millipore], and 1.000U/ml Penicillin/Streptomycin [P/S] [Lonza]) of 
C57BL/6J ES cell cultures was changed two to three hours prior to electroporation. The 
C57BL/6J ES cells were harvested following a 5 min incubation with trypsin (Sigma). The trypsin 
was inactivated with surplus ES cell medium. The cells were subsequently centrifuged for 10 
min at 300 x g and re-suspended in ES cell medium to a concentration of 1 x 107 cells/ml. 30 μg 
of the linearised plasmid (section 2.3.2) was added per 0.8 mL of re-suspended cells and 
aliquoted into electroporation cuvettes (Biorad). The cells were electroporated using a Biorad 
GenePulser at 230V, 500 μF. The time constant was set to 7.0. Following electroporation, the 
cuvettes were incubated at room temperature for 5 min and the cells were transferred to 10 
cm plates with fresh ES cell medium. 
2.3.4 ES cell selection for LacZ 
Electroporated ES cells were treated with trypsin (Sigma) for 5 min. The trypsin was 
inactivated with surplus ES cell medium. The cells were counted and diluted to a concentration 
of 200 cells/ml. 200 μl/well of this mixture was plated on wells of a 96-well plate (around 1 
cell/well final concentration). The plate was incubated at 37°C in an atmosphere of 5 % CO2 
and 95 % rH (relative humidity) for three days. Subsequently, the cells from each well were 
harvested individually. The cells were plated in duplicate into 96-well plates. One of the 96-
well plates was used for β-galactosidase staining (section 2.2.2). The A7, B4, C11, E3, E6, E11, 
F9, G1 and H4 clones (the names correspond to the well position) were positive for β-
galactosidase. The corresponding ES cell clones from the other 96-well plate were harvested 
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and used for southern blotting (section 2.3.5) and microinjection into blastocysts. The 
blastocysts were injected into pseudo-pregnant 129sv female mice. 
2.3.5 Southern blot analysis 
2.3.5.1 Gel electrophoresis and transfer 
DNA was extracted from the B4, C11, E3, E6, E11, F9, G1 and H4 ES cell clones using 
the Dynabeads DNA DIRECT Kit (Invitrogen). Subsequently the DNA was digested with 0.5 U/µl 
EcoR I (New England Biolabs), EcoR I Buffer (New England Biolabs) incubated at 37°C for 19 
hours. The digested DNA was separated on a 1 % agarose gel (w/v) (Sigma). The DNA on the 
gel was then depurinated by immersing it in 0.25 M HCl and gently rocking it for 10 min. 
Afterwards the gel was neutralised and alkaline denatured with three washes in 0.4M NaOH 
for 15 min each wash. Subsequently, the gel was submerged in 20x SSC buffer (3 M NaCl 
[Fisher Chemicals], 300 mM Na3Citrate [Trisodium citrate], pH 7) for 5 min (shaking). The 
blotting set-up was as follows (from bottom to top): 
1. 20x SCC buffer reservoir 
2. Glass plate 
3. 2x pieces of wick-blotting paper wetted with 20x SCC buffer cut to the width of the 
gel and lenth such that the wick is in contact with the bottom of the dish 
4. Agarose gel 
5. Plastic wrap to cover the entire gel 
6. Hybond N+ nylon membrane (GE healthcare) wetted with distilled water cut to the 
size of the gel 
7. 4x pieces of blotting paper cut to size of the gel (the first piece wetted with 20x SSC) 
8. Glass plate 
9. A weight to keep blot in place 
The blot was transferred overnight. Subsequently the membrane was cross-linked by UV 
using the auto-crosslink program of a Stratalinker (Stratagene). 
2.3.5.2 Probe synthesis, hybridisation and visualisation 
The membrane was prehybridised in CG solution (0.5 M NaP [Sigma] pH7.2, 7 % sodium 
dodecyl sulphate [v/v] [SDS] [BioChemika], 1 % BSA [w/v] [Sigma] and 1 mM 
ethylenediaminetetraacetic acid [EDTA] [Fluka BioChemika] pH8.0) for four to six hours. Whilst 
the membrane was prehybridising, the GSK-β-catenin probe was synthesised using the 
NEBlot kit (New England Biolabs). The probe was then added to the membrane and incubated 
at 65°C overnight. The following day, the membrane was washed three times with CG wash 
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solution (40 mM NaP [Sigma] pH7.2, 1 % SDS [v/v] [BioChemika] and 1 mM EDTA [Fluka 
BioChemika] pH8.0) at 65°C for 10 min/wash. The membrane was dried, placed in Saran Wrap 
and exposed overnight in a PhosphorImaging cassette. 
2.4 Cell culture 
2.4.1 Transfection of N2a cells 
N2a cells were grown in DMEM supplemented with L-glutamine (BioWhittaker), 10 % 
FCS (v/v) (Invitrogen) and 1.000 U/ml P/S (Lonza). 3 µL of Fugene 6 reagent (Roche) was 
diluted in 95 µL of serum free media per transfection reaction. A total of 1 µg of plasmid DNA 
was added to each Fugene/Medium mixture. N2a cells were grown at a density of 4x105 
cells/well in seven wells of two 6-well plates overnight. The following day the cells were 
transfected as follows (each combination corresponds to one well): 
1. 0.5 µg pEGFP + 0.5 µg pBlue II Ks+ (vehicle) 
2. 0.5 µg pCre + 0.5 µg pBlue II Ks+ 
3. 0.5 µg pcall2-GSK-β-catenin-IRES-GFP #3 + 0.5 µg pBlue II Ks+ 
4. 0.5 µg pcall2-GSK-β-catenin-IRES-GFP #18 + 0.5 µg pBlue II Ks+ 
5. 0.5 µg pCre + 0.5 µg pcall2-updated-IRES-GFP 
6. 0.5 µg pcall2-updated-IRES-GFP + 0.5 µg pBlue II Ks+ 
7. 0.5 µg pCre + 0.5 µg pcall2-GSK-β-catenin-IRES-GFP #3 
8. 0.5 µg pCre + 0.5 µg pcall2-GSK-β-catenin-IRES-GFP #18 
48 hours post-transfection, the cells were washed with PBS and harvested. The cells 
were then centrifuged for five minutes at 300 x g (4°C). Finally, the cell pellets were re-
suspended in 100 µL of Radio-immunoprecipitation assay (RIPA) buffer (50 mM Tris pH7.4 
[Sigma], 1 % Igepal [v/v] [Fluka BioChemika], 0.25 % Sodium Deoxycholate [w/v] [Sigma], 150 
mM NaCl [Fisher Chemicals], 1 mM EGTA [Sigma]) containing protease inhibitor (1 tablet in 7 
mL RIPA buffer)(Roche) and kept for Western blotting (section 2.6). 
2.4.2 SVZ dissection and growth of neural stem cells 
All surgical instruments were sterilised by heat or by immersing in 70 % ethanol. Mice 
were killed as previously mentioned (section 2.2.1). Brains were removed for NSC isolation; 
they were placed in a 10 cm dish containing ice-cold HIB buffer to preserve the tissue. Each 
brain was processed individually by transferring it into a sterile Petri dish and dissected under 
a Zeiss Stemi SV11 microscope as illustrated in Figure 2.1. 
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Figure 2.1 Dissection of the SVZ part 1 
Top panel: The brain is cut along the arrows shown. The brain slice is placed with the rostral side facing 
down. Bottom panel: The brain slice is cut along the green, black and red lines and the tissue 
represented in yellow is used for subsequent steps in the protocol.  
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The dissected tissue was transferred into ice-cold HIB buffer whilst the other brains 
were dissected. Following dissection, the tissue was transferred onto a sterile Teflon disk and 
minced five times (in different positions) using a Tissue Chopper (McIlwain) set to cut at 400 
µm intervals. The tissue was then treated with Papain (Worthington, USA) and mechanically 
dissociated into a single cell suspension. The cells were pelleted by centrifugation at 300 x g for 
5min at RT. The pellet was reconstituted in a DNAse-albumin-inhibitor mixture and spun in a 
discontinuous density dependent gradient over an albumin-inhibitor mixture at 70 x g for 6 
min at RT. The purified cell pellet was re-suspended in NSC medium (DMEM/Ham’s F12 
[Sigma] supplemented with 1x B27 [Gibco], 1.000 U/ml P/S [Lonza], 20 ng/ml recombinant 
murine EGF *Peprotech+ and 20 ng/ml recombinant human FGFβ [Peprotech]). The cells were 
plated in wells of a 6-well plate for five days before replacing the medium. The cells then grew 
as free-floating aggregates called neurospheres (NS). For the first passage NS were incubated 
with Accumax (Chemicon) for 5 min at 37°C and mechanically dissociated. Following this, 
media was replaced every two to three days. Further passages were performed approximately 
every seven days depending on NS size. These passages were performed by incubation in 
Accumax (Chemicon) for 20 min at 37°C and by mechanical dissociation. All cultures were 
maintained at 37°C in an atmosphere of 5 % CO2 and 95 % relative humidity. 
2.4.3 Infection of cultures with Adenovirus 
NS were collected in a 15 or a 50 mL tube and allowed to settle. All but 1 mL media 
was aspirated and a 50 µL aliquot was taken and incubated in 350 µL AccuMax (Chemicon) at 
37°C for 20 min. Following incubation, the cells were mechanically dissociated to a single cell 
suspension and counted using a Haemocytometer. The number of cells in the remaining 1 ml 
of medium was calculated. The cells were divided equally among three 10 cm plates with 10 
mL NS medium for each. One plate was for Adeno-Cre infection, one plate was for Adeno-GFP 
infection and the remaining plate was left untreated. For infection with Adeno-Cre and Adeno-
GFP, five times more virus was added than cells in a 10 cm plate (both viral titres were 
~2.5x109 pfu/ml). The NS medium was changed 2 days after infection and the NS were 
passaged the following day. Infection efficiency was determined by visualising GFP 
immunofluoresence at 488 nm excitation wavelength using a Zeiss Axiovert 200 fluorescence 
microscope. Photographs were taken with a Nikon Coolpix 995 3 Megapixel digital camera. 
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2.4.4 WST-1 assay 
The WST-1 assay was used to measure the relative proliferation rates of cells in vitro. 
The assay principle is based on the conversion of the tetrazolium salt WST-1 into an orange 
coloured dye (formazan salt) by mitochondrial dehydrogenase enzymes. Over time, this 
reaction produces a colour change of the medium, which is directly proportional to the 
amount of mitochondrial dehydrogenase, and therefore cell number, in a given culture.  This 
reaction product can be detected on a spectrophotometer (Tecan Sunrise microplate reader 
with XFluor 4 software) at detection wavelength of 440 nm, with a reference of 620 nm. 
This analysis was performed in a 96-well plate. NS were dissociated with Accumax 
(section 2.4.2) and seeded at 6 x 104 cells/well in 10 wells containing 100 µL of neural stem cell 
media. The cells were left for 3 days before the addition of 10 µL WST-1 reagent per well and 
the optical density (OD) was recorded at 4, 6 and 8 hours. Alternatively, cells were plated in 
triplicate at either 6 x 104 cells/well or 3.5 x 103 cells/well (specified in text in the relevant 
results chapters). WST-1 reagent was added to one plate at day one post-passage and OD was 
measured at 4 hours. The other plates were treated at day two and three post-passage, 
respectively, and OD was measured as previously.  
All samples were run in groups of 10 or 5 repeats (specified in text in the relevant 
results chapters) and corrected against control wells containing NSC media. Statistical analysis 
was performed using two-tailed t-test. 
2.4.5 Hoechst proliferation assay 
NS were dissociated with AccuMax (section 2.4.2) to a single cell suspension. 
Subsequently, cells were plated in quintuplate for each treatment in wells of a 96-well plate at 
a cell density of 3.5 x 103 cells/well in 100 µL of NSC medium. 96-well plates were prepared in 
triplicates. At day one post-passage, 50 µL of 5 µg/µl of Hoechst 33342 (Sigma) dissolved in 
dimethylsulfoxide (DMSO) was added to each well of one of the plates and incubated for 30 
min at 37°C. The plate was centrifuged for 1 min at 1000 x g. Subsequently, the medium was 
removed from the wells to remove as much unbound Hoechst as possible and replaced with 1X 
PBS. Fluorescence was detected using a spectrophotometer (Tecan Sunrise microplate reader 
with XFluor 4 software) with an excitation wavelength of 360 nm and an emission wavelength 
of 465 nm. This was repeated at day 3 and 5 post-plating or day 2 and 3 post-plating using the 
remaining 96-well plates (specified in text in the relevant results chapters). Statistical analysis 
was performed using a two-tailed t-test. 
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2.4.6 NS size 
NS were dissociated with AccuMax (section 2.4.2) and plated on a 6 cm plate at a cell 
density of 0.5 x 106 cells/well. On the fourth day post-passage, the cells were media changed. 
The cultures were media changed every two days thereafter. On day ten post-passage, the 
diameter of the cells was measured using an Axiovert 135 microscope (Zeiss) and Openlab 5 
software. An average diameter was calculated from ≥100 neurospheres (each diameter was 
measured twice). Statistical analysis was performed using a two-tailed t-test. 
2.4.7 Limited dilution assay 
100 µL of NSC media was pipetted into each well of a 96-well plate. NS were 
dissociated with AccuMax (section 2.4.2) and 100 µL of single cell suspension (5 x 103 cells/ml) 
was pipetted into each well of the row of wells of the plate. Using a 12-channel pipette, 100 µL 
from the top row of wells was serially diluted with each row of wells. This results in a gradient 
of cell concentrations ranging from around 250 cells/well for the top row and 1 cells/well for 
the bottom row. 
2.4.8 Differentiation of neural stem cells 
NS differentiation was induced by plating NS on laminin (1 mg/ml) coated glass 
coverslips (13 mm) in DMEM/Ham’s F12 (Sigma) with 1 % FCS (v/v) (Invitrogen), for two days. 
Cells were fixed in 4 % paraformaldehyde (w/v) for 30 min and processed for 
immunofluorescence (section 2.4.9). 
2.4.9 Immunostaining of differentiated neurospheres 
 Coverslips were washed with PBS and permeabilised with 0.1 % TritonX-100 (v/v) 
(Sigma) diluted in PBS for 10 min. The cells were washed three times with PBS for 5 min each 
time and blocked with 0.1 % BSA (w/v) for 15 min. For anti-O4 immunostaining, coverslips 
were blocked in 5 % FCS (v/v) for 30 min. Following blocking, the cells were washed three 
times with PBS for 5 min/wash and incubated with primary antibody (1:500 rabbit polyclonal 
anti-GFAP [Dako], 1:500 mouse monoclonal anti- microtubule associated protein 2 [MAP2] 
[Chemicon], 1:200 mouse monoclonal anti-Nestin [BD Pharmingen], 1:500 mouse monoclonal 
anti-β-catenin [BD Pharmingen] and 1:400 mouse monoclonal anti-O4 [Chemicon]) for 1 hour 
at room temperature. The cells were washed three times with PBS for 5 min/wash and 
incubated with 1:1000 secondary antibody (goat anti-mouse IgG Alexa 546 [Molecular probes], 
goat anti-mouse IgM Alexa 546 [Molecular probes] for anti-O4 immunostaining and goat anti-
rabbit Alexa 488 [Molecular probes] for anti-GFAP immunostaining) and 1:1000 Hoechst 33342 
diluted in DMSO (250 ng/ml) to label the nuclei. The coverslips were washed once in PBS and 
once in distilled water. Excess water was removed and the coverslips were placed on glass 
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slides face down with DAKO fluorescent mounting medium (DAKO). The slides were kept in the 
dark at 4°C.   
2.5 Immunohistochemistry (Paraffin Histology)  
Brains were fixed in formalin, embedded in paraffin, cut into sections of 3 µm nominal 
thickness and stained with haematoxylin and eosin (H&E). On selected sections, immunostains 
were carried out according to the manufacturer’s instructions: anti-GFAP (rabbit polyclonal, 
1:1000 [DAKO]), anti-neuronal nuclei (NeuN; mouse monoclonal, 1:2000 [Chemicon]), anti-
Nestin (mouse monoclonal IgG1, 1:100, [BD Pharmingen]), anti-synaptophysin (rabbit 
polyclonal, prediluted; [Zymed]), anti-BrdU (rat monoclonal, 1:100, [Abcam]); anti-GFP (rabbit 
polyclonal; 1:300, [Abcam]); anti-MAP2 (mouse monoclonal; 1:200, [Chemicon]). 
Biotinylated secondary antibodies were used in conjunction with the primary 
antibodies, and visualisation was carried out using the horseradish peroxidase-conjugated 
streptavidin system with diaminobenzidine as a chromogen. 
All immunostaining was carried out using the automated NEXES (Ventana Medical 
Systems; www.ventanamed.com), or Vision Biosystems (www.vision-bio.com) automated 
staining apparatus in accordance with the manufacturer’s guidelines. Photographs were 
obtained on a ColorView II digital camera (www.soft-imaging.de) mounted on a ZEISS Axioplan 
microscope. 
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2.6 Protein extraction and Western blotting 
2.6.1.1 Brain and NS homogenisation  
The entire procedure is performed on ice. Brain pieces were homogenised using a 
glass mortar and pestle in RIPA buffer (50 mM Tris pH7.4 [Sigma], 1 % Igepal [v/v] [Fluka 
BioChemika], 0.25 % Sodium Deoxycholate [w/v] [Sigma], 150 mM NaCl [Fisher Chemicals], 1 
mM EGTA [Sigma]) containing protease inhibitor (1 tablet in 7ml RIPA buffer) (Roche). The 
protein extracts were stored at -80°C. 
NS from a 10 cm plate were allowed to settle, washed with PBS and re-suspended in 
100 μl of RIPA buffer containing protease inhibitor. The protein extracts were stored at -80°C. 
2.6.1.2 Nuclear fractionation 
The procedure is performed on ice or at 4°C (where stated). NS were NS from a 10 cm 
plate were allowed to settle and re-suspended in 500 μl of buffer A (10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid [HEPES] [Sigma], 1.5 mM MgCl2 [Fisher 
Chemicals], 10 mM KCl [Fisher Chemicals], 0.5 mM dithriothreitol (DTT) [Sigma], 0.05 % Igepal 
[v/v] [Fluka BioChemika] pH7.9) containing protease inhibitor (1 tablet in 7ml RIPA buffer 
[Roche]). Subsequently, the cells were centrifuged at 3000 rpm for 10 min (4°C). The 
supernatant was removed and the pellet, containing the nuclei was re-suspended in 374 μl of 
buffer B (5 mM HEPES [Sigma], 1.5 mM MgCl2 [Fisher Chemicals], 0.2 mM EDTA [Fluka 
BioChemika+, 0.5 mM DTT *Sigma+, 26 % glycerol (v/v) *Sigma+ pH 7.9) and 26 μl of 4.6 M NaCl 
(final conc. 300mM) (Fisher Chemicals) and incubated for 30 min. Finally, the solution was 
centrifuged at 24000 x g for 20 min (4°C). The supernatant contained the proteins and was 
stored at -80°C. 
2.6.1.3 Determination of protein concentration.  
BSA standards of 0.2 mg/ml to 1.2 mg/ml in 0.2mg/ml increments were prepared by 
diluting BSA (stock 2mg/ml) (Fisher chemicals) in RIPA buffer. The forebrain and cerebellum 
homogenates were diluted 20-fold and 10-fold respectively with RIPA/protease inhibitor. 
Bicinchoninic acid (BCA) protein assay reagent A and B (Fisher Chemicals) were mixed in a 50:1 
ratio and 200 µL were pipetted into the wells of a 96-well plate. 10 µL of each sample were 
added in duplicate and the plate was incubated at 37°C for 30 min before analysis by a Tecan 
Sunrise microplate reader (with XFluor 4 software). Detection wavelength was 570 nm and 
reference 690 nm. Using the BSA standard, the protein concentration of the brain 
homogenates was calculated. 
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2.6.1.4 Polyacrylamide gel 
0.75 mm polyacrylamide gels were made with 10 % separating gel (10 % Bis-
acrylamide [v/v] [Promega], separating gel buffer [0.38 M Tris-base [Sigma], 1.4 mM SDS 
[BioChemika] pH8.8], 0.08 % ammonium persulfate [w/v] [APS] [Sigma], 0.2 % 
tetramethylethylenediamine [TEMED] [w/v]  [Sigma]) and 5 % stacking gel (5 % Bis-acrylamide 
[v/v] [Promega], stacking gel buffer [0.13 M Tris-base {Sigma}, 3.5 mM SDS {BioChemika}, 
traces of Bromphenolblue [Sigma] pH6.8, 0.08 % APS [w/v] [Sigma], 0.2 % TEMED [v/v] 
[Sigma]) for the wells. Prior to loading, the protein samples were made up to 1mg/ml with 1x 
XT sample buffer (BioRad), 0.35 M DTT (Sigma) and distilled water. The samples were then 
boiled for 5’ at 95°C. 10 µL corresponding to 10 µg of protein were loaded into each well. Two 
different protein markers were used, biotinylated protein ladder (Cell Signalling) and Precision 
Plus protein ladder (BioRad). Empty wells were loaded with 10 µL 1x XT sample buffer (BioRad) 
to ensure even running of the bands. The gel was then run at 200V for 30 min in ‘running 
buffer’ (250 mM Tris-base [Sigma], 1.92 M Glycine [Sigma], 1 % SDS [v/v] [BioChemika]). The 
stacking gel and any unused wells were then removed. 
2.6.1.5 Immunoblotting 
Immobilon-P membrane (Millipore) and gel bloating paper (Schleicher & Schuell) were 
cut to the size of the gel. The membrane was dipped in 100 % methanol for 15 seconds, 
washed in distilled water and equilibrated in cold transfer buffer (20 % methanol [v/v] [Fisher 
Chemicals], 25 mM Tris [Sigma], 0.2 M Glycine [Sigma]) for 5 min. The gel, four filter paper 
sheets and two foam pads were also equilibrated in cold transfer buffer for 15 min. The blot 
was assembled as follows; 1x foam pad, 2x filter paper, equilibrated gel, Immobilon-P 
membrane, 2x filter paper, 1x foam pad. A glass tube was used to gently roll air bubbles 
trapped in between the layers. The blot was placed in a cassette into the mini-trans blot cell 
(BioRad) filled with cold ‘transfer buffer’ for 1 hour at 100V. The membrane was air-dried to 
improve protein binding, dipped in 100 % methanol [Fisher Chemicals] for 10 seconds and air 
dried again. After drying, the blot was washed in tris-buffered saline tween-20 (TBST) (1 mM 
Tris-base pH7.8 [Sigma], 0.1 M NaCl (Fisher Chemicals), 0.05 % Tween-20 [v/v] [Fisher 
Scientific]) and blocked overnight in 5 % milk powder (w/v) (Marvel, Premier International 
Foods)/TBST at 4°C. After washing, the blot was incubated overnight with primary antibody 
(see below) in 1 % milk powder (w/v)/TBST at 4°C. Excess antibody was washed off with TBST 
and the blot was incubated for 1 hour with horseradish peroxidase (HRP)-conjugated 
secondary antibody (see below) in 1 % milk powder (w/v)/TBST. Excess antibody was washed 
off with TBST and the blot was incubated with SuperSignal WestPico Chemiluminescent 
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substrate (Fisher Chemicals) to enhance the HRP signal. The bands were visualised with an 
Image Station 440 (Kodak) with Kodak 1D v3.6 software. 
Antibodies: anti-β-catenin (mouse monoclonal, 1:500, [BD transduction Laboratories]), 
anti-GFP (mouse monoclonal, 1:500, [Chemicon]), anti-KT-3 (rabbit polyclonal, 1:5000, 
[Abcam]), anti-β-actin (mouse monoclonal, 1:1000, [Sigma]), anti-mouse IgG-HRP (Sigma) and 
anti-rabbit IgG-HRP (Sigma). 
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2.7 Techniques involving nucleic acids  
2.7.1 Extraction of DNA from tails or ear biopsies 
The tails of mice were anaesthetised with ethyl chloride and up to 0.5 cm were 
biopsied into separate sterile Eppendorf tubes. Each tail was submerged in 0.5 mL of tail lysis 
buffer (50 mM Tris pH8 [Sigma], 100 mM EDTA pH8 [Fluka BioChemika], 100 mM NaCl [Fisher 
Chemicals], 1 % SDS [v/v] [BioChemika]) containing 3 µL of Proteinase K (Roche) and digested 
for at least 2 hours at 55°C (shaking). 
After complete digestion, the samples were spun for 10 min at ≥16000 rpm using an 
Eppendorf centrifuge 5415D to settle debris at the bottom. The supernatant was transferred 
to Eppendorf tubes and 0.5 mL of Isopropanol (Fisher Chemicals) was added to precipitate the 
DNA. The samples were centrifuged for 1 min at ≥16000 rpm. The supernatant was discarded 
and the DNA was air-dried for 5-10 min. Finally 200 µL of tris-EDTA (TE) buffer (10 mM Tris 
pH7.5 [Sigma], 1 mM EDTA [Fluka BioChemika]) pH7 was added and the samples were 
incubated for ≥2 hours (shaking) at 37°C to dissolve the DNA. Samples were kept at 4°C 
thereafter until used for polymerase chain reaction (PCR) analysis. 
DNA was also extracted from mouse embryos tails. In this case smaller amount of 
reagents were used and the 10’ centrifugation step was omitted as no debris needed to be 
separated.  
2.7.2 Polymerase Chain Reaction 
GoTaq Flexi DNA polymerase kit (Promega) was used and kept on ice at all times. All 
PCR primers were obtained from MGW Biotech, dissolved in sterile water to a concentration of 
100 pmol/µl.  
A mastermix containing 5x Green GoTaq Flexi Buffer (1x final concentration), MgCl2 
(1.5 mM), GoTaq DNA polymerase (1U), deoxyribonucleotide triphosphates (dNTPs) (0.25 mM) 
(PCR nucleotide mix [Promega]), primers (0.5 pmol/µl) (MGW Biotech) was made. Per sample, 
1 µL of DNA was dissolved in 24 µL of mastermix. The PCR was perfomed using an AB Applied 
Biosystems GeneAmp PCR System 9700. All PCRs had a common initial heating phase of 94°C 
for 2 min to activate the Taq polymerase and a final phase of 72°C for 7 min. Annealing 
temperatures varied with the primers (see below). The PCR products were stored at 4°C for 2 
days or at -20°C until used. 
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LacZ/ JunD 
Primers : JunD 1:  5’ TCG CTC TTG GCA ACA GCG GCC GCC ACC AGG 
3’ 
  JunD 2:  5’ GGC CGC TCA GCG CCT CCT CGC CAT AGA AGG 
3’ 
  LacZ -f:   5’ CGT CAC ACT ACG TCT GAA CG 3’  
  LacZ -r:   5’ CGA CCA GAT GAT CAC ACT CG 3’  
Band size: LacZ:  500bp 
  JunD:   300bp (internal control) 
PCR program:  Denaturing 94oC 30’’ 
  Annealing 58 oC 40’’ 35 cycles 
  Extension 72 oC 1’30’’ 
 
eGFP/β-actin 
Primers: eGFP-F:  5’ CCT ACG GCG TGC AGT GCT TCA GC 3’ 
  eGFP-R: 5’ CGG CGA GCT GCA CGC TGC GTC CTC 3’ 
  Actin-F:  5’ GAT GAC GAT ATC GCT GCG CTG GTCG 3’ 
  Actin-R: 5’ GCC TGT GGT ACG ACC AGA GGC ATA CAG 3’ 
Band size: β-Actin:  1Kb (internal control) 
  eGFP:  300bp 
PCR program:  Denaturing 94oC 30’’ 
  Annealing 60 oC 45’’ 35 cycles 
  Extension 72 oC 45’’ 
 
Cre/p53 
Primers  Cre 1:  5’ ACC AGC CAG CTA TCA ACT C 3’  
Cre 2: 5’ TAT ACG CGT GCT AGC GAA GAT CTC CAT CTT 
CCA                               
     GCA G 3’ 
p53 Int10 fwd: 5’ AAG GGG TAT GAG GGA CAA GG 3’ 
p53 Int10 rev: 5’ GAA GAC AGA AAA GGG GAG GG 3’ 
Band size: Cre:   300bp 
  p53 wt:  400bp (internal control) 
  p53 floxed:  600bp 
PCR program:  Denaturing 94oC 30’’ 
  Annealing 56 oC 30’’ 35 cycles 
  Extension 72 oC 50’’ 
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Rb 
Primers  Rb18:  5’ GGC GTG TGC CAT CAA TG 3’  
  Rb19:  5’ AAC TCA AGG GAG ACC TG 3’ 
Band size: Rb wt:  690bp 
  Rb floxed:  740bp 
PCR program:  Denaturing 94oC 30’’ 
  Annealing 58 oC 40’’ 35 cycles 
  Extension 72 oC 1’ 
 
β-catenin exon 3 
 
Primers  β-cat ex3-F: 5’ GCT GCG TGG ACA ATG GCT AC 3’  
  β-cat ex3-R: 5’ GCT TTT CTG TCC GGC TCC AT 3’ 
Band size: Rb wt:  690bp 
  Rb floxed:  740bp 
PCR program:  Denaturing 94oC 30’’ 
  Annealing 58 oC 40’’ 35 cycles 
  Extension 72 oC 1’ 
 
2.7.3 Agarose Gel Electrophoresis 
The PCR products were separated by agarose gel electrophoresis. 1.5-2 % Agarose 
(w/v) (Sigma) was dissolved in 1x Tris base-acetic acid-EDTA (TAE) buffer (Sigma). 1.5 μl of 10 
mg/ml ethidium bromide (Sigma) was added per 200 mL of Agarose gel. The gel was poured 
into a mould and allowed to solidify. It was then transferred to a running chamber and filled 
with enough 1x TAE buffer to completely submerge the gel. 10 µL of PCR samples were 
pipetted into the wells. 6 µL of 100 bp ladder (Promega) was loaded as a marker and the gel 
was run at 140V for 1 hour. The bands were visualised with a BioRad Gel Doc 1000 and 
QuantityOne software. 
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3 Generation and expression analysis of GSK-β-
catenin transgenic mice  
3.1 Background 
The Wnt/β-catenin pathway plays an important role in development, stem cell 
maintenance and tumourigenesis (chapter 1). The central member of this pathway is β-
catenin, a 780 aa protein, which was originally identified as a component of E-cadherin 
junctions (Takeichi, 1991). In the absence of Wnt proteins, cytoplasmic β-catenin is 
phosphorylated at key residues and is thereby targeted for degradation (Aberle et al., 1997; 
Morin et al., 1997; Yost et al., 1996). However, in the presence of Wnt proteins this 
phosphorylation, and thus degradation, is abolished (Liu et al., 2002). Under these 
circumstances, stable β-catenin can translocate into the nucleus where it interacts with 
transcription factors to promote the expression of genes involved in proliferation and 
differentiation (Orsulic and Peifer, 1996; Prieve and Waterman, 1999). Some of the genes that 
are up-regulated by β-catenin include the potent oncogenes c-myc, cyclin D1 and MMP-7 
(Crawford et al., 1999; He et al., 1998; Shtutman et al., 1999). 
Mutations in components of the Wnt/β-catenin pathway are common in human 
cancers (Table 1.3 and Table 1.5). This pathway is aberrantly activated in central nervous 
system (CNS) tumours such as medulloblastomas, ‘CNS PNET, NOS’, Turcot’s syndrome and 
glioblastomas (Table 1.5). Of these, the most extensively studied are medulloblastomas, the 
most common malignancy in children (Central Brain Tumor Registry of the United States, 1995; 
Stevens et al., 1991). In medulloblastomas, nuclear β-catenin, a marker of pathway activation, 
has been observed in around 23 % of cases (Eberhart et al., 2000; Ellison et al., 2005; Rogers et 
al., 2009; Yokota et al., 2002). Interestingly, even though activation of the Wnt/β-catenin 
pathway is generally associated with enhanced proliferation/aggressiveness, activation in 
medulloblastomas appears to be a marker of a favourable outcome (Bondi et al., 2004; Clifford 
et al., 2006; Ellison et al., 2005; Kotsinas et al., 2002; Nhieu et al., 1999; Zechner et al., 2003). 
However, patients suffer severe neuro-cognitive defects as a result of current treatment 
regimes (Copeland et al., 1999; Mulhern et al., 1998; Mulhern et al., 1999; Mulhern et al., 
2001; Palmer et al., 2001; Palmer et al., 2003; Ris et al., 2001). Therefore, it is important to 
develop more targeted therapies in order to improve the quality of life of these individuals. 
Nevertheless, not much is known about the role of the Wnt/β-catenin pathway in 
medulloblastomas. A recent report suggests that the Wnt/β-catenin pathway may promote 
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the progression of anaplastic astrocytomas (WHO grade II) to glioblastomas (WHO grade IV) 
(Sareddy et al., 2009b). 
To understand the role of the Wnt/β-catenin pathway in tumours of the CNS, a 
transgenic mouse model was generated in which the Wnt/β-catenin pathway is constitutively 
activated. This model relies on the conditional expression of GSK-β-catenin (Barth et al., 
1999). GSK-β-catenin is a form of β-catenin, which contains the point mutations 
Serine33Alanine, Serine37Alanine, Threonine41Alanine and Serine45Alanine. These mutations 
abolish Gsk3β and Ck1α mediated-phosphorylation of β-catenin and prevent this molecule 
from being degraded (section 1.3.6.1.3). As such, GSK-β-catenin can up-regulate the 
expression of genes downstream of β-catenin in the absence of Wnt proteins (Barth et al., 
1999; Haegele et al., 2003).  
 
3.1.1 Aims 
The aim of this study was to generate a transgenic mouse model to investigate the role 
of the Wnt/β-catenin pathway in CNS tumours. 
 
3.1.2 Methods 
Restriction digestion and ligation were used to generate the pcall2-GSK-β-catenin-
IRES-GFP vector (section 2.3.1). The vector was transfected into neuroblastoma (N2a) cells 
(section 2.4.1) and Western blotting was used to confirm recombination and expression of 
ΔGSK-β-catenin (section 2.6). ES cells were electroporated with the vector (section 2.3.3) and 
β-galactosidase staining was used to confirm integration and expression of the vector (section 
2.2.2). Southern blot analysis was used to select ES cell clones with few copies of the pcall2-
GSK-β-catenin-IRES-GFP vector (section 2.3.5). Vector expression and recombination was 
assessed in mouse brains by β-galactosidase staining (section 2.2.2). Western blotting was 
performed to detect ΔGSK-β-catenin expression (section 2.6). Finally, mouse brains were 
immunohistochemically stained to visualise brain morphology (section 2.5).  
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3.2 Results 
3.2.1 Generation of the pcall2-GSK-β-catenin-IRES-GFP vector 
The pUHD10-3/GSK-β-catenin vector containing GSK-β-catenin was a kind gift from 
Dr Nelson (Barth et al., 1999). In order to excise the intact GSK-β-catenin cDNA from the 
pUHD10-3/GSK-β-catenin vector, a BamH I restriction site was inserted 5’ to the start codon. 
Subsequent BamH I restriction enzyme digestion yielded a 2.49 kb fragment containing the full 
GSK-β-catenin cDNA. This fragment was inserted into the Bgl II site of the pcall2-updated-
IRES-GFP vector. Integration of the 2.49 kb fragment into the correct site was confirmed by 
sequencing (data not shown). This new vector was named pcall2-GSK-β-catenin-IRES-GFP 
(Figure 3.1).  
 
 
Figure 3.1 pcall2-GSK-β-catenin-IRES-GFP vector 
Transgenic mice, which express this construct, were generated. The construct uses the CMV-β-actin 
promoter which confers ubiquitous expression. In non recombined cells, β-galactosidase (LacZ) is 
expressed but not GSK-β-catenin. Following Cre-recombinase administration, the loxP sites are 
recombined resulting in the excision of the LacZ stop cassette. Recombination induces the expression of 
GSK-β-catenin. 
 
 
 
 
  
LacZ loxP 
loxP 
Cre 
loxP 
pA pA GSK-β-Catenin IRES 
EGFP KT-3 
CMV-β-actin promoter  
GSK-β-Catenin IRES 
EGFP 
pA 
CMV-β-actin promoter  
KT-3 
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3.2.2 N2a cells transfected with pcall2-GSK-β-catenin-IRES-GFP vector 
express GSK-β-catenin following Cre-mediated recombination 
To confirm that expression of GSK-β-catenin and EGFP occurs only after Cre-
mediated recombination, the pcall2-GSK-β-catenin-IRES-GFP vector was transiently 
transfected into neuroblastoma (N2a) cells in the presence, or absence, of a vector expressing 
Cre-recombinase. Immunoblotting of transfected cells with anti-GFP and anti-β-catenin 
antibodies showed expression of both GSK-β-catenin and EGFP only when Cre-recombinase 
was present (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Cre-mediated recombination of pcall2-GSK-β-catenin-IRES-GFP results in expression of 
GSK-β-catenin and EGFP in N2a cells 
Cell lysates from transfected neuroblastoma (N2a) cells were immunoblotted using anti-β-catenin and 
anti-GFP antibodies. 20 μg of total protein were loaded per lane. Co-transfection of a Cre-expressing 
plasmid with the pcall2-GSK-β-catenin-IRES-GFP plasmid resulted in the expression of GSK-β-catenin 
and EGFP (lanes 2 and 3). This experiment was performed by H. Naumann, UCL Institute of Neurology, 
and Thomas Jacques, UCL Institute of Child Health.  
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3.2.3 Selection of embryonic stem cells transfected with the pcall2-GSK-β-
catenin-IRES-GFP vector for blastocyst injection 
The pcall2-GSK-β-catenin-IRES-GFP vector expresses LacZ in the absence of Cre-
recombinase (Figure 3.2). LacZ encodes the bacterial enzyme β-galactosidase, which 
hydrolyzes β-galactosidase sugars. β-galactoside expressing cells can be detected by the 
addition of X-gal, which is a synthetic compound. In the presence of β-galactosidase, X-gal can 
be hydrolysed into galactose and 5-bromo-4-chloro-3-hydroxyindole (X), a blue insoluble 
compound.  
To insert the pcall2-GSK-β-catenin-IRES-GFP vector into the genome of embryonic 
stem (ES) cells, ES cells were electroporated with the vector and clones were plated into 
duplicate 96-well plates. ES cells from one plate were stained using X-gal to confirm the 
expression of the pcall2-GSK-β-catenin-IRES-GFP vector. Nine clones (A7, B4, C11, E3, E6, E11, 
F9, G1 and H4) were positive for β-galactosidase expression (data not shown; from Dr. 
Behrens, Cancer Reasearch UK). Transfected cells may contain more than one copy of the 
transfected vector. However, β-catenin mutations in tumours occur only in one allele, with 
only one copy of the mutant gene present (Morin et al., 1997; Zurawel et al., 1998). To model 
this scenario, the ES cell clones, which were positive for LacZ expression, were analysed for the 
insertion of pcall2-GSK-β-catenin-IRES-GFP vector. DNA from each clone was harvested and 
then digested with the EcoR I restriction enzyme. Subsequently, the DNA fragments were 
separated by gel electrophoresis and analysed by southern blot hybridisation. A probe, which 
recognises the C-terminal domain of β-catenin cDNA was used to detect DNA fragments 
derived from the mutant transgene. Clones A7, C11, E11 and H4 were found to contain the 
smallest amounts of the transgene and were selected for injection into blastocysts (Figure 3.3). 
To this end, pseudopregnant foster mice were injected with A7, C11 or H4 ES cells, and 
produced chimaeric offspring. To test whether LacZ was expressed in the offspring of the 
chimaeric mice, a PCR was performed, which confirmed that the injected pcall2-GSK-β-
catenin-IRES-GFP vector had been inserted into the germline and could therefore be inherited. 
Three transgenic mouse lines were generated in this manner, which were named GSK-β-
cateninA, GSK-β-cateninC and GSK-β-cateninH, corresponding with the ES cell clone from 
which they originate (A7, C11 and H4). 
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Figure 3.3 Transfected ES cell clones were selected according to their EcoR I band pattern 
DNA from embryonic stem (ES) cell clones A7, B4, C11, E3, E6, E11, F9, G1 and H4 was digested with 
EcoR I restriction enzyme and analysed by Southern blot. The probe was generated to target the C-
terminal domain of β-catenin cDNA. A7, C11, E11 and H4 were selected for injection into blastocysts. 
This experiment was performed by Dr Thomas Jacques, in the laboratory of Dr. Behrens, Cancer Research 
UK. 
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3.2.4 GSK-β-catenin mice express LacZ in the brain and other organs 
During electroporation, vectors are inserted randomly into the genome. Hence, the 
location of insertion influences the expression level and the expression pattern. To determine 
the expression pattern of the pcall2-GSK-β-catenin-IRES-GFP insert in GSK-β-catenin mice, 
brains and somatic organs were stained for β-galactosidase expression. GSK-β-cateninA/- and 
GSK-β-cateninC/- mice showed strong β-galactosidase expression in the brain, heart and testis 
(Figure 3.4 and Figure 3.5). Additionally, GSK-β-cateninC/- mice showed weak β-galactosidase 
expression in the kidney and liver (Figure 3.4 and Figure 3.5). In contrast, GSK-β-cateninH/- 
mice weakly expressed β-galactosidase in the brain (Figure 3.4). GSK-β-catenin-/- littermate 
control mice did not show any β-galactosidase staining in the organs tested (Figure 3.4 and 
Figure 3.5).  
During development, β-galactosidase expression was strong in GSK-β-cateninA/- and 
GSK-β-cateninC/- embryos and weak in GSK-β-cateninH/- embryos (Figure 3.6). 
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Figure 3.4 GSK-β-catenin transgenic mice express LacZ in the brain 
Brains from GSK-β-catenin
A/-
, GSK-β-catenin
C/-
, GSK-β-catenin
H/-
 transgenic mice and GSK-β-
catenin
-/-
 littermate control mice were formalin-fixed and stained using the β-galactosidase staining 
assay. β-galactosidase metabolises X-gal into galactose and an insoluble blue indole compound (5-
bromo-4-chloro-3-hydroxyindole). GSK-β-catenin
A/-
 (top right panel) and GSK-β-catenin
C/-
 (bottom left 
panel) transgenic mice expressed LacZ in all visible areas of the brain (blue staining) except for the 
corpus callosum and the white matter of the cerebellum. Furthermore, in these mice weak LacZ 
expression could be detected in the brain stem and olfactory bulb. By comparison, GSK-β-catenin
H/-
 
(bottom right panel) expressed LacZ (blue staining) weakly in the cortex, cerebellum, caudate putamen, 
hippocampus and olfactory bulb. There was no LacZ expression seen in GSK-β-catenin
-/-
 littermate 
control mice (top left panel).  
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Figure 3.5 LacZ expression in somatic organs of GSK-β-catenin transgenic mice 
The heart, liver, lung, kidney, spleen and testis were dissected out from GSK-β-catenin
A/- 
(A-F), GSK-β-
catenin
C/-
 (G-L), GSK-β-catenin
H/-
 (M-R) and GSK-β-catenin
-/-
 littermate control mice (S-X), were 
formalin-fixed and stained using the β-galactosidase staining assay. LacZ expression (blue staining) was 
seen in the heart, lung and testis of GSK-β-catenin
A/-
 and GSK-β-catenin
C/-
 transgenic mice. ΔGSK-β-
catenin
C/-
 transgenic mice also showed LacZ expression in the liver and kidney. In contrast, GSK-β-
catenin
H/-
 transgenic mice showed no LacZ expression in any of the organs tested. There was no LacZ 
expression seen in GSK-β-catenin
-/-
 littermate control control mice. The GSK-β-catenin
H/-
 transgenic 
mouse tested was female, hence no testes were tested. 
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3.2.5 Nestin-Cre; GSK-β-catenin mice do not show embryonic lethality 
Previous work by Chenn and Walsh has shown that expression of oncogenic β-catenin 
(90N-β-catenin) in neuronal progenitor cells results in a gross increase in brain size, which 
culminates in embryonic lethality (Chenn and Walsh, 2002). To confirm these results in our 
mouse model, the ΔGSK-β-catenin transgenic mice were crossed with Nestin-Cre transgenic 
mice. Nestin-Cre transgenic mice express Cre-recombinase under the control of the Nestin 
promoter, which is active in neural stem cells during development and in adulthood (Lendahl 
et al., 1990; Reynolds and Weiss, 1992). However, Nestin is also expressed in the developing 
skeletal muscle (Sejersen and Lendahl, 1993). To overcome this, the Nestin-Cre transgenic 
mice used contained the Nestin second intron downstream of the promoter. These mice 
express Cre-recombinase specifically in neural stem cells and neural crest cells (Lothian and 
Lendahl, 1997). In contrast to Chenn and Walsh’s findings, Nestin-Cre; GSK-β-catenin 
transgenic mice were not embryonic lethal, despite strong β-galactosidase expression during 
development (Figure 3.6).  
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Figure 3.6 The ΔGSK-β-catenin construct is expressed in the CNS during development 
GSK-β-catenin
-/-
 littermate control (A-C), GSK-β-cateninA/- (D-F), GSK-β-cateninC/- (G-I) and GSK-β-
catenin
H/-
 (J and K) embryos from embryonic (E) days E10.5, E12.5 and E14.5 were formalin-fixed and 
stained using the β-galactosidase assay. GSK-β-catenin
A/- 
embryos showed strong LacZ expression in 
the skin and the CNS during development. Similarly, GSK-β-catenin
C/-
 embryos expressed LacZ in the 
CNS. In contrast, GSK-β-catenin
H/-
 embryos only expressed LacZ weakly in the CNS. E14.5 embryos from 
the GSK-β-catenin
H/-
 mouse line were not tested as a result of the weak expression observed at E12.5. 
GSK-β-catenin
-/-
 littermate control mice showed no LacZ expression at all time points tested. 
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3.2.6 Recombination in Nestin-Cre; GSK-β-catenin mouse brains 
To analyse which CNS regions in Nestin-Cre; GSK-β-catenin mice were recombined, 
brains from Nestin-Cre; GSK-β-cateninA/-, Nestin-Cre; GSK-β-cateninC/- and Nestin-Cre; 
GSK-β-cateninH/- were stained for β-galactosidase expression. In the mouse model studied 
here, the LacZ gene, which encodes β-galactosidase, is flanked by loxP sites and is excised 
upon Cre-mediated recombination. Hence, cells that are recombined do not express β-
galactosidase and therefore remain unstained. β-galactosidase staining of Nestin-Cre; GSK-β-
cateninA/- and Nestin-Cre; GSK-β-cateninC/- brains showed widespread recombination in 
comparison to controls (Figure 3.7 and Figure 3.8). Recombination was marked in the 
thalamus, cerebellum, caudate putamen and SVZ (Figure 3.7 and Figure 3.8). Additionally, the 
hippocampus, hypothalamus, cortex and brainstem were partially recombined (Figure 3.7 and 
Figure 3.8). Nestin-Cre; GSK-β-cateninH/- brains showed extensive recombination (Figure 3.7). 
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Figure 3.7 Nestin-Cre recombination of GSK-β-catenin
 
mouse brains (sagittal sections) 
Following dissection, brains from GSK-β-catenin and Nestin-Cre; GSK-β-catenin transgenic mice were 
formalin-fixed, sectioned in the sagittal plane and stained using the β-galactosidase assay. Nestin-Cre; 
GSK-β-catenin
A/- 
(B) showed extensive recombination in the cerebellum and thalamus, and partial 
recombination in the brainstem, cortex and olfactory bulb when compared to a GSK-β-catenin
A/-
 
control brains (A). Nestin-Cre; GSK-β-catenin
C/-
 brains showed a very similar recombination pattern (D). 
Finally, Nestin-Cre; GSK-β-catenin
H/- 
brains (F) were also extensively recombined, compared to control 
brains (E). 
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Figure 3.8 Nestin-Cre recombination of GSK-β-catenin
 
mouse brains (coronal sections)  
Following dissection, brains from GSK-β-catenin and Nestin-Cre; GSK-β-catenin mice were formalin-
fixed, sectioned coronally and stained using the β-galactosidase staining assay. Nestin-Cre; GSK-β-
catenin
A/- 
(C and D) showed complete recombination in the caudate putamen and the tissue surrounding 
the lateral ventricle, with partial recombination in the cortex and hippocampus in comparison to GSK-
β-catenin
A/- 
control brains (A and B). Nestin-Cre; GSK-β-catenin
C/-
 brains (G and H) showed a similar 
recombination pattern compared to GSK-β-catenin
C/-
 control brains (E and F).  
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3.2.7 Nestin-Cre; ΔGSK-β-catenin mice express ΔGSK-β-catenin in the brain 
Nestin-Cre; ΔGSK-β-catenin brains were recombined but were not found to be 
enlarged. This could be attributed to a lack of ΔGSK-β-catenin protein expression post-
recombination. To investigate this, forebrain and cerebella fractions of brains from Nestin-Cre; 
ΔGSK-β-cateninA/-, Nestin-Cre; ΔGSK-β-cateninC/- and Nestin-Cre; ΔGSK-β-cateninH/- mice were 
homogenised and tested for β-catenin expression by Western blot analysis. Immunoblotting 
with an anti-β-catenin antibody showed that Nestin-Cre; ΔGSK-β-cateninA/- and Nestin-Cre; 
ΔGSK-β-cateninC/- mouse brains expressed marginally higher levels of total β-catenin compared 
to control brains (Figure 3.9). However, in order to selectively visualise ΔGSK-β-catenin 
protein, brain homogenates were immunoblotted with an anti-KT-3 antibody. KT-3 is a thirteen 
amino acid tag at the C-terminus of ΔGSK-β-catenin. This demonstrated that ΔGSK-β-catenin 
protein could be detected in brain homogenates of Nestin-Cre; ΔGSK-β-cateninA/- and Nestin-
Cre; ΔGSK-β-cateninC/- mice (Figure 3.9). In contrast, very low levels of ΔGSK-β-catenin protein 
were detected in Nestin-Cre; ΔGSK-β-cateninH/- brain homogenates in comparison to controls 
(Figure 3.9). Control brain homogenates from C57Bl/6J mice also showed a weak band of the 
same size as ΔGSK-β-catenin (Figure 3.9). This was one of several non-specific bands seen as a 
result of the cross-reaction of the anti-KT-3 antibody with other targets present in the 
homogenates. GFP protein was not detected after recombination (Figure 3.9).  
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Figure 3.9 Nestin-Cre recombination activates the expression of ΔGSK-β-catenin 
Forebrain and cerebellar homogenates from Nestin-Cre; ΔGSK-β-catenin
A/-
, Nestin-Cre; ΔGSK-β-
catenin
C/-
 and Nestin-Cre; ΔGSK-β-catenin
H/-
 transgenic mice as well as C57Bl/6J control mice were 
immunoblotted for β-catenin (1:500), KT3 (1:5000), GFP (1:500) and β-actin (1:1000). 10 µg of total 
protein was loaded per lane. Expression levels of total β-catenin were not significantly increased after 
recombination. ΔGSK-β-catenin is tagged with KT-3 at the C-terminus. Immunoblotting with anti-KT-3 
antibody showed that ΔGSK-β-catenin protein could be detected in the forebrain and cerebellum of 
Nestin-Cre; ΔGSK-β-catenin
A/- 
(lanes 5 and 6), Nestin-Cre; ΔGSK-β-catenin
C/-
 (lanes 3 and 4) mice. Nestin-
Cre; ΔGSK-β-catenin
H/-
 mice (lanes 1 and 2) expressed little or no ΔGSK-β-catenin. C57Bl/6J brains (lanes 
7 and 8) showed a faint band with an equivalent size to ΔGSK-β-catenin protein. This was one of several 
unspecific bands seen as a result of the cross-reaction of the anti-KT-3 antibody with other targets. β-
actin was used as an internal loading control . 
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3.2.8 GSK-β-catenin expression does not alter brain architecture or cellular 
morphology 
Expression of GSK-β-catenin in Nestin-positive cells was not embryonic lethal as 
previously reported (Chenn and Walsh, 2002). However, it is possible that GSK-β-catenin 
expression could exert a more a subtle effect on brain morphogenesis. To examine this 
possibility, brains from Nestin-Cre; GSK-β-cateninA/- mice were immunohistochemically 
stained for the neuronal markers NeuN, MAP2 and neurofilament 200 (NF200), the glial 
marker GFAP, and for β-catenin protein. Stronger β-catenin staining was detected in the 
hippocampus, cortex and thalamus, but not in the cerebellum of recombined mice in 
comparison to GSK-β-cateninA/- control brains (Figure 3.10, Figure 3.11 and Figure 3.12). 
However, no morphological defects or tumours were detected in any region analysed (Figure 
3.10, Figure 3.11 and Figure 3.12). Of note, some morphological differences were observed in 
the cerebellum and hippocampus (Figure 3.10 and Figure 3.11). However, these were 
attributed to variations in the depth of the brain sections rather than being caused by 
expression of GSK-β-catenin.  
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Figure 3.10 No abnormalities were detected in the cerebellum of Nestin-Cre; GSK-β-catenin mice 
Immunohistochemical studies of control GSK-β-catenin
A/-
 and Nestin-Cre; GSK-β-catenin
A/-
 mice. 
Cerebella were stained with H&E (A-D), NeuN (E-H), β-catenin (I-L), NF200 (M-P), GFAP (Q-T) and MAP2 
(U-X). The first and second columns correspond to low and high power magnification of a control GSK-
β-catenin
A/-
 cerebellum. The third and fourth columns correspond to low and high power magnification 
of a Nestin-Cre; GSK-β-catenin
A/-
 cerebellum (note the slightly deeper (i.e. lateral) section of this brain 
compared to the control). High power magnification images correspond to the fifth and sixth lobule of 
the cerebellum (black box). β-catenin staining in Nestin-Cre; GSK-β-catenin
A/- 
was not altered after 
recombination (K and L) compared to control (I and J). Furthermore, recombined brains showed no 
abnormalities in comparison to controls. The structural differences observed between GSK-β-catenin
A/-
 
and Nestin-Cre; GSK-β-catenin
A/-
 are explained by the lateral depth of the histological sections. The 
scale bar in X corresponds to 1300 µm and 140 µm for low power and high power magnification 
respectively. 
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Figure 3.11 No abnormalities in the hippocampus of Nestin-Cre; GSK-β-catenin brains 
Immunohistochemical studies of control GSK-β-catenin
A/-
 and Nestin-Cre; GSK-β-catenin
A/-
 mice. 
Hippocampi were stained with H&E (A-D), NeuN (E-H), β-catenin (I-L), NF200 (M-P), GFAP (Q-T) and 
MAP2 (U-X). The first and second columns correspond to low and high power magnification of a control 
GSK-β-catenin
A/-
 hippocampus. The third and fourth columns correspond to low and high power 
magnification of a Nestin-Cre; GSK-β-catenin
A/-
 hippocampus. β-catenin staining was stronger after 
recombination (K and L) compared to control (I and J), but no abnormalities were detected. The 
structural differences between GSK-β-catenin
A/-
 and Nestin-Cre; GSK-β-catenin
A/-
 are explained by the 
lateral depth of the histological sections. The scale bar in X corresponds to 700 µm and 220 µm for low 
power and high power magnification respectively. 
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Figure 3.12 No abnormalities in the cortex and thalamus of Nestin-Cre; GSK-β-catenin brains 
Immunohistochemical studies of control GSK-β-catenin
A/-
 and Nestin-Cre; GSK-β-catenin
A/-
 mice. 
Cortex and thalamus was stained with H&E (A-D), NeuN (E-H), β-catenin (I-L), NF200 (M-P), GFAP (Q-T) 
and MAP2 (U-X). The first and second columns correspond to control GSK-β-catenin
A/-
 cortex and 
thalamus respectively. The third and fourth columns correspond to Nestin-Cre; GSK-β-catenin
A/-
 cortex 
and thalamus respectively. β-catenin staining in Nestin-Cre; GSK-β-catenin
A/-
 (K and L) was stronger 
after recombination compared to control (I and J), but no abnormalities were detected. The structural 
differences between GSK-β-catenin
A/-
 and Nestin-Cre; GSK-β-catenin
A/-
 are explained by the lateral 
depth of the histological sections. The scale bar in X corresponds to 850 µm and 450 µm for low power 
and high power magnification respectively.  
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3.3 Discussion 
The Wnt/β-catenin pathway plays an important role in the development of the CNS 
and maintenance of neural stem cells (Thomas and Capecchi, 1990; Wexler et al., 2009). 
Certain CNS tumours show aberrant activation of the Wnt/β-catenin pathway (Table 1.5). For 
example, patients with APC germline mutations have an increased risk of developing 
medulloblastomas, astrocytomas and ependymomas (Attard et al., 2007). Similarly, mutations 
of β-catenin, APC and Axin have been found in approximately 17 % of medulloblastomas 
(Dahmen et al., 2001; Huang et al., 2000; Koch et al., 2001; Rogers et al., 2009; Yokota et al., 
2002; Zurawel et al., 1998). Furthermore, mutations have also been detected in CNS PNET, 
NOS and glioblastomas, albeit rarely (Gotze et al., 2009; Koch et al., 2001; Nikuseva-Martic et 
al., 2007; Rogers et al., 2009). On the other hand, the Wnt/β-catenin pathway is commonly de-
regulated by other mechanisms, as shown by nuclear β-catenin immunoreactivity, a marker of 
pathway activity (Eberhart et al., 2000; Terris et al., 1999). Indeed, around 23 % of 
medulloblastomas and 35 % of CNS PNET, NOS cases have been shown to be positive for 
nuclear β-catenin, a much higher rate than detected pathway mutations (Eberhart et al., 2000; 
Ellison et al., 2005; Rogers et al., 2009; Yokota et al., 2002). Only about 1 % of glioblastomas 
harbour β-catenin mutations (Gotze et al., 2009; Nikuseva-Martic et al., 2007). However, a 
recent study has reported that promoter hypermethylation of Wnt inhibitors is common in 
primary and secondary glioblastomas (Gotze et al., 2009). Furthermore, expression levels of β-
catenin, TCF4, LEF1 and β-catenin downstream targets are increased in glioblastomas and 
lower grade astrocytic tumours (Sareddy et al., 2009b). Interestingly, the expression levels of 
these targets correlate with malignancy, which suggests that the Wnt/β-catenin pathway may 
play a role in glioma progression (Sareddy et al., 2009a; Sareddy et al., 2009b). 
The role of the Wnt/β-catenin pathway in tumours of the CNS is not completely 
understood. To study putative roles of this pathway in CNS tumours, transgenic mice, which 
conditionally express ΔGSK-β-catenin, were generated. ΔGSK-β-catenin has four point 
mutations at key phosphorylation residues, which renders the protein resistant to degradation 
(Barth et al., 1999). As a result, ΔGSK-β-catenin can constitutively activate the Wnt/β-catenin 
pathway (Barth et al., 1999). This was also demonstrated in ES cells, where ΔGSK-β-catenin 
expression up-regulates the expression of Wnt/β-catenin downstream target genes and 
inhibits neuronal differentiation (Haegele et al., 2003). This phenotype has been reproduced 
by expressing truncated APC (Haegele et al., 2003). Collectively, these studies provide strong 
evidence for the ability of ΔGSK-β-catenin to activate the Wnt/β-catenin pathway. 
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The transgenic mice described in this chapter express the LacZ gene prior to 
recombination. This allowed for identification of cells expressing the pcall2-GSK-β-catenin-
IRES-GFP insert using the β-galactosidase staining assay. LacZ expression was widespread in 
the CNS during development and in adulthood (Figure 3.4 and Figure 3.6). Expression could 
also be detected in somatic organs, especially in the testis and heart (Figure 3.5). In 2002, 
Chenn and Walsh reported that the expression of dominant active β-catenin (Δ90N-β-catenin) 
in Nestin-expressing cells resulted in severe CNS abnormalities (Chenn and Walsh, 2002). This 
was attributed to an increase in the proportion of ventricular zone (VZ) neural precursors, 
which continued to divide instead of differentiating (Chenn and Walsh, 2002). To compare this 
result to our experimental models, ΔGSK-β-catenin mice were crossed with Nestin-Cre 
transgenic mice. In the ΔGSK-β-catenin mice, recombination can be detected by loss of LacZ 
expression (Figure 3.1). However, despite widespread recombination, Nestin-Cre; GSK-β-
catenin transgenic mice did not show any developmental abnormalities (Figure 3.7 and Figure 
3.8). Of relevance, recombination was observed in the tissue surrounding the lateral ventricle, 
where the SVZ is located, which is anatomically related to the developmental VZ (Figure 3.8). 
However, the SVZ was not enlarged in these mice. These results suggest that the ΔGSK-β-
catenin protein may not be expressed after recombination. No difference in total β-catenin 
protein levels was detected between GSK-β-catenin and Nestin-Cre; GSK-β-catenin mouse 
brains (Figure 3.9). Of note, ΔGSK-β-catenin protein contains a C-terminal KT3 tag. Using an 
antibody raised against KT-3, ΔGSK-β-catenin protein was detected in brain homogenates from 
Nestin-Cre; ΔGSK-β-cateninA/- and Nestin-Cre; ΔGSK-β-cateninC/- mice, but not in brain 
homogenates from control mice. A faint band could be detected in ΔGSK-β-cateninH/- brain 
homogenates. However a similar band was also detected in C57Bl/6 homogenates. Therefore 
this faint band is likely to be non-specific binding of the antibody to other targets. In cancers 
with β-catenin mutations, 50 % of the expressed β-catenin is degradation-resistant. This raises 
the possibility that low-level expression of ΔGSK-β-catenin may not be sufficient to promote 
CNS abnormalities. However, in theory, degradation-resistant β-catenin should be able to 
constitutively activate the Wnt/β-catenin pathway irrespective of expression levels. This 
suggests that Nestin-Cre; ΔGSK-β-catenin mice may have a more subtle phenotype than that 
observed in the Nestin-Δ90N-β-catenin mice.  
To assess this phenotype, brains from Nestin-Cre; GSK-β-catenin mice were 
processed for immunohistological analysis. Brains were immunostained for the neuronal 
markers, NeuN, MAP2 and NF200, the glial marker GFAP, and β-catenin. No morphological 
differences were found between Nestin-Cre; GSK-β-catenin and control GSK-β-catenin mice 
(Figure 3.10, Figure 3.11 and Figure 3.12). β-catenin staining was stronger in the hippocampus, 
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cortex and thalamus of Nestin-Cre; GSK-β-catenin brains. These findings correlated with the 
loss of LacZ staining (Figure 3.7 and Figure 3.8). However, no difference in β-catenin staining 
was detected in the cerebellum, despite extensive recombination (Figure 3.7 and Figure 3.10). 
The β-catenin antibody detects both wild-type β-catenin and GSK-β-catenin. Therefore, the 
small increase in total β-catenin levels observed by Western blotting may not be sufficient to 
be visualised histologically in the cerebellum (Figure 3.9).  
 
3.4 Summary 
Transgenic mice, which conditionally expressed degradation-resistant β-catenin were 
generated. However, despite extensive recombination in the CNS and expression of the 
mutant β-catenin no developmental abnormalities were detected. To investigate the lack of a 
phenotype, we then extended our studies to in vitro systems to detect potential subtle 
functional effects of GSK-β-catenin in neural stem cells.  
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4 In vitro analysis of GSK-β-catenin expression 
4.1 Background 
 The hierarchical model for tumour development (section 1.2) postulates that only a 
subset of cells in a tumour is capable of re-generating the bulk of the tumour. This model is in 
keeping with the CSC hypothesis, which suggests that tumours are initiated and maintained by 
a population of cells with stem-like properties (Al Hajj et al., 2003; Bonnet and Dick, 1997). 
These cells have been identified in many types of cancer (Al Hajj et al., 2003; Bonnet and Dick, 
1997; O'Brien et al., 2007; Ricci-Vitiani et al., 2007). Evidence suggests that stem cells may be 
the cell of origin of tumours and CSCs (section 1.2).  
 Developmental pathways are vital for stem cell maintenance and are often 
dysregulated in CSCs. Such pathways include the Shh, Notch, Bone morphogenic protein 
(BMP), TGF-β and the Wnt pathway. The Wnt/β-catenin pathway plays a complex role in stem 
cells, regulating proliferation and differentiation (Chenn and Walsh, 2002; Hirabayashi et al., 
2004; Lie et al., 2005; Wexler et al., 2008; Wrobel et al., 2007). For example, activation of the 
Wnt/β-catenin pathway in crypt progenitor cells of the gut has been shown to promote their 
proliferation (Sansom et al., 2004). Interestingly, constitutive activation of the Wnt/β-catenin 
pathway in these progenitors promotes the development of Adenomas (Barker et al., 2009).  
The Wnt/β-catenin pathway plays an important role in NSC maintenance during 
development (Lee et al., 2000; Thomas and Capecchi, 1990). For example, Wnt1 knockout mice 
show a marked decrease in the expansion of neural precursors during mid/hindbrain 
development (Mcmahon and Bradley, 1990; Thomas and Capecchi, 1990). Similarly, Wnt3a 
knockout mice show a reduced proliferation of precursor cells in the caudomedial cortical 
epithelium (Lee et al., 2000). Conversely, increasing Wnt1 expression in turn increases 
proliferation and leads to the expansion of the developing mid/hindbrain (Castelo-Branco et 
al., 2003; Panhuysen et al., 2004).  
The Wnt/β-catenin pathway is also vital for adult NSCs. Several Wnt family members 
are expressed in the dentate gyrus, the stem cell niche of the hippocampus (Lie et al., 2005; 
Shimogori et al., 2004). Injection of a lentivirus expressing Wnt3 into the dentate gyrus of adult 
rats doubled the number of newly generated neurones (Lie et al., 2005). In contrast, injection 
with a lentivirus expressing DKK1, a Wnt antagonist, into the same area, decreased the amount 
of new neurones by 13 % (Lie et al., 2005). These results suggest that the Wnt/β-catenin 
pathway is an important regulator of hippocampal progenitor proliferation and differentiation. 
However, the role of the Wnt/β-catenin pathway in the sub-ventricular zone (SVZ) stem cell 
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niche is not completely understood. Interestingly, a report by Adachi et al. suggests that 
activation of this pathway in SVZ precursors promotes proliferation and inhibits differentiation 
(Adachi et al., 2007).  
 
4.1.1 Aims 
The aims of this study were to determine the effect of GSK-β-catenin expression in 
NSCs and to study the synergism between Wnt/β-catenin pathway activation and p53 or Rb 
knockout in NSCs and brain tumourigenesis.  
 
4.1.2 Methods 
NSC cultures were derived from the sub-ventricular zone (SVZ) and hippocampus of 
adult GSK-β-cateninA/-, GSK-β-cateninC/-, GSK-β-cateninA/A; p53loxP/loxP and GSK-β-
cateninA/A; RbloxP/loxP mice (section 2.4.2). NSCs were infected with Adeno-Cre to mediate 
recombination (section 2.4.3). Western blotting was used to detect levels of ΔGSK-β-catenin 
and cyclin D1 (section 2.6). NSC growth was assayed with the WST-1 assay (section 2.4.4), 
Hoechst assay (section 2.4.5) and neurosphere size assay (section 2.4.6). Self-renewal was 
determined with the limited dilution assay (section 2.4.7). Neurospheres were differentiated 
(section 2.4.8), and the multi-lineage potential of NSCs was assayed using 
immunocytochemistry (section 2.4.9). Nestin-Cre; GSK-β-cateninA/-; p53loxP/loxP were analysed 
histologically (section 2.5). GSK-β-cateninA/-; p53loxP/loxP mice were injected intra-ventricularly 
with Adeno-Cre to assess the interaction between p53 and the Wnt/β-catenin pathway, and 
ultimately to test a potentially tumourigenic effect (section 2.1.4). 
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4.2 Results 
4.2.1 In vitro expression of GSK-β-catenin does not influence neuronal stem 
cell biology 
 Nestin-Cre; GSK-β-catenin mice did not develop tumours or gross abnormalities 
(chapter 3). Transgenic mice expressing Δ90Nβ-catenin under the control of the Nestin 
promoter showed enlarged ventricles as a result of an increase in the pool of sub-ventricular 
zone (SVZ) progenitors (Chenn and Walsh, 2002). Chapter 3 shows that although the SVZ 
appears to be recombined in Nestin-Cre; GSK-β-catenin mice, it is not enlarged (Figure 3.8). 
As previously discussed, absence of abnormalities may be explained by low expression of 
GSK-β-catenin, but this could still result in a more subtle effect on NSCs. To test this 
hypothesis, NSCs from adult GSK-β-catenin mice were cultured in vitro. Expression of GSK-
β-catenin was achieved by infecting the cells with an Adenovirus expressing Cre-recombinase 
(Adeno-Cre) (Figure 4.1). To control for the effect of the virus, a percentage of the cells was 
infected with Adenovirus expressing GFP (Adeno-GFP). 
The WST-1 proliferation assay and neurosphere size assay were used to measure the 
growth of GSK-β-cateninA/- and GSK-β-cateninC/- expressing NSCs. Despite GSK-β-catenin 
expression after recombination, there was no significant growth difference in Adeno-Cre 
recombined NSCs compared to controls (Figure 4.2 and Figure 4.3).  
The Ccnd1 gene encodes the protein Cyclin D1, which is up-regulated during Wnt/β-
catenin signalling (Shtutman et al., 1999; Tetsu and McCormick, 1999). Immunoblotting with 
anti-Cyclin D1 antibody did not show increased levels of Cyclin D1 in Adeno-Cre treated GSK-
β-catenin (Figure 4.1).  
Similarly, no difference in self-renewal was observed using the limited dilution assay 
(Figure 4.4). 
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Figure 4.1 Adeno-Cre infected NSCs express ΔGSK-β-catenin, but do not show increased cyclin D1 
levels 
Nestin-Cre; ΔGSK-β-catenin
A/- 
brain homogenates (lane 1), ΔGSK-β-catenin
A/-
 and ΔGSK-β-catenin
C/-
 NSCs 
(lanes 2-5) were immunoblotted using anti-KT-3 (1:5000), cyclin D1 (1:2000) and β-actin (1:1000) 
antibodies. 10 µg of total protein was loaded per lane. ‘KT-3 high’ refers to long blot exposure and ‘KT-3 
low’ refers to short blot exposure. ΔGSK-β-catenin protein is only expressed in ΔGSK-β-catenin
A/-
 and 
ΔGSK-β-catenin
C/-
 NSCs that have been infected with Adeno-Cre (lanes 2 and 4 respectively). Adeno-
Cre-treated ΔGSK-β-catenin
A/-
 NSCs express markedly more ΔGSK-β-catenin than Adeno-Cre-treated 
ΔGSK-β-catenin
C/-
 NSCs. Cyclin D1 protein levels were unchanged (lane 2 versus lane 3 and lane 4 versus 
lane 5). Nestin-Cre; ΔGSK-β-catenin
A/- 
brain homogenates were used as positive controls. β-actin was 
used as an internal loading control. 
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Figure 4.2 Adeno-Cre infected NSCs do not show increased proliferation potential 
Neurospheres were passaged to a single cell suspension and plated at a concentration of 6x10
5
 cells/ml. 
Three days following passage, the WST-1 reagent was added. The reagent is metabolised by 
mitochondria into a coloured formazan salt and the optical density (OD) measured at 440nm, which 
correlates with cell number. The OD was measured 4, 6 and 8 hours after WST-1 addition. The results 
are from three independent cultures for each line. Each experiment represents an average of ten wells. 
No significant difference was detected between any two treatment groups at any time point for GSK-β-
catenin
A/-
 and GSK-β-catenin 
C/-
 NSCs (two-tailed t-test). OD values where tested for normality and 
homoscedasticity (i.e. all random variables have the same variance). 
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Figure 4.3 Adeno-Cre infected NSCs are not bigger than controls 
Neurospheres were passaged to a single cell suspension and 0.5x10
6
cells were plated on a 6 cm plate. 
Ten days following passage, the diameter of the neurospheres was measured using an Axiovert 135 
microscope (Zeiss) and the Openlab 5 software. An n=3 was calculated from three separate cultures for 
each cell line. Each experiment represents the average of 100 neurospheres. There was no significant 
difference in neurosphere diameter for GSK-β-catenin
A/-
 (A) or GSK-β-catenin
C/-
 (B) NSCs. 
Neurosphere diameter measurements where checked for normality and homoscedasticity.  
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 Figure 4.4 Adeno-Cre infected NSCs do not show increased self-renewal potential 
Neurospheres were passaged to a single cell suspension. Around 500 cells were plated into each well of 
the top row of a 96-well plate. The cells were serially diluted for each remaining row of wells. Ten days 
following passage, the number of neurospheres was counted. An n=3 was calculated from three 
separate cultures for each line. Each single experiment represents the average of twelve wells. The 
untreated and Adeno-GFP-treated results from GSK-β-catenin
A/-
 and GSK-β-catenin
C/-
 were pooled for 
an n=6. There was no significant difference in the number of neurospheres for both GSK-β-catenin
A/-
 
and GSK-β-catenin
C/-
 at any concentration. Neurosphere numbers where checked for normality and 
homoscedasticity.  
 
One of the hallmarks of NSCs is their ability to differentiate into neurones, astrocytes 
and oligodendrocytes. To investigate the effect of GSK-β-catenin in differentiation GSK-β-
cateninA/- NSCs were differentiated in vitro and analysed by immunofluorescence. Neurones 
were detected using an antibody against MAP2, astrocytes with an antibody against GFAP and 
oligodendrocytes with an antibody against O4. Type B NSCs were detected by double staining 
with an anti-GFAP and anti-Nestin antibodies (Doetsch, et al 1999). No obvious difference was 
observed for any cell population (Figure 4.5). To detect β-catenin, differentiated cells were 
immunostated with an anti-β-catenin antibody. However, no increase in nuclear β-catenin was 
observed (data not shown). As a result, an anti-KT3 antibody was used to specifically detect 
ΔGSK-β-catenin, but the staining pattern of this antibody was unspecific (data not shown). As a 
result of this and of the negative results with GSK-β-catenin mice thus far, the cells were not 
counted. 
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 Figure 4.5 No obvious difference in the differentiation of ΔGSK-β-catenin
A/- 
NSCs 
Adeno-Cre, Adeno-GFP treated and untreated ΔGSK-β-catenin
A/- 
neurospheres were plated on laminin-
coated glass slides in DMEM/Ham-F12 media supplemented with 10 % FCS. Forty eight hours post-
culture, cells were fixed with 4 % formaldehyde and immunostained with rabbit polyclonal anti-GFAP 
(1:500), mouse monoclonal anti-MAP2 (1:500) and mouse monoclonal anti-O4 (1:300). Hoechst 33342 
(1:1000) was added to label the nuclei. The scale bar in H corresponds to 76 μm (A and B) and 153 μm 
(C-I). No obvious difference in the differentiation pattern was detected 
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4.2.2 Additional deletion of p53 does not affect brain morphology and does 
not promote neoplastic transformation  
TP53, the gene encoding p53, is one of the most commonly mutated genes in human 
cancers (Hainaut and Hollstein, 2000). For example, TP53 is mutated in up to 25 % of primary 
and 65 % of secondary glioblastomas (Ohgaki et al., 2004; Watanabe et al., 1996; Watanabe et 
al., 1997). However, p53 knockout in mice does not result in brain tumour development 
(Donehower et al., 1992; Harvey et al., 1993). In contrast, combination of p53 knockout with 
phosphatase and tensin homolog (PTEN) or Rb knockout in mice, promotes the development 
of PNETs and glial tumours corresponding to human oligoastrocytomas (Jacques et al., 2010). 
Therefore, Nestin-Cre; GSK-β-catenin mice were crossed with p53loxP/loxP conditional mice to 
promote neoplastic transformation.  
Brains from GSK-β-cateninA/-; p53loxP/loxP and Nestin-Cre; GSK-β-cateninA/-; p53loxP/loxP 
mice were immunohistochemically stained for NeuN, MAP2 and NF200, GFAP and β-catenin 
but no malformations or brain tumours were detected (Figure 4.6, Figure 4.7 and Figure 4.8). 
Increased GFAP staining was detected in Nestin-Cre; GSK-β-cateninA/-; p53loxP/loxP mice, but 
not in GSK-β-cateninA/-; p53loxP/loxP mice or Nestin-Cre; GSK-β-catenin mice. This suggests 
that p53 loss of function is associated with this phenotype. GFAP marks astrocytes and type B 
NSCs (Doetsch, et al 1999). However, type B NSCs are unlikely to be present in an adult 
cerebellum. This suggests that the increased GFAP staining corresconds with an increase in 
gliosis. Additionally, there was no difference in brain weight between Nestin-Cre; GSK-β-
cateninA/-; p53loxP/loxP and GSK-β-cateninA/-; p53loxP/loxP mice (Figure 4.9). 
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Figure 4.6 There are no abnormalities in the cerebellum of Nestin-Cre; GSK-β-catenin; p53
-/-
 brains 
Cerebella from GSK-β-catenin
A/-
; p53
loxP/loxP
 and Nestin-Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 mice were 
stained for H&E (A-D), NeuN (E-H), β-catenin (I-L), NF200 (M-P), GFAP (Q-T) and MAP2 (U-X). The first 
and second columns correspond to low and high power magnification of a GSK-β-catenin
A/-
; p53
loxP/loxP
 
cerebellum. The third and fourth columns correspond to low and high power magnification of a Nestin-
Cre; GSK-β-catenin
A/-
; p53
-/-
 cerebellum. High power magnification images correspond to the fifth and 
sixth lobule of the cerebellum (black box). β-catenin staining was unchanged after recombination. 
Furthermore, recombined brains showed no abnormalities when compared to controls. Stronger gliosis 
was observed in Nestin-Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 cerebella. The scale bar in X corresponds to 
1300 µm and 140 µm for low power and high power magnifications respectively. 
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Figure 4.7 There are no abnormalities in the hippocampus of Nestin-Cre; GSK-β-catenin; p53
loxP/loxP
 
brains 
Hippocampi from GSK-β-catenin
A/-
; p53
loxP/loxP
 and Nestin-Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 mice were 
stained for H&E (A-D), NeuN (E-H), β-catenin (I-L), NF200 (M-P), GFAP (Q-T) and MAP2 (U-X) The first 
and second columns correspond to low and high power magnification of a GSK-β-catenin
A/-
; p53
loxP/loxP
 
hippocampus. The third and fourth columns correspond to low and high power magnification of a 
Nestin-Cre; GSK-β-catenin
A/-
; p53
-/-
 hippocampus. β-catenin staining was unchanged after 
recombination. Furthermore, recombined brains showed no abnormalities when compared to controls. 
Stronger gliosis was observed in Nestin-Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 brains. The structural 
differences between the hippocampi of GSK-β-catenin
A/-
 and Nestin-Cre; GSK-β-catenin
A/-
 are 
explained by the lateral depth of the histological sections. The scale bar in X corresponds to 700 µm and 
220 µm for low power and high power magnifications respectively. 
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Figure 4.8 There are no abnormalities in the cortex and thalamus of Nestin-Cre; GSK-β-catenin; 
p53
loxP/loxP
 brains 
Cortices and thalami from GSK-β-catenin
A/-
; p53
loxP/loxP
 and Nestin-Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 
mice was stained for H&E (A-D), NeuN (E-H), β-catenin (I-L), NF200 (M-P), GFAP (Q-T) and MAP2 (U-X) 
The first and second columns correspond to the cortex and thalamus of a GSK-β-catenin
A/-
; p53
loxP/loxP
 
mouse. The third and fourth columns correspond to the cortex and thalamus of a Nestin-Cre; GSK-β-
catenin
A/-
; p53
-/-
 mouse. β-catenin staining was unchanged after recombination. Furthermore, 
recombined brains showed no abnormalities when compared to controls. Stronger gliosis was observed 
in Nestin-Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 brains. The scale bar in X corresponds to 850 µm and 450 
µm for low power and high power magnifications respectively.   
139 | P a g e  
 
 
 
 
 
 
 
Figure 4.9 No significant difference in brain weight between GSK-β-catenin
A/-
; p53
loxP/loxP
 and Nestin-
Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 mice 
GSK-β-catenin
A/-
; p53
loxP/loxP
 (n=14) and Nestin-Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 (n=17) brains were 
weighed and the value converted to a percentage of body weight. There was no significant difference 
between GSK-β-catenin
A/-
; p53
loxP/loxP
 and Nestin-Cre; GSK-β-catenin
A/-
; p53
loxP/loxP
 mice (p=0.06, two-
tailed t-test). 
 
140 | P a g e  
 
4.2.3 Additional deletion of p53 or Rb in NSCs does not have a consistent 
effect on proliferation 
As GSK-β-catenin expression was predicted to be low, GSK-β-cateninA/A homozygous 
mice were generated to increase expression. These mice were then crossed with either 
p53loxP/loxP or RbloxP/loxP conditional knockout mice to assess the synergistic effect, if any, of 
these mutations in NSCs. Subsequently, NSC cultures were derived and grown as previously 
discussed.  
 NSC growth was measured using the Hoechst proliferation assay. Hoechst 33342 is a 
cell-permeant nuclear counterstain that emits blue fluorescence when bound to dsDNA; 
fluorescence is proportional to the amount DNA, which is an indication of the number of cells 
in culture. Using this assay, the amount of fluorescence was measured at days 1, 3 and 6 post-
plating. A modest increase in the proliferation of Adeno-Cre infected GSK-β-cateninA/A; 
p53loxP/loxP and GSK-β-cateninA/A; RbloxP/loxP NSCs (n=1) was detected (Figure 4.10).  
Proliferation was also assessed using the neurosphere size assay. Adeno-Cre 
recombined GSK-β-cateninA/A; p53loxP/loxP and GSK-β-cateninA/A; RbloxP/loxP NSCs grew smaller 
in size than controls (n=1) (Figure 4.11).  
The limited dilution assay was used to determine self-renewal and indicated that 
Adeno-Cre treated GSK-β-cateninA/A; RbloxP/loxP cultures grew fewer neurospheres than Adeno-
GFP treated controls (n=1) (Figure 4.12). Conversely, Adeno-Cre-infected GSK-β-cateninA/A; 
p53loxP/loxP cultures produced more neurospheres than Adeno-GFP infected controls (n=1) 
(Figure 4.12). However, the number of neurospheres was similar between untreated cultures 
and Adeno-Cre treated cultures for both cell lines.  
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Figure 4.10 Adeno-Cre-infected GSK-β-catenin
A/A
; Rb
loxP/loxP
 and GSK-β-catenin
A/A
; p53
loxP/loxP
 NSCs 
show a slightly enhanced proliferation potential 
Neurospheres from GSK-β-catenin
A/A
; Rb
loxP/loxP
 (A) or GSK-β-catenin
A/A
; p53
loxP/loxP
 (B) cultures were 
passaged to a single cell suspension. Cells were plated in quintuplet for each treatment at a density of 
3.5x10
3
 cells/well. Three identical 96-well plates were prepared. On day one post-plating, Hoechst 
33342/DMSO was added to each well of one of the plates and incubated for 30 min at 37 °C. As much 
medium as possible was removed and replaced with PBS to lower unbound background Hoechst. 
Fluorescence was measured at 360 nm excitation and 465 nm emission. The same procedure was 
repeated on days 3 and day 6 post-plating with the remaining 96-well plates. Adeno-Cre-infected NSCs 
grew slightly faster than controls. This was a single experiment, therefore the statistical significance 
cannot be determined. 
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Figure 4.11 Adeno-Cre-infected GSK-β-catenin
A/A
; Rb
loxP/loxP
 and GSK-β-catenin
A/A
; p53
loxP/loxP
 
neurospheres are smaller than controls 
Neurospheres were passaged to a single cell suspension and 0.5x10
6
cells were plated on a 6 cm plate. 
Ten days after passage, the diameter of the neurospheres was measured using an Axiovert 135 
microscope (Zeiss) and the Openlab 5 software. Each experiment was the average of 100 neurospheres. 
Adeno-Cre-infected GSK-β-catenin
A/A
; Rb
loxP/loxP
 (A) or GSK-β-catenin
A/A
; p53
loxP/loxP
 (B) neurospheres 
grew smaller than controls. This was a single experiment, therefore the statistical significance cannot be 
determined.  
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Figure 4.12 Adeno-Cre-infected GSK-β-catenin
A/A
; p53
loxP/loxP
 NSCs show higher self-renewal, but 
GSK-β-catenin
A/A
; Rb
loxP/loxP
 NSCs do not 
Neurospheres were passaged to a single cell suspension. About 500 cells were plated into each well of 
the top row of a 96-well plate. The cells were serially diluted for each row of wells. Ten days after 
passage, the number of neurospheres was counted. Each result was an average of twelve wells. Adeno-
Cre treated GSK-β-catenin
A/A
; p53
loxP/loxP
 (A) grew more spheres than Adeno-GFP controls. Conversely, 
Adeno-Cre infected GSK-β-catenin
A/A
; Rb
loxP/loxP
 grew fewer spheres than Adeno-GFP treated controls 
(B). This was a single experiment, therefore the statistical significance cannot be determined.  
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4.2.4 In vivo recombination in the SVZ niche of GSK-β-cateninA/- ; p53flox/flox 
mice does not cause CNS neoplasia 
An alternative method for inducing recombination in vivo is injecting Adeno-Cre virus 
directly into lateral ventricles, resulting in an infection of cells in the SVZ (Jacques et al., 2010). 
Nine GSK-β-cateninA/- ; p53loxP/loxP mice and nine p53loxP/loxP control mice were injected with 
Adeno-Cre and culled three hundred days post-infection. No hyperplasias or tumours were 
found in the SVZ (Figure 4.13).  
 
 
Figure 4.13 SVZ recombined GSK-β-catenin
A/-
 ; p53
flox/flox
 mice do not develop abnormal cell 
proliferations  
The lateral ventricles of GSK-β-catenin
A/-
 ; p53
flox/flox
 (n=9) (D-F) and control p53
flox/flox
 (n=9) (A-C) mice 
were injected with Adeno-Cre. Three hundred days post-injection the mice were culled and the brains 
were processed for histology. Hyperplasia or tumours were not found. The scale bar in F corresponds to 
130 µm. 
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4.3 Discussion 
Nestin-Δ90N-β-catenin transgenic mice show severe CNS developmental abnormalities 
and die prior to birth (Chenn and Walsh, 2002). In this mouse model, expression of Δ90N-β-
catenin in NSCs increases the proportion of neural stem cells, which continue to proliferate 
instead of differentiating (Chenn and Walsh, 2002). As previously discussed, Nestin-Cre; ΔGSK-
β-catenin mice do no show CNS developmental abnormalities (chapter 3). Although the 
protein is expressed in the brain, the SVZ is not enlarged as would be expected. This may be 
attributed to the weak expression of ΔGSK-β-catenin. However, the existence of a more subtle 
phenotype, which may not be detected, by histological examination, cannot be excluded. To 
investigate this possibility, the effect of ΔGSK-β-catenin expression in NSCs was investigated. 
For this purpose, NSC cultures were grown from the SVZ of adult ΔGSK-β-catenin mice. To 
induce ΔGSK-β-catenin expression, NSCs were infected with an Adenovirus expressing Cre-
recombinase. An Adenovirus expressing GFP was used as a control. Western blots of NSCs 
showed that ΔGSK-β-catenin was expressed after Adeno-Cre mediated recombination (Figure 
4.1). Of the two ΔGSK-β-catenin transgenic mouse lines tested, ΔGSK-β-cateninA/- NSCs 
expressed significantly more mutant protein than ΔGSK-β-cateninC/- NSCs. 
The WST-1 proliferation assay was used to determine NSC growth. In this assay, the WST-
1 reagent is metabolised by mitochondria into formazan, a dark red compound. The amount of 
formazan can be measured by optical density and is proportional to the number of cells in 
culture. Adeno-Cre recombined ΔGSK-β-cateninA/- and ΔGSK-β-cateninC/- NSCs did not show an 
increased growth potential in comparison to controls. However, the caveat of this method is 
that growth is not measured directly, but as a by-product of mitochondrial activity. Hence, if 
expression of GSK-β-catenin alters mitochondrial metabolism, this would have affected the 
interpretation of the data. Indeed, expression of degradation-resistant β-catenin has been 
shown to increase the mitochondrial activity of intestinal epithelial and colon cancer cells 
(Mezhybovska et al., 2009). This suggests that Adeno-Cre recombined ΔGSK-β-catenin NSCs 
may have an increased rate of formazan production, which could be misunderstood for an 
increase in proliferation. However, in our studies, Adeno-Cre recombination did not 
significantly alter formazan formation. This can be explained if GSK-β-catenin expression is 
not having an effect in these cells. This is in agreement with the results obtained in this 
chapter. 
Another method used to determine NSC growth was to measure NS size. NSCs grown 
under non-adherent conditions form spherical bodies, termed neurospheres. If a treatment 
has the potential to affect the growth of NSCs it can be hypothesised that it would also have an 
impact on the size of the neurospheres. To test this theory, NSCs were grown for ten days 
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before measuring the diameter of one hundred spheres for each treatment. Adeno-Cre treated 
ΔGSK-β-cateninA/- and ΔGSK-β-cateninC/- neurospheres were not significantly larger or smaller 
than controls. However, it is possible that neurosphere growth may have reached a plateau by 
day 10. This would indicate that growth differences may have been missed. Indeed, a report by 
Mori et al. suggests that neuropshere growth starts decreasing at around 250 µm in diameter 
(Mori et al., 2006). Moreover, in our study neurospheres rarely reached a size ≥ 250 µm.  
One of the key characteristics of stem cells is their ability to self-renew. To assess self-
renewal, cells were plated in decreasing concentrations from 250 cells/well to 4 cells/well and 
grown for 10 days. Only stem cells have the ability to form spheres. Hence, the number of 
secondary neurospheres is an indication of self-renewal potential. A caveat to this assay is that 
neurospheres freely fuse with each other (Singec et al., 2006). Coles-Takabe et al. (2008), 
closely studied the formation of non-clonal neurospheres and found that when cells were 
plated at a density of 131 cells/cm2, the percentage of non-clonal spheres was negligible if the 
cultures were left undisturbed (Coles-Takabe et al., 2008). In the limited dilution assay, cells 
are grown at 168 cells/cm2, for the highest concentration and 1 cell/cm2, for the lowest. They 
are disturbed only twice during the experiment for the addition of fresh medium and growth 
factors. Therefore, non-clonal sphere formation is likely to be negligible, especially for the 
lower concentrations. The results presented in this chapter show that there is no significant 
difference in self-renewal after Adeno-Cre recombination for either ΔGSK-β-cateninA/- and 
ΔGSK-β-cateninC/- NSCs.  
Collectively, the results here largely disagree with published data (Hirabayashi et al., 
2004; Qu et al., 2010; Yu et al., 2006). A study investigating the expression of S33Y β-catenin in 
cortical neural precursors demonstrated that S33Y β-catenin does not affect their growth and 
self-renewal (Hirabayashi et al., 2004). Although this report provides evidence in favour of the 
results presented in this chapter, the precursors in the Hirabayashi et al. study were from 
E11.5 embryos, which would have had a different expression pattern and chromatin structure 
than what occurs in adult NSCs. In disagreement with the data shown here, a report by Yu and 
colleagues suggests that activation of the Wnt/β-catenin pathway increases the proliferation 
and self-renewal of SVZ neural stem cells (Yu et al., 2006). In this report, activation of the 
pathway was induced by transfection with Wnt3a or Wnt5a. Proliferation was measured by 
BrdU incorporation, which labelled dividing cells and daughter cells. However, there are a few 
counter arguments for their results. For example, the medium used to culture the cells 
contained 10 % FCS, which has been shown to cause the irreversible differentiation of NSCs 
(Gage et al., 1995; Lee et al., 2006; McKay, 1997; Reynolds and Weiss, 1992). Hence, this may 
have influenced their results. Additionally, for self-renewal measurement, cells were plated at 
2x103 cell/cm2, which was shown by Coles-Takabe et al., to result in 15-100 % of non-clonal 
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spheres, depending on how often the plates were disturbed(Coles-Takabe et al., 2008; Yu et 
al., 2006). However, a recent report by Qu and colleagues agrees with Yu and colleagues 
results. In this report, expression of Δ90N-β-catenin is shown to increase the percentage of 
BrdU-positive cells from 34 to 49 % in SVZ NSC cultures (Qu et al., 2010). Similarly, expression 
of Wnt7a also increased proliferation and self-renewal (Qu et al., 2010). In this study, self-
renewal was measured by plating single cells under adherent conditions and counting the 
progeny, thereby removing the risk of non-clonal sphere formation.  
Despite expression of ΔGSK-β-catenin protein in NSCs, their growth was not significantly 
increased. Therefore, mice homozygous for ΔGSK-β-cateninA/A were generated to increase 
expression levels. Subsequently, these mice were crossed with p53 or Rb conditional knockout 
mice to promote growth and tumour development. p53 is involved in the cellular response to 
DNA damage and is often mutated in cancers [reviewed in (Hainaut and Hollstein, 2000)]. With 
respect to CNS tumours, p53 is mutated in up to 25 % of primary and 65 % of secondary 
glioblastomas (Ohgaki et al., 2004; Watanabe et al., 1996; Watanabe et al., 1997). Similarly, 
TP53 is mutated in medulloblastomas, albeit rarely (up to 11 % of cases) (Adesina et al., 1994; 
Alderson et al., 1996; Ohgaki et al., 1993). However, the p53 pathway is altered by alternative 
mechanisms in up to 21 % of medulloblastoma cases (Frank et al., 2004). Additionally, several 
medulloblastoma and PNET mouse models have been generated, which involve p53 
inactivation (Frappart et al., 2009; Momota et al., 2008). The RB gene encodes the 
retinoblastoma protein (Rb), which plays a crucial role in G1S phase transition (Weinberg, 
1995). Loss of heterozygosity at 13q, which affects the RB gene, was found in 12 % of primary 
and 38 % of secondary glioblastomas (Nakamura et al., 2000). Similarly, promoter 
hypermethylation of the RB gene, which has been correlated with loss of expression, was 
found in 43 % of primary and 14 % of secondary glioblastomas (Nakamura et al., 2001a).  
In vitro, Adeno-Cre treated ΔGSK-β-cateninA/A; p53loxP/loxP and ΔGSK-β-cateninA/A; RbloxP/loxP 
NSCs grew marginally faster than controls. To measure growth, the Hoechst proliferation assay 
was used. In contrast to the WST-1 proliferation assay which measures mitochondrial 
metabolism, this assay measures DNA content. The amount of DNA was measured on days 1, 3 
and 6 post-plating to more accurately follow the growth of the cells. Neurospheres from 
Adeno-Cre treated ΔGSK-β-cateninA/A; p53loxP/loxP and ΔGSK-β-cateninA/A; RbloxP/loxP NSCs grew 
smaller than controls. Additionally, some differences in self-renewal were observed. However, 
in general, these effects were very mild. 
Nestin-Cre; ΔGSK-β-cateninA/-; p53loxP/loxP mouse brains were not larger than control and 
did not show CNS abnormalities. Nestin-Cre; ΔGSK-β-cateninA/-; p53loxP/loxP brains showed 
increased level of gliosis, although this was not the case for Nestin-Cre; ΔGSK-β-cateninA/- 
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brains. These results imply that gliosis was a result of p53 inactivation and were independent 
of ΔGSK-β-catenin expression.  
Expression of degradation-resistant β-catenin may not be sufficient for neoplastic 
transformation. For example, Patched+/- mice expressing S33Y β-catenin in Nestin-expressing 
cells do not develop any tumours after eight weeks (Fults et al., 2002). Similarly, p53-/- mice 
expressing S33Y β-catenin in GFAP-expressing cells do not develop tumours within three 
months (Momota et al., 2008). The latter study was limited to three months due to the 
development of lymphomas and sarcomas, a known phenotype of p53 knockout mice (Harvey 
et al., 1993). Collectively, both studies suggest that β-catenin does not promote 
tumourigenesis. However, degradation-resistant β-catenin may promote tumour formation in 
the long-term. By using p53 conditional knockout mice the risk of sarcoma and lymphoma 
development is minimised, since p53 is not inactivated in connective tissue or the lymphatic 
system in this study. Hence, to address this possibility, the lateral ventricles of a cohort of 
ΔGSK-β-cateninA/-; p53loxP/loxP mice were injected with Adeno-Cre. However, 300 days post-
infection no brain tumours or hyperplasia were detected in the SVZ (Figure 4.13). Taken 
together these results suggest that degradation-resistant β-catenin does not have a neoplastic 
potential. Nonetheless, degradation-resistant β-catenin may be able to affect a tumour 
phenotype. For example, p53-/- mice expressing c-myc in GFAP-expressing cells developed 
PNET-like tumours with a latency of fourteen weeks (Momota et al., 2008). However, when 
S33Y β-catenin was co-expressed, the tumour latency shortened to eight weeks (Momota et 
al., 2008). Furthermore, these tumours showed a larger range of histological features 
(Momota et al., 2008). This was observed without an increase in the number of tumours 
detected, suggesting that S33Y β-catenin was not involved in the genesis of these tumours. 
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4.4 Summary 
Expression of ΔGSK-β-catenin did not alter neural stem cell proliferation or self-renewal. 
In addition, NSC proliferation was not increased, despite ΔGSK-β-catenin expression in 
conjunction with p53 or Rb inactivation. In vivo, Nestin-Cre; ΔGSK-β-cateninA/-; p53loxP/loxP mice 
did not develop tumours or CNS abnormalities. Similarly, ΔGSK-β-cateninA/-; p53loxP/loxP mice 
injected with Adeno-Cre into the lateral ventricles did not develop hyperplastic or neoplastic 
foci. As discussed above, most of these findings are in variance with existing literature. We 
assumed that the expression level of ΔGSK-β-catenin was responsible for the lack of a 
phenotype. Deletion of Rb or p53 alone does not show a significant change in stem cell 
proliferation in vitro. Additional activation of β-catenin does not further alter the proliferation 
of self-renewal of the stem cells. It was therefore concluded that expression of ΔGSK-β-catenin 
in this model system is not able to elicit a significant biological effect alone or in combination 
with inactivated Rb or p53 function. It was therefore decided not to further investigate our 
model system and obtain an alternative transgenic mouse model for expressing degradation-
resistant β-catenin. 
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5 Analysis of β-cateninΔex3 expression in the CNS 
5.1 Background 
As discussed in chapters 3 and 4, the results obtained from the ΔGSK-β-catenin 
transgenic mouse model do not agree with previous published reports (Chenn and Walsh, 
2002; Wrobel et al., 2007). Therefore, an alternative mouse model, in which degradation-
resistant β-catenin is conditionally expressed, was utilised. In this model, exon 3 of the β-
catenin gene, which encodes the Gsk3β/Ck1α phosphorylation site among other domains, is 
flanked by loxP sites. Cre-mediated recombination excises this exon and degradation-resistant 
β-cateninΔex3 is expressed. Deletion of exon 3 has been identified in some human cancer cell 
lines (Iwao et al 1998, Sparks et al 1998). Since the endogenous β-catenin gene is mutated, this 
model accurately depicts spontaneous mutations in human cancers. Furthermore, the target 
gene will be expressed at endogenous levels.  
The β-cateninlox(ex3) mice were originally generated by the group of Taketo, who 
demonstrated that expression of β-cateninΔex3 promoted intestinal polyposis (Harada et al., 
1999). Subsequent reports have indicated that expression of β-cateninΔex3 can promote 
prostate and liver tumourigenesis (Table 5.1). Currently, there is limited research into CNS 
tumourigenesis using the β-cateninlox(ex3) mouse model. Of particular interest, expression of β-
cateninΔex3 in Nestin-expressing cells has been shown to delay the maturation of radial glia 
(Wrobel et al., 2007). As a result, there is a gross expansion of the ventricular zone, the 
precursor to the SVZ, which is equivalent to the phenotype observed in Nestin-Δ90N-β-catenin 
mice (Chenn and Walsh, 2002; Wrobel et al., 2007). 
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5.1.1 Aims 
The aim of this study was to assess the role of the Wnt/β-catenin pathway in the CNS 
using β-cateninlox(ex3) transgenic mice and to test whether expression of β-cateninΔex3 at 
endogenous levels results in a different biological phenotype.  
5.1.2 Methods 
NSC cultures were derived from the SVZ and the hippocampus of adult mice (section 
2.4.2). NSCs were infected with Adeno-Cre to mediate recombination (section 2.4.3). Western 
blot analysis was used to detect β-cateninΔex3 and cyclin D1 protein levels (section 2.6). NSC 
growth was assayed using the WST-1 proliferation assay (section 2.4.4), Hoechst proliferation 
assay (section 2.4.5) and neurosphere size assay (section 2.4.6). Self-renewal was assessed by 
the limited dilution assay (section 2.4.7). Nuclear fractions were obtained from Adeno-Cre, 
Adeno-GFP and untreated β-cateninlox(ex3)/wt NSC homogenates in order to assess levels of 
nuclear β-catenin (section 2.6.1.2). Neurospheres were differentiated (section 2.4.8) and 
multi-lineage potential of NSCs was analysed by immunocytochemical methods (section 2.4.9). 
En2-Cre; β-cateninΔex3 mouse brains were analysed histologically (section 2.5). β-cateninlox(ex3) 
mice were injected intra-cranially with Adeno-Cre to recombine the SVZ (section 2.1.4). 
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Table 5.1 Selected literature regarding β-cateninΔex3 transgenic mice 
Tissue Cre expression Cre expression Effect References 
Bone Col2a1-Cre Chondrocytes Death ~E18, very severe chondrodysplasia (Akiyama et al., 2004) 
Breast 
WAP-Cre Mammary alveolar epithelium  Hyperplastic structures and squamous metaplasia (Miyoshi et al., 2002) 
Pdgfb-iCreER 
Capillary and small vessel 
endothelial cells 
Transcriptional activation of β-catenin accelerates 
blood-brain-barrier (BBB) maturation 
(Liebner et al., 2008) 
CNS 
Wnt1-Cre (cell culture) Neural Crest cells  Sensory neural cell differentiation  (Lee et al., 2004) 
Nestin-Cre Neural precursors 
Increase in radial glia population resulting in gross 
enlargement of SVZ,  
(Wrobel et al., 2007) 
Embryo 
Nes8-Cre Telencephalon 
Up-regulation of dorsal markers and down-
regulation of ventral markers 
(Backman et al., 2005) 
Brn4-Cre, Wnt1-Cre Neural tube Expansion of the progenitor pool (Ille et al., 2007) 
Eye αMHC-CrePR1 Cardiomyocytes Impaired cardiac growth or cardiac muscular atrophy (Baurand et al., 2007) 
Heart Islet1-Cre (E7.0) 
Second heart field (SHF) 
progenitors 
Stabilisation resulted in a marked enhancement of 
SHF progenitors 
(Kwon et al., 2007) 
Intestine Fabpl-Cre, Ck19-Cre Intestinal epithelium 
Cells escape mitotic arrest and apoptosis which 
results in chromosomal instability 
(Aoki et al., 2007) 
Liver Adeno-Cre (adult) Injected into tail vein 
Stable β-catenin and H-ras promoted 
hepatocarcinogenesis 
(Harada et al., 2002; Harada et 
al., 2004; Mucenski et al., 2005)  
Lung CCSP-Cre (E14.5) Respiratory epithelial cells Goblet cell hyperplasia, and pulmonary tumours (Mucenski et al., 2005) 
Prostate PB-Cre Postrate secretory epithelium Squamous metaplasia and prostate Adenocarcinoma (Cheon et al., 2006) 
Thymus Foxn1-Cre (E10.5) Thymic epithelial cells  
Impaired thymus microenvironment, unable to 
support T cell development 
(Maatouk et al., 2008) 
XY gonads Sf1-Cre (E11.5) Gonadal somatic cells  Male to female sex reversal (Maatouk et al., 2008) 
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5.2 Results 
5.2.1 Adeno-Cre treated β-cateninlox(ex3)/wt NSCs do not show an enhanced 
growth potential 
NSC cultures were derived from adult β-cateninlox(ex3)/wt mouse brains in order to assess 
the effect of β-cateninΔex3 on these cells. Expression of β-cateninΔex3 was induced by infecting 
the NSCs with Adenovirus-Cre. As expected, Adeno-Cre infected β-cateninlox(ex3)/wt NSCs 
expressed β-cateninΔex3 (Figure 5.1). Expression levels were equivalent to those of wild-type β-
catenin, confirming efficient infection and recombination. However, there was no increase in 
cyclin D1 detected (Figure 5.1), suggesting that proliferation may not be increased. 
Subsequently, growth was measured using the WST-1 and Hoechst proliferation 
assays. Growth was assessed over the course of three days. Using the standard WST-1 protocol 
NSC proliferation was found to decrease over this time period (Figure 5.2). To this end the 
starting cell number was optimised to 3.5 x 103 cells/well (Figure 5.2). No significant growth 
difference was detected between Adeno-Cre treated, Adeno-GFP treated or untreated NSCs 
(n=3) (Figure 5.3 and Figure 5.4). Similarly, no significant difference was found in the diameter 
of neurospheres (n=3) (Figure 5.5).  
NSC self-renewal was assessed using the limited dilution assay. Figure 5.6 shows no 
significant difference between Adeno-Cre and Adeno-GFP infected β-cateninlox(ex3)/wt NSCs (n=3)  
(Figure 5.6). 
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Figure 5.1 Adeno-Cre infected β-catenin
lox(ex3)/wt 
NSCs express β-catenin
Δex3
, but do not have increased 
cyclin D1 levels 
Untreated (Un), Adeno-GFP (GFP) and Adeno-Cre (Cre)-treated β-catenin
lox(ex3)/wt
 NSC protein extracts 
were immunoblotted with antibodies against β-catenin (1:500), cyclin D1 (1:2000) and β-actin (1:1000). 
10 µg of total protein was loaded per lane. This is a representative western blot. Adeno-Cre infected β-
catenin
lox(ex3)/wt
 NSCs expressed  β-catenin
Δex3
 at an equivalent level to that seen with wild-type β-
catenin. However, no increase in cyclin D1 was detected. β-actin was used as an internal loading control. 
155 | P a g e  
 
 
 
 
 
 
Figure 5.2 The optimal starting cell number for the WST-1 proliferation assay is 3.5  x 10
3
 cells/ml 
Neurospheres were passaged to a single cell suspension and untreated β-cateninlox(ex3)/wt cells plated in 
quintuplet at  densities of 3 x 10
4
, 1.5 x 10
4
, 7 x 10
3
, 3.5 x 10
3 
cells/ml in wells of a 96-well plate. Three 
identical plates were prepared. At day one, two and three after passage, WST-1 reagent was added to 
one 96-well plate. WST-1 is metabolised by mitochondria into a coloured formazan salt. The OD of the 
formazan salt can be measured at 440nm and correlates with cell number. Over the course of three 
days, the proliferation of cells plated at 3 x 10
4
 and 1.5 x 10
4 
cells/ml decreased. The proliferation of cells 
plated at 7 x 10
3
 cells/ml was found to be marginally increased. In contrast, the proliferation of cells 
plated at 3.5 x 10
3 
cells/ml was markedly higher. 
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Figure 5.3 No difference in the proliferation of β-catenin
Δex3 
expressing NSCs (WST-1 proliferation 
assay) 
Neurospheres from untreated, Adeno-GFP-treated and Adeno-Cre-treated β-catenin
lox(ex3)/wt 
cultures 
were passaged to a single cell suspension. Cells were plated in quintuplet for each treatment at 3.5 x 10
3
 
cells/well.  Three identical 96-well plates were prepared. At day one, two and three after passage, WST-
1 reagent was added to one 96-well plate. WST-1 is metabolised by mitochondria into a coloured 
formazan salt. The OD of the formazan salt can be measured at 440nm and correlates with cell number. 
The results shown represent the average of three independent cultures. No significant difference in 
proliferation was detected between any two treatment groups at any time point (two-tailed t-test). OD 
values were tested for normality and homoscedasticity. 
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Figure 5.4 No difference in the proliferation of β-catenin
Δex3 
expressing NSCs (Hoechst proliferation 
assay) 
Neurospheres from untreated, Adeno-GFP-treated and Adeno-Cre-treated β-catenin
lox(ex3)/wt 
cultures 
were passaged to a single cell suspension. Cells were plated in quintuplet for each treatment at a cell 
density of 3.5x10
3
 cells/well. Three identical 96-well plates were prepared. At day one post-plating, 50 
ng of Hoechst 33342/DMSO was added to each well of one of the plates and incubated for 30 min at 
37°C. The plate was subsequently centrifuged for 1 min at 1000 x g and as much medium as possible 
was removed and replaced with 1X PBS, which allowed the amount of unbound Hoechst to be lowered. 
Hoechst fluorescence was detected at 360 nm excitation and 465 nm emission. The same procedure was 
repeated at days two and three post plating with the remaining 96-well plates. No significant growth 
difference was detected between any two treatment groups (two-tailed T-test). OD values where tested 
for normality and homoscedasticity. 
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Figure 5.5 No difference in the size of neurospheres from β-catenin
Δex3 
expressing NSCs 
Neurospheres from untreated, Adeno-GFP-treated and Adeno-Cre-treated β-catenin
lox(ex3)/wt 
cultures 
were passaged to a single cell suspension and plated at 0.5 x 10
6 
cells in individual 6 cm diameter plates. 
Ten days after passaging, the diameter of the neurospheres was measured using an Axiovert 135 
microscope (Zeiss) and the Openlab 5 software. The diameter of a 100 neurospheres was measured for 
each treatment group. An n=3 was calculated from three separate cultures for each treatment group. 
No significant difference in neurosphere size was found (two-tailed T-test). Neurosphere diameter 
measurements where checked for normality and homoscedasticity. 
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Figure 5.6 There is no difference in self-renewal between Adeno-Cre and Adeno-GFP treated NSCs  
Neurospheres from untreated, Adeno-GFP-treated and Adeno-Cre-treated β-catenin
lox(ex3)/wt 
cultures 
were passaged to a single cell suspension. Around 500 cells were plated into each well of the top row of 
a 96-well plate. The cells were serially diluted for each row of wells. Ten days after passage the number 
of neurospheres was counted. The results from each cell concentration were the average of twelve 
wells. An n=3 was calculated from three individual cultures for each treatment group. No significant 
difference in self-renewal was detected between Adeno-Cre and Adeno-GFP treated NSCs. The self-
renewal of untreated β-catenin
lox(ex3)/wt 
NSCs was significantly higher than Adeno-Cre and Adeno-GFP 
treated NSCs at 250 cells/well (p ≤0.001). Similarly, the self-renewal of untreated β-catenin
lox(ex3)/wt 
NSCs 
was significantly higher than Adeno-GFP treated NSCs at 125 cells/well (p ≤0.05). 
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5.2.2 Expression of β-cateninlox(ex3)/wt does not increase differentiation 
The role of the Wnt/β-catenin pathway in NSC differentiation is not completely 
understood. To assess the effect of β-cateninΔex3 expression in NSC differentiation, Adeno-Cre 
and Adeno-GFP treated β-cateninlox(ex3)/wt neurospheres were cultured on laminin-coated 
chamber slides. To promote differentiation, the neurospheres were cultured in media 
complemented with 10 % foetal calf serum, in the absence of growth factors. Forty eight hours 
post-culture, cells were immunostained for GFAP (marker for astrocytes), MAP2 (marker for 
neurones), O4 (marker for oligodendrocytes), Nestin (marker for undifferentiated cells) and β-
catenin (Figure 5.7 and Figure 5.8). In view of the fact that MAP2 immunostaining failed for 
two of the three experiments, quantification was not possible. O4-positive cells were rare in 
both treatment groups (≤ 1 % of cells per field of view). Interestingly, O4-positive cells were 
predominantly found near neurospheres. However, the number of neurospheres plated per 
well was variable. To this end, quantification of O4-positive cells would be biased by the 
number of neurospheres plated. As expected, nuclear β-catenin was significantly increased in 
Adeno-Cre treated cells (Figure 5.9). No significant difference was detected in the percentage 
of GFAP- or Nestin-expressing cells (Figure 5.9). 
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Figure 5.7 β-catenin
lox(ex3)/wt 
NSCs express MAP2, O4 and GFAP 
Adeno-Cre and Adeno-GFP treated β-catenin
lox(ex3)/wt 
neurospheres were plated on laminin-coated 
chamber slides in DMEM/Ham-F12 media supplemented with 10 % foetal calf serum (FCS). Forty eight 
hours post-culture, cells were fixed with 4 % formaldehyde and immunostained with rabbit polyclonal 
anti-GFAP (1:500) (C, D, G and H), mouse monoclonal anti-MAP2 (1:500) (A-D) and mouse monoclonal 
anti-O4 (1:300) (E-H). Hoechst 33342 (1:1000) was added to label the nuclei. The scale bar in H 
corresponds to 150 μm 
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Figure 5.8 β-catenin
lox(ex3)/wt 
NSCs express Nestin, β-catenin and GFAP 
Adeno-Cre and Adeno-GFP treated β-catenin
lox(ex3)/wt 
neurospheres were plated on laminin-coated 
chamber slides in DMEM/Ham-F12 media supplemented with 10 % foetal calf serum (FCS). Forty eight 
hours post-culture, cells were fixed with 4 % formaldehyde and immunostained with rabbit polyclonal 
anti-GFAP (1:500) (C and D), mouse monoclonal anti-Nestin (1:200) (A-D) and mouse monoclonal anti-β-
catenin (1:500) (E and F). Hoechst 33342 (1:1000) was added to label the nuclei. The white arrows in (E 
and F) represent β-catenin nucleo-positive cells. The scale bar in F corresponds to 150 μm   
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Figure 5.9 No difference in differentiation between Adeno-Cre and Adeno-GFP treated β-
catenin
lox(ex3)/wt
 NSCs 
Adeno-Cre and Adeno-GFP treated β-catenin
lox(ex3)/wt 
neurospheres were plated on laminin-coated 
chamber slides in DMEM/Ham-F12 media supplemented with 10 % foetal calf serum (FCS). Forty eight 
hours post-culture, cells were fixed with 4 % formaldehyde and immunostained for GFAP, Nestin and β-
catenin.  Cells were counted from three random fields of view for each immunostaining. The results 
presented are an average from three independent cultures for each treatment. There was no significant 
difference in the percentage of GFAP and Nestin positive cells between Adeno-Cre and Adeno-GFP 
treated β-catenin
lox(ex3)/wt
 NSCs. However, the percentage of cells with nuclear β-catenin was significantly 
higher in Adeno-Cre treated cells (p= 0.002) (two-tailed T-test). 
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5.2.3 Nuclear wild type β-catenin is more abundant than nuclear β-
cateninΔex3 in Adeno-Cre treated cells 
As mentioned previously, Adeno-Cre treated β-cateninlox(ex3)/wt NSCs do not show 
enhanced growth or self-renewal. These results are different from published data. One 
possible explanation may be that β-cateninΔex3 did not translocate into the nucleus. Although 
β-cateninΔex3 has been shown to translocate into the nucleus of ES cells (Harada et al., 1999), 
activating mutations in β-catenin are not always associated with nuclear translocation in 
tumours (Abraham et al., 2001; Anna et al., 2000; Kobayashi et al., 2000). To assess nuclear β-
catenin protein levels, Adeno-Cre, Adeno-GFP and untreated β-cateninlox(ex3)/wt NSC nuclear 
fractions were isolated. Subsequently, protein extracts from these fractions were 
immunoblotted for β-catenin. Interestingly, all three NSC treatment groups showed high levels 
of nuclear wild-type β-catenin (Figure 5.10). In contrast, no β-cateninΔex3 was detected in 
Adeno-Cre treated cultures (n=2) (Figure 5.10). This may explain why no increase in growth 
and self-renewal was detected in these cells. 
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Figure 5.10 β-catenin
Δex3
 protein is not detected in the nucleus of Adeno-Cre recombined NSCs 
Nuclear fractions from untreated, Adeno-GFP and Adeno-Cre treated β-catenin
lox(ex3)/wt
 NSC were 
immunoblotted with antibodies against β-catenin (1:500) and β-actin (1:1000). 10 µg of total protein 
was loaded per lane, except for lane 7 where nuclear protein yield was low. Control Adeno-Cre treated 
β-catenin
lox(ex3)/wt
 NSC total protein was loaded into lane 1. Nuclear fractions in lanes 2-4 and 5-7 are 
from two independent cultures respectively. All treatment groups contained nuclear wild-type β-
catenin. However, there was no nuclear β-catenin
Δex3/wt
 detected, despite its strong expression in total 
protein fractions. β-actin was used as an internal loading control. 
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5.2.4 En2-Cre; β-cateninlox(ex3)/wt mice show developmental abnormalities 
To assess the role of degradation-resistant β-catenin in the CNS, β-cateninlox(ex3)/wt mice 
were crossed with Nestin-Cre and En2-Cre mice. No Nestin-Cre; β-cateninΔex3/wt double mutant 
mice were born from this crossing. These results are in agreement with published reports; a 
recent study demonstrated that Nestin-Cre; β-cateninΔex3/wt mice are embryonic lethal (Wrobel 
et al., 2007). This phenotype is similar to that observed in Nestin-Δ90N-β-catenin mice (Chenn 
and Walsh, 2002).  
Instead, En2-Cre; β-cateninΔex3/wt double mutant mice were viable. Engrailed 2 (En2) 
belongs to a family of evolutionary conserved transcription factors. During early development, 
En2 is expressed in spatially-restricted domains across the mid/hind-brain junction, the region 
from which the cerebellum develops (Davis and Joyner, 1988; Davis et al., 1988; Davis et al., 
1991; Davidson et al., 1988). En2-Cre; β-cateninΔex3/wt mouse brains showed marked reduction 
of the cerebellar vermis, resulting in a tissue defect (Figure 5.11 and Figure 5.12). The 
phenotype was so pronounced that the vermis was not fused at the midline (Figure 5.11). 
Furthermore, the cerebella showed severe lobular abnormalities. In Figure 5.12 A, all lobules 
but the tenth were missing. Similarly, in Figure 5.12 B, only lobules III, IX and X are visible. 
However, in this example lobule III and IX are clearly abnormal when compared to controls 
(Figure 5.12 C). Of note, lobule II fails to fold back resulting in the inner granule layer meeting 
with the inferior colliculus (Figure 5.12). 
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Figure 5.11 The cerebella of En2-Cre; β-catenin
Δex3/wt
 mice show signs of severe hypoplasia (coronal) 
Coronal sections of cerebella from En2-Cre; β-catenin
lox(ex3)/wt
 (A) and control β-catenin
lox(ex3)/wt
 (B) mice 
were stained for H&E. Compared to the control, the En2-Cre; β-catenin
Δex3/wt
 cerebellum is showing 
severe hypoplasia in the vermis. The roman numerals represent the different cerebellar lobules. The 
scale bar in B corresponds to 1500 µm. 
168 | P a g e  
 
 
 
 
 
 
 
Figure 5.12 The cerebella of En2-Cre; β-catenin
lox(ex3)/wt
 mice show signs of severe hypoplasia (sagittal) 
Sagittal sections of cerebella from En2-Cre; β-catenin
lox(ex3)/wt
 (A-B; D-E; G-H) and β-catenin
lox(ex3)/wt
 (C, F, 
I) mice were stained for H&E (A-C), calbindin (Calb) (D-F) and NeuN (G-I). The roman numerals represent 
the different cerebellar lobules. En2-Cre; β-catenin
Δex3/wt
 cerebella (A) show severe lobular abnormalities 
compared to the control. Although lobules III and IX are present in (B), they are abnormal. Lobule X 
appears unaffected in En2-Cre; β-catenin
Δex3/wt
. Interestingly, lobule II fails to fold back in En2-Cre; β-
catenin
Δex3/wt
 mice, resulting in the internal granule layer fusing with the inferior colliculus. The scale bar 
in I corresponds to 1300 µm. 
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5.2.5 β-cateninlox(ex3)/wt mice develop SVZ hyperpasia, but no neoplasia 
following Adeno-Cre injection 
To express β-cateninΔex3 in the SVZ, the ventricles of adult β-cateninlox(ex3)/wt mice were 
injected with Adeno-Cre virus. 100 days post-infection, mice were injected with BrdU and then 
sacrificed (n=5). The brains were then sectioned coronally and stained for GFAP (astrocytes), 
Synatophysin (SYP; neurones) and BrdU (dividing cells and daughter cells). Small growths were 
detected in the SVZ of Adeno-Cre injected β-cateninlox(ex3)/wt mice. These growths consisted of 
an underlying layer of GFAP+/SYP-/BrdU+ cells and a mass of GFAP-/SYP-/BrdU- cells, which 
protruded into the ventricle (Figure 5.13). Although GFAP+/SYP-/BrdU+ cells share the 
expression profile of SVZ neural stem cells, more work is needed for confirmation (Doetsch, et 
al 1999). In contrast, the identity of the GFAP-/SYP-/BrdU- cells was not clear. It is unlikely that 
they were transit-amplifying daughter cells, as such cells have a high proliferative potential and 
would have stained strongly for BrdU. 
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Figure 5.13 β-catenin
lox(ex3)/wt
 mice develop SVZ enlargements after Adeno-Cre intra cranial (i.c.) 
injections 
β-catenin
lox(ex3)/wt
 mice were injected with Adeno-Cre into the ventricles. After 100 days, mice were 
injected with BrdU and culled. SVZ staining for H&E (A-C), synaptophysin (SYP) (E-G), GFAP (H-J) and 
BrdU (K-M) shows abnormal growths. These growths are composed of a layer of GFAP+/SYP-/BrdU+ 
cells and GFAP-/SYP-/BrdU- cells. The GFAP+/SYP-/BrdU+cells may be stem cells. The identity of the 
GFAP-/SYP-/BrdU- cells is unclear. The control panels (D and N) correspond with a Rosa26 LacZ mouse 
injected with Adeno-Cre (90 days incubation). The scale bar in N corresponds to 130 µm. 
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5.3 Discussion 
Results from the ΔGSK-β-catenin mouse model and NSC cultures, presented in 
chapters 3 and 4, did not show a significant phenotype and after careful testing it was decided 
to use an alternative mouse model. The β-cateninlox(ex3)/wt mouse model is the most commonly 
used model for studying the effect of degradation-resistant β-catenin (Harada et al., 1999). In 
this model, exon 3 of the endogenous β-catenin gene, which encodes the phosphorylation 
motif of β-catenin is flanked by loxP sites. Following Cre-mediated recombination, exon 3 is 
deleted and degradation-resistant β-cateninΔx3 is expressed. This model confers two key 
advantages. First, as β-cateninΔex3 expression is controlled by the endogenous β-catenin 
promoter and regulatory elements, this model depicts β-catenin mutations in cancer more 
accurately than the ΔGSK-β-catenin mouse model. Second, as β-cateninΔex3 is 76 aa smaller 
than wild-type β-catenin, they can be distinguished from one another by simple 
immunoblotting based on size (using the same antibody).   
To assess the role of β-cateninΔex3 expression on NSCs in vitro, neurospheres were 
derived, expanded and recombined as described in chapter 2. Immunoblotting analysis of 
Adeno-Cre-treated NSCs showed expression of β-cateninΔex3, the protein levels of which were 
similar to those of wild-type β-catenin (expressed by the other allele), and confirmed efficient 
recombination. However, expression of β-cateninΔex3 did not elicit an increase of cyclin D1 
protein levels. Similarly, Adeno-Cre-treated cells did not grow significantly faster or larger than 
controls and no differences were detected in NSC self-renewal. One possible explanation for 
these results is that β-cateninΔex3 may not translocate into the nucleus of our cultured cells. β-
cateninΔex3 protein has been shown to translocate into the nucleus of ES cells (Harada et al., 
1999). However, activating mutations in β-catenin are not always associated with nuclear 
translocation in tumours (Abraham et al., 2001; Anna et al., 2000; Kobayashi et al., 2000). 
Therefore, to test this hypothesis, nuclear extracts were isolated from Adeno-Cre, Adeno-GFP 
and untreated β-cateninlox(ex3)/wt NSCs. Western blotting analysis (using an anti-β-catenin 
antibody) demonstrated high levels of wild-type β-catenin, but not β-cateninΔex3. This is in 
contrast to the results obtained with total protein fractions. One reason for this could be loss 
of protein during nuclear fractionation. However, no β-cateninΔex3 was detected in either of the 
Adeno-Cre treated NSC nuclear protein fraction samples. These results suggest that in 
undifferentiated NSC cultures, β-cateninΔex3 does not appear to translocate into the nucleus. 
This would explain the lack of any significant differences in growth and self-renewal, but more 
evidence is needed to substantiate these results.  
Results presented in this chapter contradict with published data. Expression of 
degradation-resistant β-catenin has been shown to increase the proliferation and self-renewal 
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of NSCs in vitro (Lie et al., 2005; Qu et al., 2010; Yu et al., 2006). A possible explanation for this 
discrepancy could be the NSC culture conditions in our system. For example, in the study by Yu 
et al., NSCs were cultured in medium containing DMEM/HAMS F12, EGF, FGF, B27 supplement 
and 10 % FCS. Of note, serum has been shown to cause irreversible differentiation of NSCs and 
therefore was not considered as a suitable condition (Gage et al., 1995; Lee et al., 2006; 
McKay, 1997; Reynolds and Weiss, 1992). Similarly, during isolation of adult hippocampal NSCs 
by Lie and colleagues (2005), cultures were treated with DMEM/HAMS F12 and 10 % FCS for 
24 hours before treatment with media supplemented with N2 and FGF (Lie et al., 2005). Apart 
from irreversible differentiation, culturing NSCs in FCS allows for the permanent decrease of 
NSC proliferation (Lee et al., 2006). Another study however, disagrees with these findings and 
their interpretation. In a study by Qu and colleagues, NSCs were cultured under similar 
conditions as in our study (Qu et al., 2010). However, the NSCs grew in monolayers and not as 
free-floating spheres. It is possible that the cells in the study of Qu and colleagues were grown 
in laminin-coated culture plates. It remains to be shown whether growth as a monolayer 
influences the translocation of degradation-resistant β-catenin into the nucleus. 
The Wnt/β-catenin pathway plays a complex role in differentiation and maintenance of 
NSCs. To assess the role of β-cateninΔex3 expression in differentiation, NSCs were grown in 
laminin-coated chamber slides and cultured in differentiation medium (DMEM/HAMS F12 
supplemented with 10 % FCS). 48h post-culture, cells where immunostained for GFAP 
(astrocytes), MAP2 (neurones), O4 (oligodendrocytes), β-catenin and Nestin (undifferentiated 
cells). Expression of β-cateninΔex3 increased the fraction of cells with nuclear β-catenin. 
However, there was no significant difference in the fraction of GFAP-positive or Nestin-positive 
cells. Results from MAP2 immunostaining were inconclusive. O4-positive cells were rare, 
ranging from 0-5 cells per field of view. They were more prominently found in close proximity 
to neurospheres. However, the number of neurospheres plated per well was variable. 
Therefore, it was not possible to accurately compare the O4 immunostaining between the 
different treatment groups. Taking into account the lack of a significant difference in Nestin 
staining, these results suggest that expression of β-cateninΔex3 is not increasing differentiation. 
This is in disagreement with known roles of the Wnt/β-catenin in NSC differentiation. The 
Wnt/β-catenin pathway appears to have a dual role in differentiation depending on the 
developmental stage of cells. Constitutive activation of the Wnt/β-catenin pathway during 
early development appears to inhibit NSC differentiation without an increase in proliferation 
(Chenn and Walsh, 2002; Wrobel et al., 2007). Similarly, during adulthood, low-level Wnt/β-
catenin pathway activity has been proposed to maintain NSCs in an undifferentiated state 
(Wexler et al., 2009). However, constitutive activation of the pathway during late development 
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and in adult NSCs increases neuronal differentiation (Hirabayashi et al., 2004; Lie et al., 2005; 
Wexler et al., 2008). These results could be explained by an increase in the proliferation of cell 
committed to neuronal differentiation rather than by a putative increase in differentiation. Lie 
et al. reported that Wnt3 can increase the amount of new neurones by five- to ten-fold under 
non-proliferating conditions. However, even under such conditions, five percent of cells were 
found to still be proliferating (Lie et al., 2005). These authors do not mention the percentage 
of cells proliferating without Wnt3 treatment. Therefore, the possibility remains that five 
percent of proliferating cells could give rise to this increase in neurogenesis. In this case the 
prospect that the Wnt/β-catenin pathway may promote the proliferation of neuronally 
committed precursor cells rather than increasing proliferation is still possible. If so, it may 
explain why the percentage of cells expressing Nestin were not decreased in NSC cultures 
expressing β-cateninΔex3.   
To assess the effect of β-cateninΔex3 in the CNS, β-cateninlox(ex3)/wt mice were crossed 
with two CNS Cre-recombinase-expressing mouse lines: Nestin-Cre (expression in neural 
precursors and adult neural stem cells) and En2-Cre, which drives expression in spatially-
restricted domains across the mid/hind-brain junction, which develop into the cerebellum 
(Davis and Joyner, 1988; Davis et al., 1988; Davis et al., 1991; Davidson et al., 1988). As 
expected, no Nestin-Cre; β-cateninΔex3/wt double mutant mice were born. These mice have 
been reported to be embryonic lethal due to abnormalities in the maturation of radial glia 
(Wrobel et al., 2007). Instead, En2-Cre; β-cateninΔex3/wt double mutant mice were viable and 
showed ataxia after 3 weeks, caused by a defect in the cerebellar vermis, where the Cre 
transgene is expressed (Zinyk et al., 1998). Furthermore, most of the cerebellar lobules were 
either missing or were abnormal, except for the tenth lobule. Interestingly, this phenotype was 
similar to that observed in mice that express orthodenticle homeobox 2 (Otx2), a gene 
involved in cerebellar patterning, under the control of Engrailed 1 (En1wt/Otx2LacZ mice) (Broccoli 
et al., 1999). Like in En2-Cre; β-cateninΔex3/wt cerebella, the vermis of these mice was reduced 
and not fused at the midline (Broccoli et al., 1999). Furthermore, only the posterior lobules 
VIII, IX and X are present (Broccoli et al., 1999). In order to compare these two transgenic 
mouse models it is necessary to discuss certain aspects of cerebellar development.  
From anterior to posterior, the neural tube is composed of the prosencephalon, the 
mesencephalon, the metencephalon and the myelencephalon. Studies in quail-chick chimaeras 
have indicated that both the mesencephalon and metencephalon contribute to cerebellum 
development (Hallonet et al., 1990; Hallonet and Le Douarin, 1993; Hatten and Heintz, 1995). 
The isthmic organizer (IO), located just caudally to the junction of these two regions, functions 
in releasing signalling proteins required for the correct patterning of the mid-hindbrain (Bally-
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Cuif et al., 1992; Bally-Cuif and Wassef, 1994; Martinez et al., 1991) (Figure 5.14). The IO is in 
turn organised by a complex gene expression pattern. Specifically, the negative interaction of 
two genes, namely Otx2 and gastrulation brain homeobox 2 (Gbx2), defines IO positioning in 
the brain (Broccoli et al., 1999; Katahira et al., 2000; Millet et al., 1999). One of the main 
signalling proteins originating from the IO is Fgf8, which induces Wnt1 expression (Adams et 
al., 2000; Reifers et al., 1998). Subsequently, Wnt1 regulates the expression of En1 and En2 
(Bally-Cuif et al., 1992; Mcmahon et al., 1992).  
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Figure 5.14 Patterning of the midbrain/hindbrain region
5
 
(a) Formation of the mid-/hindbrain region is dependent on proper functioning of the isthmus organizer, 
which is formed by the interaction, or reciprocal repression, of Otx2 and Gbx2. En1 is expressed in both 
the mid- and hindbrain regions. (b) The genetic interactions among Otx2, Gbx2, Fgf8, Wnt1 and En1. 
En1, engrailed 1; Fgf8, fibroblast growth factor 8; Gbx2, gastrulation brain homeobox 2; Otx2, 
orthodenticle homologue 2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                          
5
 Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience, Vincent Y. 
Wang and Huda Y. Zoghbi, Genetic regulation of cerebellar development, 2: 484-491, copyright (2001). 
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In En1wt/Otx2LacZ transgenic mice, Otx2 expression is pushed caudally (Broccoli et al., 
1999). As a result, Wnt1 expression is shifted into the rhombic lip, the germinal area from 
which granule neurones, glutamergic deep nuclear neurones and unipolar brush cells originate 
(Alder et al., 1996; Englund et al., 2006; Fink et al., 2006; Machold and Fishell, 2005; Wang et 
al., 2005) (Figure 5.15). In the En1wt/Otx2LacZ mouse model, Wnt1 is expressed in the anterior 
region of the rhombic lip. Interestingly, mapping experiments have shown that precursors 
from this area give rise to the cerebellar vermis (Sgaier et al., 2005). Furthermore, Wnt1 acts 
through the canonical pathway in cerebellar development (Panhuysen et al., 2004). 
Collectively, these studies suggest that activation of the Wnt/β-catenin pathway in the 
rhombic lip is detrimental to cerebellar development. This is in agreement with the data 
obtained from the En2-Cre; β-cateninΔex3/wt mouse model presented here. Of note, conditional 
APC loss-of-function in neural crest-derived cells results in a massive apoptosis of neural crest 
cells (Hasegawa et al., 2002). Hence, activation of the Wnt/β-catenin pathway may promote 
the apoptosis of cerebellar rhombic lip precursors.  
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Figure 5.15 Granule neurone development in mice
6
 
(a) At embryonic day (E) 9, the rhombic lip (blue and orange) is a zone of proliferation between the 
fourth ventricle and the neural tube. The cells in the blue region give rise to the cerebellar granule 
neurons and pontine nucleus, whereas cells in the red region yield other rhombic lip derivatives such as 
the inferior olivary nucleus. (b) At about E13, cells from the rhombic lip migrate outwards to populate 
the cerebellar anlage.  
 
 
 
 
 
 
 
 
 
                                                          
6
 Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Neuroscience, Vincent Y. Wang 
and Huda Y. Zoghbi, Genetic regulation of cerebellar development, 2: 484-491, copyright (2001). 
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De-regulation of the Wnt/β-catenin pathway has been documented for tumours of the 
CNS (Table 1.5). Previous reports have documented that constitutive activation of the Wnt/β-
catenin pathway in SVZ neural stem cells was not sufficient to elicit tumours (Fults et al., 2002; 
Momota et al., 2008). However, the latest time point in these studies was three months. 
Jacques et al. showed that conditional inactivation of two or even three tumour suppressor 
genes in the SVZ results in brain tumours after up to eight months (Jacques et al., 2010). 
Therefore, constitutive activation of the Wnt/β-catenin pathway may still promote 
tumourigenesis in the long-term. To assess this, β-cateninlox(ex3)/wt mice were injected with 
Adenovirus-Cre into the lateral ventricles, where the SVZ is located. This experiment is 
currently ongoing. However, a cohort of mice was culled for analysis 100 days post-infection. 
Encouragingly, these mice showed abnormal enlargements in the SVZ. Immunohistochemical 
staining of these growths for GFAP, BrdU and synaptophysin (SYP) indentified two cell 
populations. The first population consisted of GFAP+/SYP-/BrdU+ cells, which correspond with 
markers expressed by type B neuronal stem cells. The second population consisted of GFAP-
/SYP-/BrdU- cells, which do not match with markers for either type C transit-amplifying cells or 
type A neuroblasts. Hence, these preliminary results presented here suggest that activation of 
the Wnt/β-catenin pathway in the SVZ promotes neural stem cell expansion in vivo. However, 
one year post injection the mice did not develop any tumours (Brandner, S, private 
communication). 
 
5.4 Summary 
Expression of β-cateninΔex3 in NSCs does not significantly increase growth or self-
renewal potential in vitro. This may be attributed to β-cateninΔex3 not translocating into the 
nucleus. However, more data is needed to confirm this result. However, mice, which expressed 
β-cateninΔex3 under the control of the En2 promoter, had a developmental defect in the area 
corresponding to embryonal Cre expression, which later becomes the cerebellar vermis. 
Finally, activation of dominant active β-cateninlox(ex3)/wt mice in the stem/progenitor cell 
compartment of the SVZ in the lateral ventricles resulted in small hyperplasias, but no 
neoplastic lesions in the SVZ. Experiments are ongoing to assess the collaboration with other 
oncogenic signals, such as p53 or RB pathway inactivation.  
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6 Conclusion and future work 
6.1 Summary 
To study the role of the Wnt/β-catenin pathway in the CNS, we generated transgenic 
mice that conditionally express degradation-resistant β-catenin (ΔGSK-β-catenin). However, as 
described in chapter 3 and 4, ΔGSK-β-catenin expression in developing and the adult CNS did 
not result in detectable developmental abnormalities (with or without p53 expression). In vitro 
expression of ΔGSK-β-catenin did not alter the proliferation or self-renewal of adult NSCs. 
Similarly, additional deletion of the tumour suppressor genes Tp53 or Rb did not convincingly 
alter the proliferation or self-renewal of these cells. To directly recombine the SVZ neural stem 
cells, ΔGSK-β-catenin; p53loxP/loxP mice were injected with Adeno-Cre into the lateral ventricles. 
Nonetheless, no mice were found to have developed hyperplasias or tumours as late as one 
year after intraventricular injection. The most plausible explanation for the absence of a 
phenotype is that the expression levels of ΔGSK-β-catenin might have been insufficient to elicit 
an effect. However, this hypothesis has not been confirmed experimentally. Instead, we 
obtained an alternative transgenic mouse model for expressing degradation-resistant β-
catenin; these were β-cateninlox(ex3)/wt transgenic mice. Expression of β-cateninΔex3 in NSCs did 
not significantly alter growth or self-renewal. This may be attributed to β-cateninΔex3 not 
translocating into the nucleus. However, more data is needed to confirm this result. In vivo, no 
Nestin-cre; β-cateninΔex3 were born as expected, whilst mice expressing β-cateninΔex3 under the 
control of the En2 promoter survived to term. These mice showed severe cerebellar vermis 
abnormalities. The cause for this phenotype was not determined in this study as time did not 
permit. However, existing literature suggests that constitutive activation of the Wnt/β-catenin 
pathway during early development can cause severe apoptosis of neuronal crest derived cells. 
Finally, β-cateninlox(ex3)/wt mice injected with Adeno-Cre into the lateral ventricles developed 
growths in the SVZ one hundred days post-injection. These growths did not appear to be highly 
proliferative, but there are mice available for analysis at later time-points.  
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6.2 Future work 
6.3 Synergism between Wnt/β-catenin, p53, PTEN and Rb 
pathways in CNS tumours 
One of the goals of this study was to investigate the synergism between the Wnt/β-
catenin pathway and the p53, Rb and PTEN pathway in brain tumourigenesis. However, due to 
complications with the ΔGSK-β-catenin mice this was not achieved. Therefore, the alternative 
mouse model, β-cateninlox(ex3)/wt ,should be used to ascertain the role of the abovementioned 
pathways in tumourigenesis. 
 
6.3.1 TP53, PTEN and RB in gliomas  
Astrocytic gliomas progress from low-grade diffuse astrocytomas (WHO grade II) to 
anaplastic astrocytomas (WHO grade III) and subsequently to (secondary) glioblastomas (WHO 
grade IV). TP53 is mutated in more than 60 % of diffuse astrocytomas (Okamoto et al., 2004; 
Reifenberger et al., 1996; Watanabe et al., 1996). The frequency of these mutations does not 
change during tumour progression, which suggests that TP53 mutations are important for 
tumourigenesis (Sidransky et al., 1992; von et al., 1992; Watanabe et al., 1996; Watanabe et 
al., 1997).  
The RB1 gene encodes the retinoblastoma protein, which plays a crucial role in G1 to S 
phase transition during proliferation (Weinberg, 1995). The RB1 gene is found at chromosome 
13q, which is lost in 12 % of primary and 38 % of secondary glioblastomas (Nakamura et al., 
2000). Additionally, promoter hypermethylation occurs in 12 % of primary and 43 % of 
secondary glioblastomas (Nakamura et al., 2001a). Interestingly, de-regulation of the Rb 
pathway also occurs in anaplastic astrocytomas (Reifenberger et al., 1994; Schmidt et al., 
1994). These findings suggest that the pathway is important for progression from diffuse 
astrocytomas to anaplastic astrocytomas. 
PTEN is a tumour suppressor that antagonises the phosphatidylinositol-3-kinase (PI3K) 
pathway (Maehama and Dixon, 1998). Loss of chromosome 10q, where PTEN is located, occurs 
in 70 % of glioblastomas (Ohgaki et al., 2004). This incidence is similar between primary and 
secondary glioblastomas (Tohma et al., 1998). Loss of chromosome 10q is infrequent in low 
grade gliomas, but has been reported in 35 % to 60 % of anaplastic astrocytomas, suggesting a 
role in progression (Balesaria et al., 1999; Bigner and Vogelstein, 1990; Ichimura et al., 1998; 
James et al., 1988).  
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β-catenin is rarely mutated in gliomas (Gotze et al., 2009). However, β-catenin, TCF4, 
LEF1, c-myc and cyclin D1 expression increases with glioma malignancy grade (Sareddy et al., 
2009b). This effect may be partially attributed to an increase in promoter hypermethylation of 
Wnt antagonists (Gotze et al., 2009). Similarly, Wnt antagonist promoter hypermethylation is 
common in secondary glioblastomas (Gotze et al., 2009). These results suggest that activation 
of the Wnt/β-catenin pathway may be involved in both glioma progression and spontaneous 
development of primary glioblastomas.  
In summary, aberrations in the p53 pathway are vital for glioma tumourigenesis. On 
the other hand mutations in the PTEN, Rb and Wnt/β-catenin pathways also seem to play a 
role in tumour progression. Taking these findings into account, it is unlikely that β-
cateninlox(ex3)/wt; RbloxP/loxP or β-cateninlox(ex3)/wt; PTENloxP/loxP mice will develop gliomas. However, 
β-cateninlox(ex3)/wt; p53loxP/loxP mice might develop gliomas, which would shed some light into the 
role of the Wnt/β-catenin pathway in these tumours.  
Finally, p53loxP/loxP; RbloxP/loxP and p53loxP/loxP; PNETloxP/loxP mice develop PTEN-like and 
glioma-like tumours (Jacques et al., 2010). Therefore it would be interesting to determine how 
the expression of β-cateninΔex3 may influence the tumour phenotype of these mice. 
 
6.3.2 TP53, PTEN and RB in medulloblastomas 
TP53 mutations are rare in medulloblastomas (5-10 %), but if present are associated 
with poor prognosis (Adesina et al., 1994; Alderson et al., 1996; Ohgaki et al., 1993) (Tabori et 
al., 2010). Additionally, the p53 pathway is altered by alternative mechanisms in up to 21 % of 
medulloblastomas (Frank et al., 2004). Interestingly, mice null for double-strand break repair 
genes and p53 develop medulloblastomas (Frappart et al., 2009; Yan et al., 2006). These 
tumours often acquire mutations in components of the Shh pathway (Frappart et al., 2009; 
Yan et al., 2006). This is relevant since mutations in the Wnt and Shh pathways are mutually 
exclusive events in medulloblastoma (Thompson et al., 2006). This suggests that mutations in 
the p53 pathway may not correlate with medulloblastomas with Wnt/β-catenin pathway de-
regulation. Hence, β-cateninlox(ex3)/wt; p53loxP/loxP mice may not be biologically relevant for 
modelling medulloblastomas. 
PTEN mutations are also rare in medulloblastomas (Rasheed et al., 1997). However, 
loss of 10q is found in 18 % to 42 % of medulloblastoma cases (Avet-Loiseau et al., 1999; 
Gilhuis et al., 2000; Mendrzyk et al., 2005; Reardon et al., 1997; Shlomit et al., 2000). 
Furthermore, PTEN promoter hypermethylation can be detected in 50 % of medulloblastomas 
(5/10 cases investigated) (Hartmann et al., 2006). 
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No mutations in the RB gene have been detected in medulloblastomas (Lee et al., 
1987). However, mice with conditional deletions of Rb and p53 in GFAP-expressing cells 
develop tumours with medulloblastoma features and combined inactivation of Rb and p53 in 
SVZ stem/progenitor cells give rise to PNETs, which are histologically similar to 
medulloblastomas (Jacques et al., 2010; Marino et al., 2000). Hence, de-regulation of the Rb 
pathway may play a role in medulloblastoma development.  
As discussed in chapter 1, activation of the Wnt/β-catenin pathway has been reported 
in around 23 % of medulloblastomas (Table 1.5). Interestingly, medulloblastomas with nuclear 
β-catenin immunoreactivity tend to: 
1. Have β-catenin mutations (92 %, 23/25) 
2. Have lost of a copy of chromosome 6 (70 %, 14/20) 
3. Show few other chromosomal abnormalities 
4. Show histological features of classical medulloblastomas (85 %, 40/47) 
 (Clifford et al., 2006; Ellison et al., 2005; Thompson et al., 2006). This suggests that loss of 
chromosome 10 and 13, which are associated with PTEN and Rb loss, does not correlate with 
the Wnt/β-catenin pathway in medulloblastomas. However, genes lost on chromosome 6 may 
be involved in the p53, PTEN or Rb pathway. Hence, β-cateninlox(ex3)/wt; RbloxP/loxP or β-
cateninlox(ex3)/wt; PTENloxP/loxP or β-cateninlox(ex3)/wt; p53loxP/loxP mice might develop 
medulloblastomas. 
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6.3.3 Tumour suppressor genes on chromosome 6 
Full or partial loss of chromosome 6 has been reported for other types of cancer, 
including breast cancer, lymphomas and melanomas (Noviello et al., 1996; Offit et al., 1993; 
Trent et al., 1983). This suggests that important tumour suppressor genes are present on this 
chromosome. In support of this argument, microcell-mediated transfer of chromosome 6 into 
the breast cancer cell line MDA-MB-231, resulted in reduced in vitro invasion and tumourigenic 
potential (Theile et al., 1996). Some tumour suppressor genes located on chromosome 6 are 
summarised in (Table 6.1). 
 
 
Table 6.1 Selection of tumour suppressor genes located on the human chromosome 6 
 
Human gene Abbreviation 
Chromosomal 
position 
Cyclin-dependent kinase inhibitor 1A CDKN1A 6p21.2 
Nucleolar protein 7 NOL7 6p23 
Absent in melanoma 1 AIM1 6q21 
Cyclin C CCNC 6q21 
Protein tyrosine phosphatase, receptor type K PTPRK 6q22.33 
Pleiomorphic Adenoma gene-like 1 PLAGL1 6q24.2 
SAM and SH3 domaint containing 1 SASH1 6q24.3 
Large tumour suppresor, Drosophila homolog 1 LATS1 6q25.1 
 
  
Of the genes listed in Table 6.1, LATS1 and PLAGL1 are of particular interest. LATS1 is 
the human homolog of Drosophila warts (wts), a member of the Hippo pathway (Justice et al., 
1995). In Drosophila, the Hippo pathway inhibits cell proliferation and promotes proliferation 
by inhibiting Yorkie (Yki) (Huang et al., 2005). The mammalian homolog of Yki is Yes-associated 
protein 1 (YAP1), which is phosphorylated and inhibited by LATS1 (Dong et al., 2007; Oh and 
Irvine, 2009). Interestingly, YAP1 is up-regulated in medulloblastomas with an active Wnt/β-
catenin pathway (Fernandez et al., 2009). This suggests that de-regulation of the Hippo 
pathway may be an important event in medulloblastomas with Wnt/β-catenin pathway 
activation. The Hippo pathway partly regulates proliferation by negatively regulating the 
Wnt/β-catenin pathway. Small interfering RNA knockdown of LATS1 in a human embryonal 
kidney cell line (HEK293T) increased the Wnt3a-dependent expression of AXIN2 and enhanced 
the luciferase expression of the TOPflash Wnt/β-catenin pathway reporter plasmid (Varelas et 
al., 2010). Interestingly, TEA domain 1 (TEAD1), the major transcriptional partner of YAP1, is 
also up-regulated in medulloblastomas (Fernandez et al., 2009; Zhao et al., 2008). TEAD1 is 
negatively regulated by p38α MAPK, which is located on chromosome 6 (Ambrosino et al., 
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2006). Therefore, deregulating the Hippo pathway seems an attractive target for studying 
Wnt/β-catenin medulloblastomas.   
PLAGL1 is a member of the novel subfamily of zinc-finger transcription factors, 
consisting of PLAG1, PLAGL1 and PLAGL2. PLAGL1 has been shown to induce apoptosis and G1 
arrest, in a manner similar to p53 (Spengler et al., 1997). Subsequently, it was found that 
PLAGL1 could directly bind to p53 and significantly enhance the expression of p53-responsive 
genes (Huang et al., 2001). This effect was not observed in the absence of p53, suggesting that 
PLAGL1 is a transcriptional co-factor of p53 (Huang et al., 2001). In the cerebellum, PLAGL1 
expression was detected in the external granule layer from postnatal (P) day 2 to 7 (Ciani et al., 
2003). Nuclear PLAGL1 was also detected in Purkinje cells at P7 (Ciani et al., 2003). In the adult 
cerebellum, PLAGL1 expression is low and primarily found in Purkinje cells (Ciani et al., 2003). 
Interestingly, PLAGL1 expression co-localises with neuronal stem cell markers (Nestin, GFAP, 
proliferating cell nuclear antigen [PCNA] and BrdU) during CNS development (Valente et al., 
2005). Furthermore, promoting PLAGL1 expression by raising cyclic Adenosine monophosphate 
(cAMP) decreased BrdU incorporation in cerebellar granule neurons (Contestabile et al., 2005). 
These results suggest that PLAGL1 has a key role in controlling neuronal stem cell proliferation. 
The PLAGL1 gene is paternally imprinted in mice and humans (Kamiya et al., 2000; Smith et al., 
2002). This means that PLAGL1 is only expressed from the paternal chromosome 6. 
Medulloblastomas with Wnt/β-catenin pathway activation tend to lose one copy of 
chromosome 6. It would be interesting to assess if this is the copy of chromosome 6 that is lost 
in these tumours. 
No conditional knockout mouse models have been published for either of these genes. 
Once they have been generated, it will be interesting to cross them with β-cateninlox(ex3)/wt mice 
to determine if they can synergistically promote medulloblastoma development. 
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